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Summary
New agents for the diagnosis, prevention and treatment of tuberculosis are urgently
required. Yet, despite extensive tuberculosis research over recent years, no new drugs,
vaccines or diagnostics have been identified to date. It is widely speculated that the major
obstacle to the identification of new therapies is the lack of understanding of the host-
pathogen interaction.
This study has investigated whether patterns of antigen expression correlate with
molecular epidemiological data and strain virulence through the analysis of protein expression
and antigen recognition profiles of different M tuberculosis clinical isolates. Using
polyacrylamide gel electrophoresis, enzyme-linked immunosorbent assay, and Western
blotting, protein expression and antigen recognition by two genotypically different clinical
strains that differed in their frequency in the study population have been compared. In
addition to differences in protein expression and antigen recognition between the clinical
strains and the reference strain H37Rv, protein expression differences between the clinical
strains themselves were observed which may relate to strain frequency and virulence.
Differential protein expression by M tuberculosis strains, may explain the
heterogeneous host humoral immune response and why no fully effective serodiagnostic test
has been developed to date. To explore this hypothesis, the potential of serodiagnosis in this
community, where patients are infected with a wide variety of genotypically distinct strains,
was investigated. IgG levels to three mycobacterial antigens showed that serodiagnosis of TB
is possible in this community, despite infection by a wide variety of genotypically different
M tuberculosis strains. Disease episode affected antibody levels, suggesting that care should
be taken when evaluating serological diagnosis for repeat episode patients.
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This study has shown that M tuberculosis protein expression is dynamic and that the
bacillus presents a hypervariabie array of antigens to the host immune system. It is likely that
different antigens become immunodominant as antituberculosis chemotherapy progresses, and
that these differentially expressed antigens may be tracked as predictors of treatment outcome.
This hypothesis was tested by correlating Ag85-specific IgG with treatment response, as
assessed by sputum smear conversion after two months of antimycobacterial chemotherapy.
No significant correlation between antibody levels and treatment responses was observed,
suggesting that antibodies may not be useful surrogate markers or that the incorrect antibody
type or mycobacterial antigen were selected. Results were consistent with previous findings
where patient-to-patient variation dictated the host humoral response.
The results obtained in this study have demonstrated that although bacteriological
factors may influence strain prevalence due to antigen variation and immune evasion, both
bacteriological and host factors affect humoral immunity. Differential protein expression by
M tuberculosis strains has potentially important implications for serodiagnosis and the
development of subunit or DNA vaccines, by suggesting that multi-antigen cocktails should
be used. Differential protein expression may also explain why patients do not develop
adequate protective immunity and are susceptible to reinfection.
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Opsomming
Daar is 'n dringende behoefte vir nuwe middels vir die diagnosering, voorkoming en
behandeling van tuberkulose. Ondanks intense tuberkulose navorsing gedurende die afgelope
paar jaar, is daar geen nuwe tuberkulose medikasie, vaksines of diagnostiese metodes
geïdentifiseer nie. Daar word gespekuleer dat die hoof struikelblok vir die identifisering van
nuwe medikasie die onkunde oor die tuberkulose patogeen is.
Deur die analise van proteien-uitdrukking en antigeen-erkenning profiele van
verskillende M tuberculosis kliniese isolate is daar tydens hierdie studie ondersoek ingestel
of die patroon van antigeen uitdrukking korreleer met molekulêre epidemiologiese data and
stam-virulensie. Proteien-uitdrukking en antigeen-erkenning deur twee genotipies
verskillende kliniese stamme wat verskil in hul frekwensie in die bestudeerde populasie, is
vergelyk deur middel van poli-akrielamied gel elektroforese, ensiem-gekoppelde
immuunabsorberende analise en Westelike oordrag. Addisoneel tot die verskille in proteien-
uitdrukking en antigeen-ekenning tussen kliniese stamme en die verwysingstam H37Rv, is
daar ook verskille aangedui tussen die kliniese stamme self wat kan dui op starn frekwensie
en virulensie.
Differensiële proteien-uitdrukking deur M tuberculosis stamme, kan moontlik die
heterogene gasheer se humorale immuunreaksie verduidelik en daarmee saam die rede
waarom daar nie tot op hede 'n effektiewe sero-diagnostiese toets ontwikkel is nie. Daar is
dus ondersoek ingestel na die potensiaal van sero-diagnose in 'n gemeenskap waar pasiënte
geïnfekteer is met 'n wye verskeidenheid genotipiese stamme. Die IgG vlakke van drie
mikobakteriële antigene het aangedui dat sero-diagnose van tuberkulose moontlik is in hierdie
gemeenskap, ten spyte van infektering deur 'n wye verskeidenheid genotipies-verskillende M
tuberculosis stamme. Die tussenspel van die siekte het teenliggaampie-vlakke beïnvloed wat
v
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daarop dui dat daar versigtig moet gelet word tydens die evaluering van serologiese diagnose
van geïnfekteerde pasiënte wat voorheen siek was.
Hierdie studie toon dat M tuberculosis proteïen-uitdrukking dinamies is en dat die
bacillus 'n groot variëteit van antigene tot die immuun sisteem bied. Dit is moontlik dat
verskillende antigene immuundominant kan word soos wat antituberkulose chemoterapie
toeneem, en dat hierdie verskillend-uitgedrukte antigene as 'n gevolg daarvan gebruik kan
word as voorspellers vir behandeling. Hierdie hipotese is getoets deur die korrelering van
Ag85-spesifieke IgG met die reaksie op behandeling soos geëvalueer deur speeksel-monster
verandering na twee maande se anti-mikobakteriële chemoterapie. Daar was geen
noemenswaardige korrelasie tussen teenliggaampie vlakke en die reaksie op behandeling nie,
wat daaop dui dat die teenliggaampies nie toepaslike surrogaat merkers is nie of dat die
verkeerde teenliggaampie-tipe of mikobakteriële antigeen geselekteer is. Hierdie resultate
bevestig vorige bevindinge waar pasiënt-tot-pasiënt verskille die gasheer se humorale
immuunreaksie gedikteer het.
Die resultate wat uit hierdie studie volg dui dat alhoewel bakteriologiese faktore die
stam-frekwensie kan beïnvloed as gevolg van antigeen-variasie en immuun-ontduiking, kan
beide bakteriologiese en gasheer faktore die humorale immuunreaksie beïnvloed.
Differensiële proteiën uitdrukking deur 'n verskeidenheid M tuberculosis stamme het
potensieël belangrike toepassings vir sero-diagnose en die ontwikkeling van subeenheid of
DNS vaksines wat impliseer dat multi-antigeen mengsels gebruik moet word. Differensiële
proteiën uitdrukking mag ook verduidelik waarom pasiënte nie 'n voldoende beskermende
immuniteit opbou nie en sodoende ontvanklik is vir her-infeksie.
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Chapter 1
INTRODUCTION
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1.1 Tuberculosis: Burden of Disease
2
Tuberculosis (TB) is an ancient disease dating back at least to 5000 BC (Sager et al.
1972). In 1993 the World Health Organization (WHO) declared TB a global health emergency
(WHO, 1993). Despite continuing efforts to control the epidemic, TB is still a major cause of
mortality and morbidity worldwide, resulting in approximately 2 million deaths and 8 million
new cases per year (Corbett et al. 2003). TB is a global problem, although developing countries
in Africa, South East Asia and the Western Pacific are the worst hit, accounting for 80% of the
world's TB burden (Figure 1.1, 1.2, 1.3).
Estimated TB Incidence Rates, 2001
....
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Figure 1.1 The global estimated TB incidence for 2001 (WHO, 2003; http://www.who.int).
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Figure 1.2 The proportion global TB burden in each of the 22 high burden countries, The graph was
drawn usin estimated TB statistics for 2000 Corbett et al. 2003' WHO 2003' htt ://www.who.int .
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Figure 1.3 The TB incidence (blue) and total number ofTB deaths (red) per 100 000, worldwide and for the 22
high burden countries. The graph was drawn using estimated TB statistics for 2000 (Corbett et al. 2003; WHO,
2003; http://www.who,int).
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41.2 Tuberculosis and Human Immunodeficiency Virus - "A new disease"
Coinfection with TB and human immunodeficiency virus (HIV)/Acquired
Immunodeficiency Syndrome (AIDS) is a deadly combination. About 2 billion people (a third of
the world's population) are infected with Mycobacterium tuberculosis, of whom at least Il
million are coinfected with HIV (Corbett et al. 2003; http://www.tballiance.org). TB is the most
common cause of death in HIV/AIDS patients, killing one third of these patients worldwide, and
up to two thirds in some African countries (http://www.tballiance.org).Alinear correlation
between HIV seroprevalence and TB incidence in African countries is observed (Figure 1.4).
HIV is a major risk factor for reactivation of latent TB, increasing the 10% lifetime risk of
reactivation of latent TB to an annual risk of 10% (Bloom and Murray, 1992). HIV/AIDS also
accelerates the progression of TB after primary or reinfection (Daley et al. 1992; Shafer et al.
1995), possibly due to downregulation of cellular immune responses. The effect of HIV/AIDS on
TB transmission is unclear, some studies reporting no effect (Migliori et al. 1994; Tanzania
Tuberculin Survey Collaboration, 2001), while one study has reported that HIV/AIDS does effect
TB transmission (Odhiambo et al. 1999). TB patients infected with HIV often present with
extrapulmonary disease that may be smear negative (De Cock et al. 1992) and are considered to
be less infectious that HIV negative TB patients (Cruciani et al. 2001). Furthermore, TB
enhances HIV replication, accelerating the progression to AIDS and death in dually infected
patients, and reducing transmission (Goletti et a1I996; Toossi et al. 2001).
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Figure 1.4 HIV prevalence and TB burden. UNAIDS estimates of adult HIV seroprevalence
(http://www.unaids.org) and WHO estimates of tuberculosis incidence (Corbett et al. 2003) for the 22 high burden
countries (A) and for the 9 African high TB burden countries (B).
1.3Mycobacterium tuberculosis
In 1882 Robert Koch identified M tuberculosis as the causative agent of TB (Koch,
1882). The genus Mycobacterium consists of more than 70 species that are divided into two
groups according to their generation times on solid media (Figure 1.5). Fast growers require less
than seven days to form colonies, while slow growers form visible colonies only after seven days
(Shinnick and Good, 1994). Slow growers include many pathogenic mycobacterial species, with
the tubercle bacillus M tuberculosis being arguably the most important. M tuberculosis is a
facultative intracellular pathogen with a cell envelope consisting of peptidoglycan, lipids and
glycoplipids such as lipoarabinomannan (LAM). The cell envelope has been implicated in
virulence and resistance to certain antibiotics (Daffé and Draper, 1998), and is also responsible
for acid-fastness of M tuberculosis, the ability to retain a basic fuchsin dye when treated with an
acidified alcohol solution. M tuberculosis has developed successful strategies to evade the host
immune response, and is often referred to as the world's most successful pathogen (Hingley-
Wilson et al. 2003).
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Figure 1.5 Phylogenetic tree of the genus Mycobacterium. The phylogenetic tree was constructed using 16S
rRNA sequence information. Mycobacteria classified as rapid or slow growers are indicated. *M farcinogenes
is a slow-growing mycobacterium. Pathogenic species are underlined. Species belonging to the M tuberculosis
or M. avium complex are indicated. Figure reproduced with kind permission by Dr. NC Gey van Pittius,
Department of Medical Biochemistry, University of Stell enbosch, originally adapted from Shinnick and Good,
1994 and Springer et al. 1996.
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7Clinical strains display a wide spectrum of phenotypes (Mitchison et al. 1963; Sultan et
al. 1960). Studies of virulent (M tuberculosis H37Rv) and avirulent (M tuberculosis H37Ra and
Mycobacterium bovis bacille Calmette-Guérin (BCG» mycobacteria have shown that this may be
mediated by differential capping of LAM, affecting mannose receptor-mediated uptake of
mycobacteria and the rate of mycobacterial proliferation within macrophages (Schlesinger et al.
1996). Intracellular growth rate (Hoal-van Helden et al. 2001a; North and Izzo, 1993a; Silver et
al. 1998; Zhang et al. 1999) and induction of different immunopathological patterns (Bishai et al.
1999; Hoal-van Helden et al. 2001b; Lopez et al. 2003; Manabe et al. 2003; Manca et al. 1999)
may also relate to virulence.
More recently molecular typing of M tuberculosis clinical strains has identified strains
thought to be more virulent or prevalent than others. Examples of these include, CDC1551
(Valway et al. 1998), the C-strain (Friedman et al. 1997), the Beijing or strain W family (Bifani
et al. 2002; Glynn et al. 2002), and subpopulations of the Beijing strain family, strain 210 (Zhang
et al. 1999) and the W4 strain (Bifani et al. 1999). CDC1551 is a clinical strain responsible for
widespread infection in a rural community in the United States (Valway et al. 1998). It was
initially thought that CDC1551 was highly virulent, although later studies have shown that
CDC 1551 is not more virulent but induces a more rapid and vigorous host immune response
(Bishai et al. 1999; Manca et al. 1999). Friedman et al. (1997) reported that the high prevalence
of the C strain may be due to intrinsic resistance to reactive nitrogen intermediates produced by
activated macrophages. The mechanism for the success of the Beijing strain family, measured by
global dissemination, is not known, although Zhang et al. (1999) reported that these strains may
be able to proliferate better in human macrophages.
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8Using the rabbit model, Manabe et al. (2003) demonstrated that the relative pathogenicity
of a specific strain may relate to strain genotype. The genetic variability between clinical isolates
has long been exploited by molecular epidemiological studies. Mycobacterial DNA repetitive
elements have been most commonly used for genotyping (Chaves et al. 1996; Groenen et al.
1993; Supply et al. 2000; van Embden et al. 1993). DNA fingerprinting using the insertion
sequence IS6110 as a probe is the most commonly used method and classifies strains according
to the number of IS6110 elements present within their genome (van Embden et al. 1993).
Recently genomic deletions and single nucleotide polymorphisms have also been identified as a
source of genetic variability (Betts et al. 2000; Fleischmann et al. 2002).
One of the potentially most interesting sources of genetic variation is between members of
the PE (Pro-Glu) and PPE (PPE) protein families. Cole et al. (1998) hypothesized that the PE and
PPE protein families consisting of 99 and 68 members respectively, may be sources of antigenic
variation due to their highly polymorphic C-terminal domains. Variation in the genes encoding
these proteins (Betts et al. 2000; Fleischmann et al. 2002), as well as the mRNA (Flores and
Espitia, 2003) and protein (Banu et al. 2002) expression patterns between clinical isolates support
the hypothesis for their role in antigenic variation. The finding that these proteins are expressed
on the cell-surface (Brennan et al. 2001; Sampson et al. 2002) and are immunodominant antigens
(Espitia et al. 1999; Choudhary et al. 2003; Okkels et al. 2003) further support their role in
antigenic variation, a possible immune evasion mechanism of M tuberculosis.
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91.4 Pathogenesis
The response to M tuberculosis infection, a complex interplay between the pathogen and
the host immune system, has a variety of outcomes (Figure 1.6). The immune response of
individuals can result in elimination of the pathogen (no infection) or long-term containment, but
not elimination of the pathogen in about 90% of individuals (latent infection) (Fenton and
Vermeulen, 1996). Individuals with latent infection are identified by a positive tuberculin (PPD)
skin test without signs of active disease. About 10% of latently infected individuals may develop
active disease during their life (Enarson and Rouillon, 1994). Immunosuppression increases the
risk of reactivation of latent infection (Flynn and Chan, 2001), with HIV coinfection being the
biggest risk factor for reactivation disease, increasing the lifetime risk of 10% to an annual risk of
10% (Bloom and Murray, 1992).-
..,# active disease
/' (-10%)
M. tuberculosis infection
..,# (-10%) ~/' ~ -10% lifetime risk
Exposure .,.,.....-.
latent disease -.. reactivation
(PPD) (-90%) ...........
-10% annual risk (HIV infection)~ no infection
(-90%)
Figure 1.6 Exposure to TB can result in a variety of outcomes.
1.5 Disease pathology
M tuberculosis can cause disease in any organ, although pulmonary disease is the most
common manifestation of tuberculosis in adult humans (Hopewell, 1994). Infection is usually
caused by inhalation of aerosol droplets containing M tuberculosis (Riley et al. 1959). In the
majority of individuals, less than 10% of inhaled M tuberculosis bacilli reach the lung, where
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they are phagocytosed by alveoli macrophages (Fenton and Vermeulen, 1996). Macrophages may
terminate the infection immediately by destroying bacilli. Alternatively, infected macrophages
recruit additional phagocytes, T lymphocytes and natural killer (NK) cells to the site of infection
(Flynn and Chan, 2001). Interaction between these cells leads to interferon gamma (IFNy)
production, causing macrophages to become bactericidal (Flesch and Kaufmann, 1987).
Activated macrophages secrete tumour necrosis factor alpha (TNFa), which initiates granuloma
formation (Flynn et al. 1995) (Figure 1.7). The granuloma, a complex network of macrophages
and lymphocytes that surround the infected cells (Gonzalez-Juarrero et al. 2001; Saunders and
Cooper, 2000) creates a hostile environment that restricts mycobacterial growth, resulting in
containment of the infection (North and Izzo, 1993b; Saunders et al. 1999). Later, granulomas are
encapsulated and the centre of the granuloma becomes necrotic. Encapsulation promotes
mycobacterial containment and these granulomas are signified by small fibrous and calcified
lesions. Alternatively, liquefaction of the granuloma results in the replication and release of
mycobacteria from the granuloma, resulting in destruction of lung tissue, and dissemination to
other parts of the body (reactivated disease) (Dannenberg and Rook, 1994).
Macrophages
Caseous Necrosis
Lymphocytes
Giant Cell
Figure 1.7 Schematic representation of a necrotic granuloma. Figure reproduced with kind permission by
Miss L.Moses, PROMEC unit, Medical Research Council, South Africa.
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1.6 Diagnosis, treatment and vaccination
DOTS (directly observed therapy shortcourse ) is the internationally recommended
strategy to control TB, and aims to detect 70% of sputum smear positive cases and attain 85%
cure rates by 2005. Since its global introduction in 1995, DOTS coverage increased from 22% to
61% worldwide and from 24% to 61% in high burden countries. By the end of 2001, 155
countries, including all 22 of the highest burden countries had adopted DOTS (WHO, 2003;
http://www.who.int) (Figure 1.8).
... I
"
DOTS coverage
o non-DOTS
0< 10%pop
.10-90%pop
• > 900/0pop
o low incidence
o Noreport I I
Figure 1.8 Worldwide implementation of DOTS (WHO, 2003; http://www.who.int).
1.6.1 Diagnosis
DOTS detects highly infectious TB cases by medical evaluation (history and risk
assessment), chest x-ray or microscopic examination. In 2000, DOTS detected only 27% of the
estimated total number ofTB cases (WHO, 2002; http://www.who.int), only increasing by 5% by
the end of 2001 (WHO, 2003; http://www.who.int). The WHO predicts that if this trend
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continues, the 70% target will only be reached by 2012. Explanations for the low case detection
rate include: possible over-estimation of the annual incidence of smear positive pulmonary TB,
limited or no access to health services, presentation to the private health sector, and incorrect
diagnosis due to the quality of the sputum sample, extent of disease, non-specificity, and
laboratory error (WHO, 2003; http://www.who.int). Even if the targeted 70%, or best-case
scenario, 100% of sputum positive cases are detected, this will not represent all TB. Smear
positive TB represents only 45% of the world's total TB burden (Corbett et al. 2003). Diagnosis
of extrapulmonary and childhood TB is extremely difficult and notoriously unreliable
(Bothamley, 1995; Chan et al. 2000). The increase in HIV/AIDS further complicates detection of
smear positive TB, since coinfected patients often present with extrapulmonary TB and maybe
smear negative (Cruciani et al. 2001; De Cock et al. 1992). DOTS aims to detect infectious cases,
however studies have shown that smear negative patients may also transmit TB (Behr et al.
1999a; Coleblunders et al. 2001).
Clinical symptoms of TB include coughing, fatigue, weight loss, fever and hemoptysis
(coughing of blood) (Hopewell, 1994). Risk assessment is by the tuberculin skin test, which
identifies exposure. The test involves intradermal injection of PPD, a crude mixture of M
tuberculosis extracellular proteins (Seibert and Glenn, 1941), and measurement of delayed type
hypersensitivity (DTH) responses (local skin induration and erythma) after 48 to 72 hours
(Huebner et al. 1993; Snider, 1982). The tuberculin skin test is prone to false-positivity, due to
exposure to environmental mycobacteria and BCG vaccination (Daniel and Janicki, 1978; Fine,
1994) and false-negative results, due to anergy, are common in both healthy and
immunocompromised individuals (Toossi and Ellner, 1996). New skin tests incorporating M
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tuberculosis specific antigens are currently being developed (Colangeli et al. 2000; Haga et al.
1995).
Clinical suspicion of TB in smear negative patients may be confirmed by bacteriological
diagnosis. Bacteriological culture can confirm diagnosis in approximately 60% of smear negative
individuals (Levy et al. 1989), but due to the slow growth of M tuberculosis, may take up to 6
weeks before a positive culture is obtained. Radiometric methods (BACTEC 460) can confirm
smear negative disease after approximately 15 days (Pfyffer et al. 1997a, 1997b). New
fluorescent-based culture systems (Mycobacteria Growth Indicator Tube (MGIT) and BACTEC
9000 MB) have been developed with promising results (Chew et al. 1998; Huang et al. 2001;
Pfyffer et al. 1997a, 1997b). However, these techniques require sophisticated equipment and are
therefore currently thought to be too complex and expensive to use in developing countries where
they are most needed.
Another avenue of exploration involves nucleic acid amplification (NAA) assays. To date
the Food and Drug Administration (FDA) in the USA has approved two NAA tests, the Amplicor
Mycobacterium tuberculosis test, and the E-MTD test. The Amplicor Mycobacterium
tuberculosis test involves amplification of the 16S rRNA gene with mycobacterial genus-specific
primers. The sensitivity of the test is 79.4-91.9% and 40-73.1 % in smear positive and smear
negative individuals, respectively (AI Zahrani et al. 2000; Bergmann and Woods, 1996; Stauffer
et al. 1995; Tevere et al. 1996). The E-MTD test involves amplification of mycobacterial RNA.
This test is able to confirm TB in 90.9-95.2% of smear positive, and in 83-100% of smear
negative patients (Bergmann et al. 1999; Gamboa et al. 1998; Smith et al. 1999).
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A large number of serological tests with diagnostic potential have been developed, with a
number of these being commercially available (Chan et al. 2000; Bothamley, 1995; Pottumarthy
et al. 2000). Evaluation of serodiagnostic tests in populations where they are most needed,
namely smear negative, extrapulmonary, tuberculosis meningitis (TBM), and children has
demonstrated sensitivities of 70% (Wilkins and Ivanyi, 1990), 73% (Wilkins and Ivanyi, 1990),
82% (Chandramuki et al. 2002), and 75.5% (Gupta et al. 1997), respectively. Despite these
promising results no serological test has been recommended for clinical use. Current research
efforts are focused on identifying antibodies to multiple M tuberculosis antigens (Chandramuki
et al. 2002; Houghton et al. 2002), antibodies bound in circulating immune complexes (Raja et
al. 2002), and antibody-antigen avidity (Arias-Bouda et al. 2003).
Another possibility for a diagnostic test is measurement of T cell responses to M
tuberculosis species specific antigens. ESAT6, a protein secreted by members of the M
tuberculosis complex but not by Mbovis BCG (Harboe et al. 1996; Behr et al. 1999b) and the
majority of environmental mycobacteria (Harboe et al. 1996; Pollock and Andersen, 1997) is the
most promising. Despite doubts being raised about the species specificity of ESAT6 (Gey van
Pittius et al. 2001), studies have demonstrated the potential of ESAT6 as a diagnostic agent for
TB (Doherty et al. 2002; Lalvani et al. 2001; Lein et al. 1999; Ulrichs et al. 1998). These studies
have shown that ESAT6 is recognized by a variety of different HLA types, identifies subclinical
infection, is useful to distinguish between Mbovis BCG vaccination and M tuberculosis
infection, and can differentiate between pulmonary disease due to M tuberculosis and M avium.
Hussain et al. (2002) reported that T cell responses to M tuberculosis culture filtrate proteins
may also have diagnostic potential.
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Diagnostic tests that are dependent on an intact host immune system may be adversely
affected by HIV/AIDS, fuelling the development of tests that measure mycobacterial antigen.
Measurement of M tuberculosis Ag85 in serum is able to discriminate between TB patients and
healthy individuals (Bentley-Hibbert et al. 1999; Landowski et al. 2001), BCG vaccination and
M tuberculosis infection (Landowski et al. 2001) and disease due to M tuberculosis and M
avium (Bentley-Hibbert et al. 1999). Mycobacterial antigen detection in cerebrospinal fluid
(CSF) has also shown promise for the diagnosis of TBM (Radhakrishnan et al. 1991; Sada et al.
1983).
1.6.2 Treatment
TB is treated in a recommended standard protocol usually involving a combination of four
drugs, isoniazid, ethambutol or streptomycin, rifampicin and pyrazinamide over a period of six to
eight months (http://www.who.int). DOTS treatment is supervised by a health care worker or
volunteer, especially during the intensive phase (first two months) of treatment. Patient progress
and treatment outcome is monitored, recorded and reported to the national health department. The
WHO reported that by the end of2001, 82% of DOTS registered cases were successfully treated.
This varied from 73% in Africa to 92% in the Western Pacific region. The lower level of
treatment success in Africa is due to death of 7% of patients, 10% of patients defaulting, 7% of
patients being transferred to other clinics without follow up, and 3% of patients were not
evaluated. The limitations of the DOTS programme include lack of qualified staff,
decentralization of health care systems, lack of political commitment and inadequate drug supply.
These have all led to the emergence of multiple drug resistant (MDR) M tuberculosis strains,
defined as those strains resistant to at least isoniazid and rifampicin (Kochi et al. 1993). At least
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4% of TB cases are MDR, and in 1998 the WHO introduced DOTS-Plus, a strategy to aid the
management ofMDR-TB (http://www.who.int).
No novel TB drugs have been introduced smee rifampicin m 1972
(http://www.tballiance.org). Patient default (non-compliance) is linked to the lengthy duration of
antimycobacterial chemotherapy, and therefore new drugs, which will shorten the length of
treatment, are urgently needed (O'Brien and Nunn, 2001). The biological difficulty of working
with M tuberculosis, the lack of investment in tuberculous research by pharmaceutical
companies due to the lack of perceived commercial return, the cost of drug development,
pressures on pricing and access, and the length and cost of clinical trials are major obstacles
facing tuberculosis drug development (Duncan, 2003).
1.6.3 Vaccination
Vaccination is considered the most successful prophylactic measure against infectious
disease in general. Most vaccines currently available are targeted against extracellular pathogens
and viruses, and induce humoral immunity (Seder and Hill, 2000). However, immunity to TB
requires induction of cell-mediated immune responses and is not as simple as influenza, smallpox
or polio virus vaccines which only require neutralizing antibodies.
1.6.3.1 The BeG vaccine
The attenuated strain of Mycobacterium bovis, Bacille Calmette-Guérin (BeG) was
introduced as a vaccine to try to protect against TB in 1921 (Weill-Hallé and Turpin, 1925).
Since then it has been administered to more than 3 billion people worldwide, being the most
widely used vaccine today (Fine et al. 1989). BeG vaccination is considered safe, although
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disseminated BeG can occur in individuals who are immunocompromised (Talbot et al. 1997)
and in those suffering from defects in their IFNy receptor or IL12 genes (Dëffinger et al. 2002).
BeG confers protection by enhancing cell-mediated immunity and controlling mycobacterial
replication after establishment of infection (Marchant et al. 1999). BeG is administered to
newborns in many countries throughout the world, and may effectively prevent childhood
disease. However, the efficacy of BeG against pulmonary disease in adults is questionable (Stern
et al. 1998). A variety of factors such as BeG strain type, dosage, genetic differences between
populations and prior exposure to environmental mycobacteria (Fine, 1995) may explain the
variable protective efficacy of BeG. Recently Lopez et al. (2003) reported that M tuberculosis
strain type may also affect the protection afforded by BeG. Attempts to improve the efficacy of
BeG by two successive BeG vaccinations have been unsuccessful (Karonga Trial Prevention
Group, 1996). However boosting (Brooks et al. 2001) and priming BeG (Feng et al. 2001) with
vaccines that are not dependent on mycobacterial replication has shown promising results.
1.6.3.2 Vaccine development
The development of a more effective vaccine against TB is a major priority (Andersen,
2001; Brennan and Fruth, 2002). These include the development of both prophylactic and
immunotherapeutic vaccines. Areas of vaccine research include the development of recombinant
and auxotrophic BeG and M tuberculosis, and subunit vaccines and DNA vaccines expressing
antigens of interest.
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1.6.3.2.1 Recombinant and auxotrophic vaccines
Live vaccines have the advantage of antigen persistence and inducing optimal protection
since they produce most of the antigens present in vivo (Andersen, 2001). A recombinant BCG
(rBCG) vaccine is BCG modified to express antigens considered to be important, especially those
thought to have been lost during the attenuation of BCG (Behr and Small, 1997). Potential rBCG
vaccines developed include those expressing mycobacterial antigens (Bao et al. 2003; Horwitz et
al. 2000; Horwitz and Harth, 2003; Pym et al. 2003) or Thl inducing cytokines (Murray et al.
1996; O'Donnell et al. 1994; Slobbe et al. 1999; Young et al. 2002).
BCG and M tuberculosis auxotrophic mutants have also been developed. These
nutritionally deficient strains are avirulent and may result in active mycobacterial replication, but
the duration of the infection in host cells is limited. Chambers et al. (2000) reported that a leucine
auxotroph of BCG was able to protect guinea pigs, without sensitization to tuberculin, while
Guleria et al. (1996) developed an auxotrophic mutant that was protective and safe in
immunocompromised mice. Auxotrophic mutants of M tuberculosis were shown to be protective
in guinea pigs (Hondalus et al. 2000; Jackson et al. 1999). Deletion ofRD1, a region absent from
the genome of all BCG strains (Behr et al. 1999b), from M tuberculosis resulted in decreased
virulence and is a possible candidate for an attenuated vaccine strain (Lewis et al. 2003). Studies
have also employed signature-tagged mutagenesis to develop attenuated mutants (Camacho et al.
1999; Cox et al. 1999).
1.6.3.2.2 Subunit and DNA vaccines
Concerns that live vaccines are unsafe in immunocompromised individuals have directed
vaccine development toward subunit and DNA vaccines. These vaccines have the added
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theoretical advantage of including only protective antigens, while excluding disease-enhancing
antigens (Turner et al. 2000; Yeremeev et al. 2000). Subunit vaccines consist of mycobacterial
antigens that have been identified as both immunogenic and protective in a suitable adjuvant.
Promising results have been achieved using mycobacterial culture filtrates (Andersen, 1994; Pal
and Horwitz, 1992), members of the antigen 85 (Ag85) complex (Horwitz et al. 1995), the 38
kDa phosphate-binding protein (Falero-Diaz et al. 2000), ESAT6 (Brant et al. 2000; Olsen et al.
2000), heat shock protein 65 (Silva, 1999) and an Ag85BlESA T6 fusion protein (Olsen et al.
2001). Brandt et al. (2002) showed that in contrast to BCG, the efficacy of subunit vaccines is not
affected by prior exposure to environmental mycobacteria. Although subunit vaccines and
adjuvants are highly specific and have a low risk of side effects, their immunostimulatory and
protective efficacy is generally weaker than BCG in animal models.
DNA vaccination involves immunization with a plasmid vector encoding the gene of
interest directly into the skin, resulting in endogenous production of the vaccine antigen. DNA
vaccination induces both long-lasting humoral and cellular immunity, does not require adjuvants,
and is easy and inexpensive to develop (Huygen, 1998). A number of candidate antigens, such as
ESAT6 (Kamath et al. 1999; Lowrie et al. 1999), Ag85 (Kamath et al. 1999), Hsp65 (Lowrie et
al. 1999; Tascon et al. 1996), Hsp70 (Lowrie et al. 1999), MPT64 (Delogu et al. 2000; Kamath et
al. 1999), MPT63 and MPT83 (Morris et al. 2000), and MPT41 (Skeiky et al. 2000), have been
investigated with variable levels of success. Modifications of conventional DNA vaccination
include, "heterologous boosting" or "prime boosting" (McShane et al. 2001), co-immunization
with multiple DNA vaccines (Kamath et al.1999; Morris et al. 2000), co-expression of cytokines
and mycobacterial proteins (Martin et al. 2003), and co-delivery of DNA and subunit vaccines
(Kwissa et al. 2003).
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1.7 Host defence mechanisms
TB immunity involves a complex interplay between macrophages, lymphocytes and
cytokines, briefly outlined below.
1.7.1 Macrophages
Macrophages are the first line of defence against invading mycobacteria. They are innate
cells that recognize and engulf mycobacteria using a variety of cell surface receptors (Ernst,
1998). After internalization, macrophages process the antigens for presentation to the adaptive
immune system. Macrophages may also terminate the infection using a variety of killing
mechanisms, such as phagosome acidification and phagosome-lysosome fusion (Deretic and
Fratti, 1999) and production of reactive oxygen and nitrogen intermediates (Zahrt and Deretic,
2002).
1.7.2 T lymphocytes
T lymphocytes are involved in protection against TB, and T cells expressing the
alpha/beta (aJ3) T cell receptor, also known as CD4+ and CD8+ T cells, are crucial for TB
immunity. CD4+ T cells are the major effector cells in cell-mediated immunity to TB (Flynn and
Chan, 2001). These cells recognize antigens presented by MHC class II molecules on the surface
of antigen presenting cells, and secrete cytokines that stimulate intracellular killing of infected
macrophages. CD4+ T cells, also known as T helper (Th) cells, are divided into groups Thl and
Th2, according to their pattern of cytokine secretion (Modlin, 1994). CD8+, or cytolytic T cells
are also important in protection against TB (Smith and Dockrell, 2000), and recognize antigens
presented by MHC class I molecules. These cells lyse infected macrophages, thereby releasing
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mycobacteria possibly for ingestion and destruction by more efficient macrophages (Flynn and
Chan, 2001). CD4+ T cells are important during active infection, while CD8+T may be important
in protection against reactivation of latent disease (Van Pinxteren et al. 2000).
1.7.3 Cytokines
Coordinated expression of cytokines is required for protective immunity. It is thought that
a Thl-type response, characterized by production ofinterleukin 12 (ILI2) and IFNy in particular,
is required for protection, while a Th2-type response, associated with production of IL4, amongst
others, is considered non-protective. The relative contribution of these cytokine patterns in TB
immunity is controversial (Flynn and Chan, 2001; Jung et al. 2002). Mycobacterial infection
induces IL12 production by macrophages which stimulate the production of IFNy in activated
Thl cells (Murphy et al. 1994). Defects in IL12 (Cooper et al. 1997; Frucht and Holland, 1996)
and IFNy (Cooper et al. 1993; Flynn et al. 1993) production are associated with increased
susceptibility to mycobacterial infections. During infection, macrophages secrete TNFa, which
activates macrophages to inhibit mycobacterial growth and also promotes granuloma formation
(Flynn et al. 1995). IFNy, together with TNFa are the main triggering agents for macrophages to
become bactericidal (Flesch and Kaufinann, 1990). Response to TNFa also includes tissue
damage over time.
The differentiation of naïve T cells into Th 1 or Th2 is determined by the local cytokine
environment. IL4 stimulates a Th2 response, while IL12 stimulates a Thl response (Constant and
Bottomly, 1997). A Th2-type response induces B cell proliferation and drives antibody
production (Lundgren et al. 1989; Punnonen and de Vries, 1994). The dose of antigen affects the
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cytokine response, with a very low or very high antigen dose promoting a Th2 response, while a
moderate dose predisposes naïve cells to become Thl (Power et al. 1998; Rogers et al. 2000).
Infection with M tuberculosis induces a Th 1 response with a switch to a Th2 response after the
infection is cleared, thus preventing host tissue destruction (Sander et al. 1995).
1.7.4 Humoral immunity
B cells and antibodies are generally considered non-protective In TB. Studies have
reported that cellular and humoral immunity is inversely related (Bhatnager et al. 1977; Daniel et
al. 1981; Lenzini et al. 1977), and that antibodies and immune complexes are
immunosuppressive in TB (Campa et al. 1986; Torres et al. 1994). However, recent findings
support a role for antibodies in protection against TB. Antibodies to mycobacterial surface-
exposed epitopes enhance survival of animals experimentally infected with mycobacteria
(Teitelbaum et al. 1998), affect clearance and organ distribution of mycobacterial virulence
factors (Glatman-Freedman, 2000), interfere with mycobacterial dissemination (Pethe et al.
2001), and induce TNFa production (Hussain et al. 2000; 2001). A role for B-cells in protection
against TB, specifically granuloma formation, was reported by Bosio et al. (2000). In 1998 it was
proposed that the controversy surrounding the role of antibodies in TB pathogenesis is due to the
presence of protective, non-protective, and disease-enhancing antibodies in polyclonal antibody
preparations (Glatman-Freedman and Casadevall, 1998).
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1.7.5 Host immunogenetics
The importance of host factors in TB immunity is inferred from familial clustering noted
as far back as the 1ih century (Dubos and Dubos, 1987), and was confirmed by studying disease
concordance in monozygotic and dizygotic twins (Comstock et al. 1978). More recent studies
have reported that MHC affects both CD4+ T cell (Agrewala and Wilkinson, 1999) and antibody
responses (Bothamley et al. 1989). A number of susceptibility genes have been identified,
including the natural resistance associated macrophage protein 1 (NRAMP 1) gene, now known as
the solute carrier family 11A member 1 (SLC 11Al) gene (Bellamy et al. 1998a), the vitamin D
receptor gene (Bellamy et al. 1999) and those encoding proteins essential for the Th 1 type
immune response (Ottenhoff et al. 2002; Rossouwet al. 2003).
1.8 Proteomics
Sequencing of the genome of M tuberculosis H37Rv (Cole et al. 1998) and CDC1551
(Fleischmann et al. 2002), and the development of sensitive mass spectrometry techniques to
identify proteins have facilitated the study of M tuberculosis proteomics. The total protein
complement of the genome is defined as the "proteome" (Wasinger et al. 1995). Analysis of the
proteome identifies which genes are really expressed, as the presence of a gene does not imply
expression (Andersen et al. 1992), and genetic conservation between strains may not mean
similar protein expression patterns (Betts et al. 2000). A recent study by Jungblut et al. (2001)
identified 6 proteins not originally predicted from open reading frames (ORFs) from the genome
sequence, illustrating the importance of proteomics. Conventional expression proteomics relies
on high-resolution two-dimensional (2D) gel electrophoresis, mass spectrometry and database
searching for protein identification (Figure 1.9) (Blackstock and Weir, 1999). Using 2D
electrophoresis, proteins are separated according to their isoelectric points in the first dimension
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(isoelectric focusing (lEF)) and then according to molecular weight in the second dimension
(O'Farrell, 1975). Proteins are visualized and quantified by radiolabelling, staining with
Coomassie-blue, silver or fluorescent dyes.
Proteomics has been used as a tool to study protein expression under supposed host-
relevant conditions in order to gain insight into mechanisms of pathogenicity (Betts et al. 2002a;
Boon et al. 2001; Lee et al. 1995; Monahan et al. 2001; Yuan et al. 1996), identify antigens for
subunit or DNA vaccines (Covert et al. 2001; Rosenkrands et al. 2000a, 2000b; 2002), identify
new diagnostic markers (Hendrickson et al. 2000), and to identify virulence factors (Betts et al.
2000; Jungblut et al. 1999; Mattow et al. 2001).
Strain A or condition 1 (eg. aerobic growth) Strain B or condition 2 (eg. anaerobic growth)
2Dgel
electrophoresis
. I.
·,tt .'
t
i mage analysis
and spot comparison
· ..' t Spot excision
I • • and trypsin digestion
Il .I
Mass spectrometry
and database search
Figure 1.9 Proteomics. Proteins extracted from two different mycobacterial strains or from two
different growth conditions are separated by two-dimensional gel electrophoresis. After
electrophoresis gels are stained and compared, spots of interest are excised from gels, digested with
an enzyme, usually trypsin, and proteins identified using mass spectrometry and database searching
(Figure adapted from Betts, 2002b).
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1.9 Objectives
1.9.1 Part 1
Protein expression and antigen recognition patterns of clinical isolates will be investigated
to gain insight into:
a) Immune evasion mechanisms and strain prevalence
Immune evasion due to differential protein expression has been reported for a number of
pathogens (Smith et al. 2002). It was decided to investigate this phenomenon in M
tuberculosis by comparing protein expression patterns of two local clinical isolates that differ
in their frequency in a high incidence TB community (Warren et al. 2000). Differential
protein expression by these clinical strains may relate to strain prevalence and may explain
why strain SAWC1524 is at least 10 fold more frequent than strain SAWC1296 (Warren et
al.2000).
b) Exogenous reinfection and failure of serological tests
Differential gene expression by M tuberculosis strains as they infect and cause disease in
different individuals may explain why patients are susceptible to exogenous reinfection (van
Rie et al. 1999a), even after successful cure. Differential gene expression may also explain
some of the humoral heterogeneity amongst TB patients (Lyashchenko et al. I998a), and why
no serodiagnostic test for TB has been developed to date (Bothamley, 1995; Chan et al.
2000).
Protein expression patterns will be analysed using one-dimensional and two-dimensional
polyacrylamide gel electrophoresis. Expression of selected M tuberculosis proteins will be
monitored by Western blot analysis with monoclonal antibodies specific to the proteins of
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interest. Antibodies are markers of antigen expression in vivo, therefore antigen presentation
by the strains will be analysed using one-and two-dimensional Western blotting, where
proteins extracted from each of the three strains will be probed with plasma or sera from TB
patients.
1.9.2 Part 2
Investigate antibody responses of TB patients to:
a) assess the potential of serodiagnosis in a high incidence TB setting
Early identification and treatment of TB patients is crucial to limit disease transmission
and thereby control the epidemic. However, the current methods used to diagnose TB are
inadequate, thereby sparking interest into the development of alternate methods to diagnose
TB. Serodiagnosis has shown potential, however, no test has yet been accepted for clinical
use (Bothamley, 1995; Chan et al. 2000). It is thought that the failure of serodiagnosis is due
to the heterogeneous host humoral immune response (Lyashchenko et al. 1998a), which is
due to, amongst other things, differential gene expression by M tuberculosis strains as they
infect and cause disease in different individuals. TB patients in high incidence settings may
be infected with a wide variety of genotypically and phenotypically different M tuberculosis
strains (van Helden et al. 2002). Differential protein expression by these strains may explain
the humoral heterogeneity amongst TB patients. To investigate the potential of using serology
to diagnose TB in a high incidence setting we will measure IgG levels to three mycobacterial
antigens. Furthermore, IgG levels will be correlated with patient smear status, disease episode
and the genotype of the infecting M tuberculosis strain.
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b) identify a potential biomarker that will predict treatment response
The lengthy course of antimycobacterial chemotherapy results in high levels of treatment
failure due to patient non-compliance (WHO, 2003; http://www.who.int). One of the biggest
obstacles facing the development of new drugs is the clinical assessment of drug efficacy.
The identification of biomarkers, which can be used to speed up the evaluation of new drugs,
is urgently needed (Duncan, 2003). Studies have reported that the antibody profile of TB
patients changes during antituberculosis chemotherapy (Bothamley et al. 1992a; Imaz and
Zerbini, 2000). We decided to dissect the IgM and IgG response of TB patients at diagnosis
and after four weeks of chemotherapy to determine whether IgM or IgG levels could
potentially be used as markers to evaluate treatment efficacy.
This thesis is divided into 8 chapters, consisting of a literature review chapter, six chapters
which are presented as manuscripts and a general discussion and conclusion chapter. Introductory
material and methodology may be repeated throughout the thesis, because of this. For ease of
referencing, literature cited in each of the chapters has been listed at the end.
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Chapter 2
OPTIMISATION OF TECHNIQUES
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2.1 Introduction
This chapter describes optimisation of some of the techniques used in this study,
specifically two-dimensional polyacrylamide gel electrophoresis (chapter 4 and 5), enzyme-
linked immunosorbent assay (chapter 3, 4, 5, 6 and 7), and one-dimensional (chapter 3, 4 and 5)
and two-dimensional (chapter 4 and 5) Western blotting. The detailed protocols for these
techniques are described in the chapters where they are used.
2.2 Two-dimensional polyacrylamide gel electrophoresis
Proteomics is dependent on high resolution two-dimensional (2D) polyacrylamide gel
electrophoresis (PAGE), first introduced by O'Farrel in 1975 (O'Farrell, 1975). Proteins, due to
their amphoteric nature, are separated by isoelectric focusing in the first dimension, and then
separated according to relative molecular weight in the second dimension. Gels are usually
stained with silver (detection limit of I-lOng) and compared by visual examination or using
sophisticated computer programs. If interesting protein spots are noted, gels are rerun and
proteins visualized with a stain compatible with mass spectrometry. Spots of interest are excised
from the gel, digested with an enzyme, usually trypsin, and proteins identified using mass
spectrometry and database searches. The following section describes some of the optimisation
steps used.
2.2.1 Sample preparation
M tuberculosis proteins were extracted by glass bead homogenization in a ribolyser,
where the abrasive action of the vortexed beads breaks cell walls, thereby liberating the contents
of the cell. Cells were disrupted in a SDS-Iysis solution, containing phenylmethylsulfonyl
fluoride (PMSF) to inhibit serine proteases. Addition of a cocktail of inhibitors, including serine
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protease, cysteine protease and metalloproteases inhibitors (Complete Protease Inhibitor Cocktail,
Roche Molecular Biochemicals, Mannheim, Germany) to the lysis buffer resulted in better
quality gels (Figure 2.1).
Figure 2.1 Effect of adding a protease inhibitor cocktail. Inclusion of
only PMSF in the lysis solution resulted in poor quality gels (A and
B). Addition of a protease inhibitor cocktail to the lysis buffer resulted
in increased spot definition and improved quality of gels (C and D).
2.2.2 Isoelectric focusing
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Proteins were separated in the first dimension using commercially available immobilised
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pH gradient (IPG) strips (Gërg et al. 2000). Due to ease and high protein loading ability,
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rehydration of lPG strips in the presence of sample is preferred to sample cup application. These
two methods of sample loading, using two different concentrations of sample and two different
running conditions, were compared. Results showed no significant differences between the two
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methods, although the use of sample cups resulted in some precipitation at the point of
application (Figure 2.2). Rehydration loading was adopted for all future work. Neither isoelectric
focusing using 43 600 Vh or 61 100 Vh, nor using 15 ug or 20 ug of protein significantly
affected protein separation (Figure 2.2). Improved sample separation was obtained using pH 4-7
lPG strips compared to pH 3-10 !PG strips (data not shown). Horizontal streaking or
incompletely focused spots, possibly due to ionic impurities in the sample, was observed. Instead
of desalting the sample by dialysis, or precipitation with trichloroacetic (TeA) acid and acetone,
which can result in protein losses, the isoelectric focusing protocol was modified, by adding a
pre-step of 100 V for 2 hours, allowing the ions in the sample to move to the ends of the lPG strip
and resulting in better quality gels (data not shown).
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Figure 2.2 Isoelectric focusing conditions. Addition of samples to rehydration buffer (A, C, E, G) and to sample cups
(B, D, F, II) were compared using 20 ug of protein and 43 600 Vh (A, B, E, F) and 15 ug of protein and 61 100 Vh
(C, D, G, II).Arrows indicate the direction in which the first and second dimension electrophoresis was performed.
The vertical smears on the gels represent sample precipitation due to sample cup loading.
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2.3 Enzyme-linked immunosorbent assay
The quantification of antigens and antibodies in biological samples has been facilitated by
the enzyme-linked immunosorbent assay (ELISA), which was first described in 1971 (EngvalI
and Perlman, 1971). Subsequent adaptation of the ELISA to the microtiter plate format has
resulted in widespread application (Daniel and Debanne, 1987). Antibodies, antigens or
carbohydrates are passively adsorbed to a solid-phase, usually plastic, whereafter subsequent
reagents are added and unreacted materials are washed away. The addition of an enzyme-labelled
reagent, followed by the relevant substrate, causes a colour change from which the biological
activity of the sample can be determined. In this study, indirect and sandwich ELISAs were
applied to quantify antigen in a complex mixture of M tuberculosis proteins using monoclonal
antibodies (mAbs) specific to the antigen of interest, and to quantify antibody (IgM, IgG and IgG
subclasses) responses in TB patients. This section will discuss some of the steps used to optimise
the indirect ELISA. Optimisation of the sandwich ELISA will be discussed in chapter 7.
2.3.1 Antigen concentration
It is important to assess the effect of different antigen concentrations, since antigen
concentration may affect the outcome of the ELISA. To determine the optimal concentration of
whole-cell lysate and culture filtrate proteins for coating we used Purified Protein Derivative
(PPD), since PPD was readily available and also consists of a complex mixture of M
tuberculosis proteins. The optimal concentration of PPD was determined by titrating various
concentrations against plasma from TB and control individuals (Figure 2.3). A plateau region
was observed when coating wells of ELISA plates with 0.5 ).lgof PPD, implying that the binding
capacity of the polystyrene plates has been reached and that no more antigen can bind. High
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concentrations of antigen may inhibit antibody binding through steric hindrance, or may increase
stacking or layering of antigen, resulting in a less stable interaction with subsequent reagents
(Cantarero et al. 1980).
2
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PPD concentration (uglwell)
Figure 2.3 ELISA to optimise antigen concentration. Concentrations of PPD ranging from
0.2 ug to 4 ug per well were probed with plasma from TB (clear bars) and control
individuals (shaded bars). Each bar represents the average of two measurements. Error bars
show the standard deviations from the mean.
2.3.2 Secondary antibody concentration
The optimal dilution of horseradish peroxidase (HRP) conjugated goat anti-human
immunoglobulin G (lgG) was determined by titrating various dilutions (l:1 000; 1:2 500; 1:5
000; 1:10000; 1:12 500; 1:15 000) against PPD. Dilutions between 1:1 000 and 1:12 500 resulted
in no significant difference (Figure 2.4), suggesting that saturating concentrations were achieved.
AI: 10 000 dilution was used for future work because it occurred in a non-critical region where
the OD values plateau.
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Figure 2.4 ELISA to optimise secondary antibody concentration. The optimal
dilution of HRP-conjugated goat anti-human IgG was determined by titrating various
dilutions against 1 ug per well of PPD, using al: 100 dilution of plasma from a TB
patient. Each bar represents the average of two measurements. Error bars show the
standard deviations from the mean.
2.3.3 Plasma dilution
The effect of plasma dilution on reactivity of samples from TB and control individuals
was investigated. Various dilutions of plasma were tested against PPD (Figure 2.5). A stepwise
decrease in reactivity was observed using higher dilutions of plasma, with a dilution of 1:10
showing the highest reactivity, and a dilution of 1:400 showing the lowest reactivity for both TB
and control individuals. Results suggest that a number of plasma dilutions should be analysed
since single dilutions may be inaccurate, for example a 1:400 plasma dilution did not accurately
distinguish between TB patients and controls in this investigation.
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Figure 2.5 The effect of plasma dilution on reactivity of samples. Plasma samples from TB
(clear bars) and control (shaded bars) individuals were diluted between 1:10 and 1:400 and
reacted with PPD. Each bar represents the average of two measurements. Error bars show the
standard deviations from the mean.
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2.3.4 Discrimination between TB patients and control individuals
The use of serodiagnosis for tuberculosis is hampered by the presence of cross-reactive
antibodies in control individuals (Laai et al. 1997). It was hypothesized that optimal ELISA
conditions should allow better discrimination between TB patients and control individuals. To
determine the effect of plasma dilution and incubation temperature on the discrimination between
TB and control individuals, different dilutions of plasma at room temperature (RT) and at 37°C
were analysed. Plasma samples were probed against PPD, M tuberculosis H37Rv whole-cell
lysate and culture filtrate proteins (CFP), and E. coli whole-cell lysate proteins. Table 2.1 shows
the ratios obtained by dividing the 00450 readings obtained with TB plasma by the 00450
readings obtained with control individuals, for each of the antigens tested at RT and at 37°C. The
best discrimination between TB patients and control individuals (highest ratio) was achieved
using 1:300 plasma dilutions, possibly due to the diluting out of non-specificity. The
discrimination between patients and controls was further improved by incubation at 37°C. The
difference between TB and control individuals was greater (higher ratios) when measuring
reactivity against M tuberculosis antigens compared to E. coli antigens (smaller ratios). This is
expected because all individuals (healthy or diseased) have E. coli reactive antibodies (Laai et al.
1997). For M tuberculosis antigens, the discrimination between TB patients and control
individuals was greater for PPD and M tuberculosis culture filtrate proteins compared to whole-
cell lysate proteins. Whole-cell lysates contain most of the regulatory proteins which are
conserved throughout bacteria (Shinnick et al. 1988), whereas culture filtrates contain mostly
secreted proteins, which are specific to M tuberculosis (Andersen et al. 2000).
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Table 2.1 Response of TB and control individuals towards PPD, M tuberculosis H37Rv whole-cell lysate
(WCL) and culture filtrate (CF) proteins, and E. coli whole-cell lysate (WCL) proteins. The differences
between the two groups of individuals were calculated according to the formula 450 run TB/450 nm control. so that the
numbers represent the ratio between TB and control individuals as explained.
RT 37°C
1:200 1:300 1:400 1:200 1:300 1:400
PPD 5.62 7.66 6.6 6.44 8.34 7.62
H37RvWCL 3.22 4.89 3.6 3.9 5.9 6.2
H37RvCF 5.28 7.54 6.77 5.46 8 7.6
E.coliWCL 1.4 1.48 1.2 1.33 1.61 1.29
2.4 Western blotting
The combination of gel electrophoresis and specific localization of antigen on the basis of
its interaction with a specific antibody and its relative molecular weight was first described by
Burridge in 1976 (Burridge, 1976). In his approach, antigen was directly detected on the gel,
although transfer of proteins from the gel onto a membrane support, usually nitrocellulose, and
then probing with specific antibodies has now become the method of choice (Burnette, 1981;
Towbin et al. 1979). Western blotting is a robust, relatively simple, and sensitive technique and is
a commonly used technique to calculate the relative abundance of a specific protein in a complex
mixture, or to characterize new antibody preparations. Most gel electrophoresis techniques
involve denaturation of the protein sample, so the major constraint of Western blotting is that
antibodies will only bind denaturation-resistant (linear) epitopes. In this study, Western blot
analysis was applied to analyse expression of specific M tuberculosis proteins by probing crude
cell lysates and culture filtrates with mAbs, and to investigate the host humoral immune response
to M tuberculosis antigens. For increased resolution, both ID and 2D Western blotting were
36
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used. Western blotting using mAbs did not require optimisation as they were diluted according to
the manufacturer's instructions. Western blotting with patient samples required optimisation, and
will be discussed.
2.4.1 One-dimensional Western blotting
Western blot analysis using minigels showed that TB patients and control individuals
generally recognised the same proteins in whole-cell Iysates and culture filtrates from M
tuberculosis H37Rv and Mbovis BeG (Figure 2.6). Quantitative differences between TB and
control individuals were noted, which has been previously reported by Rojas-Espinosa et al.
(1999). To improve resolution so that differences between TB and control individuals could be
identified, Western blotting with larger format gels (14x14 cm) was attempted (Figure 2.7).
Larger gels resulted in improved resolution, although a broad diffuse smear between 30 kDa and
40 kDa obscured proteins in this region. This smear probably corresponds to lipoarabinomannan
(LAM) (Hunter et al. 1986), a cell wall glycolipid and virulence factor (Daffé and Draper, 1998).
High backgrounds, which varied from sample to sample, were observed (data not shown). This is
possibly due to the sensitivity of the detection system used, prompting us to investigate alternate
detection systems.
A B
2 3 4 5 6 2 3 4 5 6
97kDa 97kDa
66kDa 66kDa
36 kDa 36 kDa
29kDa
20kDa
14.2 kDa 14.2 kDa
6.5 kDa 6.5 kDa
Figure 2.6 Western blot analysis of TB and control individuals using minigels. Ten micrograms of M.
tuberculosis H37Rv whole-cell lysate (lanes 1, 2), M. bovis BCG whole-cell lysate (lane 3), H37Rv
culture filtrate (lanes 4, 5), and BCG culture filtrate (lane 6) was separated by 12% SDS-PAGE,
transferred to nitrocellulose, and probed with plasma from TB patients (A) and control individuals (B).
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Figure 2.7 Western blot analysis of TB and control individuals using large
gels. M tuberculosis H37Rv culture filtrate proteins (50 ug, lane 1; 100 ug
lane 2) was separated by 12% SDS-PAGE, transferred to nitrocellulose, and
probed with various dilutions of plasma (A, 1:100; B, 1:200; C, 1:300; D,
1:400). Blots were developed using the ECL™ Western blotting detection
system.
The ECL™ Western blotting detection system (Amersham Pharmacia Biotech, Little
Chalfont, UK) is reported to be approximately 20 fold more sensitive than chromogenic detection
systems and has become the method of choice to detect antibodies bound to proteins immobilized
on membranes. The system produces chemiluminescence when horseradish peroxidase,
conjugated to the secondary antibody, catalyses the oxidation of luminol in the presence of
hydrogen peroxide. Results showed high backgrounds in certain cases, varying from patient to
patient (data not shown). It has been reported that iron in the heme group of red blood cells can
react with luminol, producing luminescence (Laux, 1991). It was hypothesized that hemolysis in
plasma samples was responsible for the high backgrounds observed and therefore the TMB and
the BCIPINBT colorimetric detection systems (Kirkegaard and Perry Laboratories Inc.,
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Gaithersburg, USA) were investigated. The TMB (3,3' ,5,5'-tetramethylbenzidine) detection
system produces a blue colour when horseradish peroxidase, coupled to the secondary antibody,
reacts with hydrogen peroxide. The BCIPINBT (5-bromo-4-chloro-3-indolyl-phosphate/nitroblue
tetrazolium) detection system produces a black/purple precipitate when alkaline phosphatase,
conjugated to the secondary antibody, dephosphorylates BCIPINBT. Comparison of the TMB,
BCIPINBT, and ECL detection systems supported the hypothesis that the high background
observed with ECL was probably due the reaction between the iron group in patient plasma
samples and the luminol in the ECL system (Figure 2.8). The BCIPINBT detection system was
thus chosen since this system was more sensitive and displayed decreased fading compared to the
TMB system.
1 2 3 4 5 6
Figure 2.8 Western blot analysis using different detection systems.
M tuberculosis whole-cell lysate (lanes 1, 3, 5) and culture filtrate
(lanes 2, 4, 6) proteins were separated by SDS-PAGE, transferred to
nitrocellulose, and probed with plasma pooled from TB patients.
Blots were developed using the BCIPINBT (lanes 1,2), TMB (lanes
3,4) and the EeL (lanes 5, 6) detection systems.
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2.4.2 Two-dimensional Western blotting
Two-dimensional (20) Western blotting was employed to increase the resolution obtained
from IDWestern blotting. Proteins were separated by 20 PAGE and transferred to nitrocellulose
or PVDF (polyvinylidenedifluoride) membranes using tank electroblotting, where the gel-
membrane sandwich is placed in a vertical buffer tank with platinum electrodes. To check the
efficiency of transfer, gels were stained with 0.25% (w/v) Coomassie Brilliant Blue R-250 in
50% methanol and 10% acetic acid, and destained in 25% methanol and 7.5% acetic acid.
Membranes were stained with 0.5% (w/v) Amido Black in 25% isopropanol and 10% acetic acid
for 1 minute, and destained by several washes in distilled H20. Staining of gels and membranes
after transfer showed suboptimal transfer. Increasing transfer time caused the transfer unit to heat
up considerably, prompting us to try semi-dry blotting, where the gel-membrane sandwich is
placed between horizontal graphite plates. Staining of gels and membranes after semi-dry transfer
showed improved transfer efficiency, consistent with other studies reporting on this simpler,
cheaper and faster method (Kyhse-Andersen, 1984). Various transfer times, buffer systems
(continuous and discontinuous) and protein concentrations were investigated. Transfer at
lmá/cnr' for 2 hour, using the Towbin buffer system (Towbin et al. 1979) showed the best
transfer and was used for future work (data not shown). Transfer efficiency was related to the
concentration of protein separated by 20 PAGE (Figure 2.9). PVDF membranes are reported to
have higher protein binding capacity and improved mechanical strength compared to
nitrocellulose membranes. PVDF (Amersham Pharmacia Biotech) and nitrocellulose (S&S
Protran BA85, Schleicher & Schuell Inc., Keene, USA) membranes were compared by probing
with monoclonal antibodies (Figure 2. 10) or by probing with patient plasma (Figure 2.11).
Transfer efficiency was better when using nitrocellulose membranes.
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Figure 2.9 Effect of protein concentration on transfer efficiency. Thirty (A) and sixty
(B) micrograms of M tuberculosis H37Rv whole-cell lysate proteins was separated by
2D PAGE, transferred to PVDF, and stained with Amido Black.
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• •
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Figure 2.10 Comparison of transfer membranes using a monoclonal antibody. Sixty
micrograms of M tuberculosis H37Rv whole-cell lysate protein was separated by 2D
PAGE, transferred to PVDF (A) or nitrocellulose (B), and probed with a mAb directed to
the 65 kDa heat shock protein.
A
Figure 2.11 Comparison of transfer membranes using patient plasma. Sixty
micrograms of M tuberculosis H37Rv whole-cell lysate protein was separated by 2D
PAGE, transferred to PVDF (A) or nitrocellulose (B), and probed with plasma pooled
from TB patients.
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2.5 Conclusions
Optimisation of the conditions described resulted in high reproducibility. Our 2D PAGE
analysis was able to identify protein changes detected by others (Betts et al. 2002a). Similarly,
ELISA and Western blot results using mAbs supplied by the National Institute of Health and the
National Institute of Allergy and Infectious Diseases (Department of Microbiology, Colorado
State University) were consistent with other investigators (Sonnenberg and Beslisle, 1997).
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Chapter 3
PROTEIN EXPRESSION IN MYCOBACTERIUM TUBERCULOSIS
DIFFERS ACCORDING TO GROWTH STAGE AND STRAIN TYPE
The results presented in this chapter were published as "Protein Expression in Mycobacterium
tuberculosis Differs According to Growth Stage and Strain Type. Carmen Pheiffer, Joanna
Betts, Pauline Lukey and Paul van Heiden. Clinical Chemistry and Laboratory Medicine,
2002: 40, 869-875."
The style and referencing system suggested by Clinical Chemistry and Laboratory Medicine has
been altered to conform to the style of the thesis.
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3.1 Introduction
Response to infection by M tuberculosis is heterogeneous. For example, only 5-10% of
individuals infected with M tuberculosis are likely to develop disease in the absence of
immunosuppression (Enarson and RouiIIon, 1994). Of these, 95% of patients who comply with
therapy and do not harbour a drug resistant isolate are cured and fewer than 5% will "relapse"
within 2 years after completion of therapy (Iseman and Sbarbaro, 1991). It is known that
"relapse" can occur due to reactivation of latent infection or exogenous reinfection. In addition,
in some patients M tuberculosis is rapidly eradicated and patients are cured after 2-3 months of
antituberculosis treatment, while in others organisms may persist for many months (Wallis et al.
1999).
The variability in the response to M tuberculosis infection and the severity of disease
may be due to differences in susceptibility of individuals, and a variety of acquired and innate
host factors have been described that can change the outcome of M tuberculosis infection
(Bellamy and Hill, 1998b). Phenotypic differences such as induction of different immune
responses of macrophages (Hoal-van Helden et al. 2001a, 2001b) and different rates of
transmission (Warren et al. 2000) and adaptive immunity (Manca et al. 1999) have been reported
for a variety of M tuberculosis strains, fuelling speculation that some strains of M tuberculosis
are "hypervirulent" . One may therefore hypothesize that this variability between strains may be
due to antigenic differences which could cause variable responses in patients infected with M
tuberculosis, allowing certain strains to evade host defenses and cause disease in a subset of
individuals, while other strains may be easily killed by those same individuals. Differential
antigen expression by M tuberculosis strains may explain why individuals are susceptible to
Stellenbosch University http://scholar.sun.ac.za
45
exogeneous reinfection (van Rie et al. 1999a) and may succumb to TB several times or may
succumb to one strain type even while infected by others (Du Plessis et al. 2001).
Comparison between the genomes of M tuberculosis H37Rv and CDC1551, a clinical
isolate exhibiting a more vigorous host immune response than H37Rv (Manca et al. 1999), has
revealed >99% identity at the nucleotide level (Deicher et al. 1999). Recent studies have
suggested that single nucleotide substitutions are not a major source of genetic diversity within
the M tuberculosis complex but that insertion and deletion events could account for the
perceived phenotypic differences between strains (Brosch et al. 2001). Using microarray
analysis, Kato-Maeda et al. (2001) showed deletions of between 3 and 38 open reading frames
(ORPs) among 15 clinical isolates when compared to H37Rv. Comparative proteomics detected
seven proteins unique to CDC1551, three proteins unique to H37Rv, two proteins upregulated in
H37Rv and one protein with different vertical mobility between H37Rv and CDC1551 when
grown in vitro (Betts et al. 2000). However, identification of protein differences by mass
spectrometry showed no obvious association with phenotype. The two-dimensional (2D) gel
electrophoresis technology used in this study identified at most approximately 44% of the
predicted 3924 ORPs of M tuberculosis H37Rv (Cole et al. 1998) and the limitations of the
technology may have contributed to the failure to identify many differences (Betts et al. 2000).
In this study we compared protein expression by M tuberculosis H37Rv and two M
tuberculosis strains isolated from sputum specimens of TB patients residing in a community with
high notification rates of TB (>1 000/100 000) in South Africa (Warren et al. 2000). We
monitored somatic protein expression by the different strains at various stages of growth using
one-dimensional (ID) sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
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PAGE). We also performed time course analysis using Western blotting and enzyme-linked
immunosorbent assays (ELISAs) with a panel of mouse monoclonal antibodies (mAbs) directed
to a-crystallin, the antigen 85 (Ag85) complex, PstS 1, L-alanine dehydrogenase and the 65 kDa
antigen (Hsp65). The 16 kDa antigen a-crystallin homologue is induced during stationary phase
growth in vitro (Yuan et al. 1996) and elicits both B- and T- cell responses (Wilkinson et al.
1998). The antigen 85 complex (Ag85A, Ag85B and Ag85C) is a group of fibronectin-binding
proteins possessing mycolyl transferase activity and all have been shown to be potent T-cell
stimulants (Daffé, 2000). PstS 1, a 38 kDa phosphate-binding lipoprotein, is a known B- and T-
cell stimulant that has been suggested as a potential immunodiagnostic reagent (Wilkinson et al.
1997). Analysis of in vitro cultures has shown expression of L-alanine dehydrogenase in M
tuberculosis but not the vaccine strain Mycobacterium bovis bacille Calmette-Guérin (BCG)
(Andersen et al. 1992) and the gene encoding this protein (aid) has been found to be upregulated
during nutrient starvation of M tuberculosis (Betts et al. 2002). Hsp65 is a highly
immunoreactive heat shock protein which is conserved and expressed in all bacteria (Shinnick et
al. 1988). Results showed that these proteins are differentially expressed according to the growth
stage of the M tuberculosis strain, but no major differences between strains were observed.
Stellenbosch University http://scholar.sun.ac.za
47
3.2 Materials and Methods
3.2.1 Mycobacterium tuberculosis strains
M tuberculosis H37Rv was obtained from Paul Meyers (Department of Medical
Microbiology, University of Cape Town, South Africa). Two clinical strains with different
genotypes and frequencies in the study community were selected from the M tuberculosis strain
bank maintained at the University of Stellenbosch (Warren et al. 2000). Strain genotypes were
confirmed using IS6110 as described elsewhere (Warren et al. 2000) as well as by spoligotyping
as described in the Isogen Bioscience BV manual (Isogen Bioscience BV, The Netherlands). All
strains were fully drug sensitive.
3.2.2 Mycobacterial cultures
Mycobacterium tuberculosis strains were grown in 10 ml of Middlebrook 7H9 media
(Difco, Becton Dickinson, USA) supplemented with 10% albumin-dextrose-catalase (ADC) and
0.05% Tween-80 (MADCTW). Cultures were stirred with 8 mm Teflon-coated magnetic stirrer
bars at 37eC until an optical density at 600 nm (OD6oo) >0.6 was observed. Thereafter, aliquots
were frozen at -70eC. Aliquots stored at -70eC were thawed at room temperature, diluted 1:50
into 10 ml of MADCTW and grown with stirring at 37eC for 10 days. Cultures were removed
from the incubator, mixed well with a 1 ml syringe, and then diluted between 1:80 and 1:200 into
20 ml of MADCTW, depending on the OD600 readings. Proteins were harvested after 4, 7, 14, 28
and 42 days. At each time point morphology and acid fastness was verified by Ziehl-Nielsen
(ZN) staining (Heifets and Good, 1994).
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3.2.3 Growth measurement
Optical densities at 600 nm (00600) were measured in a spectrophotometer (LKB
Biochrom, Cambridge, UK) using 2 ml of culture. In addition, a modified protein determination
method for determining bacterial growth (Meyers et al. 1998) was used as follows: 1 ml of
culture was centrifuged at 10 000 g for 10min. Pellets were washed with 1 ml of phosphate
buffered saline (PBS)I1% (v/v) Tween-20 and centrifuged as before (10000 g, 10 min). Pellets
were frozen at -20°C until all samples were collected (all time points). Samples were thawed at
room temperature, after which they were resuspended in 0.1 ml of 1 M NaOH and boiled for 10
min. Thereafter, samples were neutralised by adding 0.02 ml of 5 M HCI. Eight hundred and
eighty microlitres of PBS was added, the samples were centrifuged for 30 min at 10 000 g, where
after 800 JlI of supernatant was removed for protein determination according to the formula:
Protein concentration (ug/ml) = (183 X A230) - (75.8 X A260). All assays were performed in
duplicate.
3.2.4 Extraction of mycobacterial proteins
Whole-cell extracts were prepared by harvesting two 20 ml cultures of each strain after 4,
7, 14, 28 and 42 days of growth. Cultures were pooled and pelleted by centrifugation at 1 900 g
for 20 min. Pellets were washed twice in PBS/l% (v/v) Tween-20 and centrifuged (4 000 g, 5
min). Mycobacterial cells were resuspended in lysis buffer (0.3% (w/v) SDS, 200 mM OTT, 50
mM Tris-HCI pH 7.0, 1 mM PMSF and complete protease inhibitor cocktail (Roche Molecular
Biochemicals, Mannheim, Germany)). An equal volume of Silica/Ceramic Matrix Beads (BIO
101, Vista, USA) was added, samples were mixed by vortexing and thereafter heat-killed at 80°C
for 20 min prior to bead disruption in a ribolyser (BIO 101, Vista, USA). After boiling for 5 min,
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samples were clarified by centrifugation at 10 000 g for 10 min and protein concentrations
estimated using the Bradford assay (Bradford, 1976). Whole-cell lysates received from the
Department of Microbiology, Colorado State University, through funds from the National
Institutes of Health, National Institute of Allergy and Infectious Disease, Contract NO 1-AI-
75320 were used as controls.
3.2.5 Monoclonal antibodies
Mouse monoclonal antibodies (mAbs) IT-4, IT-7, IT-13, IT-23 and IT-49 raised against
the 16 kDa (a-crystallin), 40 kDa (L-alanine dehydrogenase), 65 kDa (Hsp65), 38 kDa (PstS 1)
and 32-33 kDa (Ag85 complex) M tuberculosis proteins (Engers et al. 1986; Khanolkar- Young
et al. 1992; Sonnenberg and Beslisle, 1997) were made available by the Department of
Microbiology, Colorado State University through funds from the National Institutes of Health,
National Institute of Allergy and Infectious Disease, Contract NO 1-AI-75320.
3.2.6 SDS-PAGE and Western blotting
Total cellular proteins were separated by SDS-PAGE using a 4% stack over a 12%
resolving gel. Gels were stained with Coomassie Blue or proteins were transferred to
polyvinylidene fluoride (PVDF) membranes (Amersham Pharmacia Biotech, Little Chalfont,
UK) and incubated with mAbs (IT-4:1:1 000, IT-7:1:2 500, IT-13:1:500, IT-23:1:100, IT-
49: 1:100). Blots were screened for antibody binding using horseradish peroxidase-conjugated
goat anti-mouse immunoglobulin G (lgG, CALTAG laboratories, Burlingame, USA), and bound
antigens were detected using chemiluminescence detection reagents (ECL™ Western blotting
detection reagents, Amersham Pharmacia Biotech, Little Chalfont, UK).
Stellenbosch University http://scholar.sun.ac.za
50
3.2.7 Enzyme-linked immunosorbent assay
Fifty microlitres of lysate sample diluted to 10 ug/ml in 0.025 M NaHC03 was allowed to
bind to duplicate wells of ELISA plates (Nunc, Roskilde, Denmark) at 4°C overnight. After three
washes with PBS/0.05% (v/v) Tween-20 the wells were blocked with 2% (w/v) non-fat milk
powder in PBS/0.05% (v/v) Tween-20 (blocking buffer) for 2 h at 37°C. Thereafter, various
dilutions ofmAbs (IT-4:1:500, IT-7:1:1 000, IT-13:1:500, IT-23:1:200, IT-49:1:200) in blocking
buffer were added and incubated for 2 h at 3rC. Following this, plates were washed six times
with PBS/0.05% (v/v) Tween-20 and 50 JlI peroxidase-conjugated goat anti-mouse IgG
(CALTAG laboratories, Burlingame, USA) diluted 1:10 000 in blocking buffer was added to the
wells and left for 1 h at 37°C. Plates were washed six times with PBS/0.05% (v/v) Tween-20 as
before and 100 JlI of tetramethylbenzidine substrate (TMB, Kirkegaard & Perry Laboratories
Inc., Gaithersburg, USA) was added. After 10 min at room temperature, colour development was
stopped by adding 100 JlI of 1M H2S04• Plates were read at 450 nm using a bench top microplate
reader (Bio-Rad laboratories, Hercules, USA).
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3.3.1 Strain typing
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M tuberculosis H37Rv and clinical strains that had originally been cultured from sputum
specimens of TB patients were genotyped using IS6110 and spoligotyping. DNA fingerprinting
showed that M tuberculosis strain 1296 and strain 1524 had 9 and 22 hybridizing copies of
IS6110, respectively (Figure 3.1A). Fourteen copies of IS6110 were present in M tuberculosis
H37Rv. Different spoligotyping patterns were observed for each of the M tuberculosis strains
(Figure 3.1B). Strain 1524 was classified as a Beijing family strain, because it contained only 9
spacer sequences and had a characteristic IS6110 pattern (van Soolingen et al. 1995).
A B
3.0kb
23kb
1.8kb
1.4kb ·..·..• •• •
l.Okb • ••• •••
Figure 3.1 IS6110 RFLP and spoligotype patterns of strains
investigated. A. M tuberculosis strain 1296 (lanes 1 and 2), strain
1524 (lanes 3 and 4) and H37Rv (lane 5) were genotyped using
IS6110 restriction fragment length polymorphism analysis. DNA
fragment sizes are indicated on the right. B. Schematic representation
of spoligotypes of M tuberculosis strain 1296 (lane 1), strain 1524
(lane 2) and H37Rv (lane 3).
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.. - 7.0kb
123
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3.3.2 Growth ofM. tuberculosis
Mycobacterial growth was analysed over a period of 42 days using OD600 measurements
(Figure 3.2A) and a protein determination method (Meyers et al. 1998) (Figure 3.2B). This
method is useful for heavily clumped cultures where accurate spectrophotometric measurements
and colony forming units (CFU) counts are difficult or impossible. Comparison of the growth
rates of the strains showed that strain 1524 initially grew slower (had a longer lag phase) but cell
numbers were similar to H37Rv and strain 1296 at day 42. The two methods of growth
determination correlated well. ZN staining of cultures showed no contamination during growth.
Although ZN staining is not quantitative, ZN results appeared to correlate with growth as
determined by OD600 and protein determination (data not shown).
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Figure 3.2 Analysis of mycobacterial growth. Growth of M
tuberculosis strain 1296 (.), strain 1524 (.A.) and H37Rv (.) in
Middlebrook 7H9 medium was analysed using OD600 (A) and a
protein determination method (B). Each data point represents the
average of two measurements. Error bars show the standard
deviations from the mean.
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3.3.3 Analysis of protein expression by different M. tuberculosis strains during in vitro
growth
Protein expression by strains 1296, 1524 and H37Rv was analysed by ID SOS-PAGE at
various time points during growth (day 4, 7, 14, 28 and 42). Comparison of the different M
tuberculosis extracts (Figure 3.3) revealed mainly quantitative differences that appeared to be
growth-, rather than strain-dependent. The most prominent bands ranged in size from 16 kDa to
66 kDa. Major variants at approximately 10 kDa, 16 kDa, 24 kDa, 26 kDa, 45 kOa, 60 kDa and
65 kDa are indicated by arrows in Figure 3.3. The fewer bands observed at day 28 and day 42
could be due to shut-down of protein synthesis or protein degradation later in the culture period.
Our results illustrate modulation of M tuberculosis proteins during growth, even with a relatively
crude measurement tool.
Strain 1296 1524 H37Rv
Day 4 7 14 2842 4 7 14 28 42 4 7 14 28 42
Lane 2 3 4 5 6 7 8 9 10 Il 12 13 14 15
66kDa
45kDa
29kDa
24kDa
14.2 kDa
6.5 kDa
Figure 3.3 Analysis of protein expression by M tuberculosis strains. SDS-
PAGE separation of proteins extracted from M tuberculosis strain 1296 (lanes
1-5), strain 1524 (lanes 6-10) and M tuberculosis H37Rv (lanes 11-15).
Proteins were extracted from cell pellets after 4, 7, 14, 28 and 42 days of in
vitro growth and 30!lg of protein from each time point was separated by 12%
SDS-PAGE. Molecular weight markers are indicated on the left. Arrows
indicate protein variants at approximately 10 kDa, 16 kDa, 24 kDa, 26 kDa, 45
kDa, 60 kDa and 65 kDa.
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3.3.4 Comparison of expression of proteins reactive with mAbs during growth of different
M. tuberculosis strains
Total proteins harvested from the different M tuberculosis strains at the various time
points were probed with a panel of five mAbs to further characterize the differentially expressed
proteins observed by SDS-PAGE. Western blot analysis showed that varying levels of the
proteins to which the mAbs react are produced during different growth stages of the M
tuberculosis strains, as indicated in Figure 3.4. Although differences were noted, protein
expression in H37Rv and strain 1296 were essentially similar. Levels of a-crystallin generally
increased over the time course, consistent with previous reports of it being a stationary phase
associated protein (Yuan et al. 1996). Conversely, levels of Hsp65 decreased across the time
course, with the lowest levels observed at day 42. PstSl levels peaked between day 14 and day
28 and then declined. Strain 1524 showed similar patterns of Hsp65 and Ag85 complex
expression to the other strains but very little a-crystallin (except at day 28 and day 42) and PstSl
were detected. The Ag85 complex band appeared as a doublet, probably corresponding to Ag85A
and Ag85B (Figure 3.4B). Most of the differences between the three strains were observed for L-
alanine dehydrogenase expression.
Monoclonal antibody IT-7 reacted with two products, the expected band of 40 kDa and a
band of 16 kDa. This is in agreement with Sonnenberg and Beslisle (Sonnenberg and Beslisle,
1997) who also reported that this mAb reacted with a band of 16 kDa. Of interest is the increased
size of the 40 kDa antigen in H37Rv in day 7 and day 14 extracts (Figure 3.4D). This could be
due to protein modifications such as phosphorylation or glycosylation. Furthermore additional
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bands, probably due to protein degradation, were observed below the expected bands of 40 kDa
and 16 kDa in the day 42 extract of strain 1296.
ELISA essentially corroborated Western blot results, with a-crystallin, PstS 1, L-alanine
dehydrogenase and Hsp65 expression varying during growth of the M tuberculosis strains (data
not shown). Again levels of a-crystallin, PstS 1 and L-alanine dehydrogenase were lower for
strain 1524 than the other strains. However, the Ag85 complex was not detected in any of the
strains by ELISA.
Our results show that although expression of the antigens investigated differed
quantitatively during growth, expression seemed to be conserved in the strains investigated.
Reactivity of the mAbs with our H37Rv whole-cell lysate proteins was comparable to that of
whole-celllysates received from the NIH in both Western blots and ELISAs (data not shown).
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32-33 kDa protein --- --AI' - - 32-33 kDa
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Figure 3.4 Western blot analysis. Proteins extracted from M tuberculosis strain 1296 (lane 1), strain 1524 (lane
2) and H37Rv (lane 3) were probed with monoclonal antibodies (mAbs) directed to the 16 kDa (a-crystallin)
protein (A), the 32-33 kDa (Ag85 complex) protein (B), the 38 kDa (PstSI) protein (C), the 40 kDa (L-alanine
dehydrogenase) protein (D) and the 65 kDa (Hsp65) protein (E). Proteins were extracted from cell pellets after 4,
7, 14, 28 and 42 days of in vitro growth and 10 J.1gseparated by 12% SDS-PAGE. After transfer onto PVDF
membranes, proteins were probed with various dilutions of mAbs as described before.
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3.4 Discussion
Recent studies have suggested that phenotypic differences between strains can possibly
contribute to different outcomes after M tuberculosis infection (Hoal-van HeIden et al. 2001a,
2001b). Furthermore, differential antigen expression by M tuberculosis strains may potentially
explain why certain patients are susceptible to a repeat episode of TB, particularly from a
different strain. In this study we compared protein expression by M tuberculosis H37Rv and two
clinical isolates to determine whether differential antigen expression contributes to the different
phenotypes expressed by these strains.
DNA fingerprinting identified strain 1296 and strain 1524 as belonging to family 23 (9
hybrid ising copies of IS6110) and 29 (22 hybrid ising copies of IS6110), respectively.
Epidemiological studies in our community have shown that the frequency of family 29 isolates is
>10 times that of family 23 strains (Warren et al. 2000). Furthermore, spoligotyping revealed that
strain 1524 (family 29) belongs to the Beijing family of strains, speculated to have originated in
Asia (van Soolingen et al. 1995) and reported to be responsible for most of the outbreaks of drug
resistance in our community (van Rie et al. 1999b).
Comparison of growth over a time course of 42 days showed no significant difference in
growth rate of the M tuberculosis strains, suggesting that growth rate of mycobacteria in vitro is
not an indicator of transmissibility. Our findings are in agreement with others (Betts et al. 2000;
Manca et al. 1999) who also failed to show differences in growth rates of M tuberculosis
H37Rv, CDC 1551 and two clinical isolates when grown in vitro and in vivo.
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SDS-PAGE and Coomassie staining of total cellular proteins obtained from M tuberculosis
H37Rv and the two clinical isolates showed that protein profiles changed during growth in
culture. M tuberculosis H37Rv has 3924 predicted genes (Cole et al. 1998) and although ID (or
even 2D) gel electrophoresis will not enable all the expressed proteins to be visualised, we were
able to show that variation of the major proteins identified appeared to be growth-stage, rather
than strain-dependent. The genomes of M tuberculosis strains are relatively stable (Musser et al.
2000) and our results are in agreement with previous studies showing few differences between M
tuberculosis strains at the proteome level (Betts et al. 2000).
ELISAs and Western blot analysis confirmed our findings using SDS-PAGE, where
variation of protein expression appeared to be largely independent of M tuberculosis strain
analysed but showed modulation during growth. Although variable levels were expressed during
growth, all strains investigated expressed a-crystallin, PstS 1, L-alanine dehydrogenase and
Hsp65 to some extent. Interestingly, strain 1524 expressed lower levels of a-crystallin, PstS 1 and
L-alanine dehydrogenase compared to the other strains. The least variation between strains was
observed with Hsp65. No Ag85 expression was detected by ELISA, whereas Western blot
analysis showed Ag85 expression in all strains. Using ELISA we have been able to detect Ag85
expression within a culture filtrate protein fraction (data not shown), suggesting that levels of
these proteins are low in the whole-cell lysates of the strains studied and that Western blot
detection is simply more sensitive than ELISA. PVDF membranes have greater protein binding
capacity than microtitre plates and, for Western blot detection, proteins are separated and more
total protein can be applied. Furthermore, mycobacteria are rich in lipids which may compete
with proteins in the ELISA assay. Slight conformational differences in the antigen when bound to
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the ELISA plate compared to the PVDF, causing partial obstruction of the epitope may also
explain the differences observed between ELISA and Western blotting.
Our results suggest that the antigen repertoire presented to the host immune response may
be quantitatively dependent on the growth stage of the infecting M tuberculosis strain. This
implies that the profile of antigens presented to the host immune response may be affected by
disease progression, as previously suggested by Samanich et al. (1998). In addition, although the
same antigens may be expressed in all strains, a quantitative difference may also evoke
considerable differences in the host response. This could possibly explain some of the
heterogeneous humoral immune response observed in TB patients and why no fully effective
serodiagnostic has been developed to date (Lyashchenko et al. 1998a). These results suggest that
antigens that are not susceptible to growth phase variation should be used for development of
serodiagnostic tests. It should be noted, however, that antigenic differences between strains may
be more pronounced in culture filtrates, where the secreted proteins are found (Andersen et al.
1991) and therefore these should be investigated. Future studies in our laboratory are being
directed to analysis of secreted proteins using 2D gel electrophoresis.
Although protein expression varied with growth stage of the strains, all strains expressed
the antigens analysed at some time, suggesting that differential antigen expression may not
explain why certain patients are susceptible to a repeat episode of TB (van Rie et al. 1999a).M
tuberculosis may adapt to different host environments (within macrophages, granulomas, necrotic
lesions, etc.) by adopting differential gene expression strategies (Cappelli et al. 2001). Our
current studies are focused on comparing antigen expression by different M tuberculosis strains
when grown under environmental conditions that more closely mimic the host environment.
Stellenbosch University http://scholar.sun.ac.za
60
Chapter 4
SERODIAGNOSIS OF TUBERCULOSIS COMPLICATED BY VARIABLE
PROTEIN EXPRESSION OF MYCOBACTERIUM TUBERCULOSIS
STRAINS AND THE HETEROGENEOUS HOST HUMORAL IMMUNE
RESPONSE
The results presented in this chapter have been submitted to the Journal of Clinical and
Diagnostic Laboratory Immunology as "Serodiagnosis of tuberculosis complicated by
variable protein expression of Mycobacterium tuberculosis strains and the heterogeneous
host humoral immune response. Carmen Pheiffer, Joanna Betts, Pauline Lukey and Paul van
HeIden" and is currently under review.
The style and referencing system suggested by Clinical and Diagnostic Laboratory Immunology
has been altered to conform to the style of the thesis.
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4.1 Introduction
The need to develop a faster, easier, more sensitive but economical method to diagnose
tuberculosis (TB), especially smear negative pulmonary TB, extrapulmonary TB and childhood
TB (Bothamley, 1995; Chan et al. 2000), has sparked interest in serodiagnosis, particularly in
developing countries where the greatest proportion of the world's TB burden lies (Dye et al.
1999). Although many potential tests have been developed, no test has shown satisfactory
sensitivity and specificity for general clinical use (Chan et al. 2000). The failure of serology for
acceptance for TB diagnosis is thought to be mainly due to the heterogeneous host humoral
immune responses of TB patients (Lyashchenko et al. 1998a). Several factors, including host
genetics (Bothamley et al. 1989), geographical location (Daniel and Debanne, 1987) and extent
of disease (Samanich et al. 1998) can contribute to the humoral heterogeneity observed amongst
TB patients.
Studies have suggested that Mycobacterium tuberculosis strain-related differences may
also influence the host antibody response (Lyashchenko et al. 1998a; Samanich et al. 2001).
Identification of proteins differentially expressed by different M tuberculosis strains may shed
some light on the reasons for the heterogeneous host humoral immune responses of TB patients,
as antigenic diversity due to differential protein expression has been reported for a number of
pathogens, including bacteria, viruses, helminths and protozoa (Smith et al. 2002). Furthermore,
it has been speculated that strains belonging to the Beijing family, a family of M tuberculosis
strains distributed worldwide and often associated with drug resistance (Glynn et al. 2002), have
a genetic advantage and that the dominance of such families, compared to other less prevalent
clinical isolates, may be related to differential protein expression (Bifani et al. 2002).
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Previously, proteornics has been used to compare protein expression of the M
tuberculosis strains H37Rv and Erdman to the vaccine strain Mycobacterium bovis Bacille
Calmette-Guérin (BCG) in an attempt to identify proteins contributing to the pathogenesis of M
tuberculosis (Jungblut et al. 1999). Comparative proteornics of M tuberculosis H37Rv and the
clinical strain CDC 1551, believed to elicit a more vigorous host immune response (Manca et al.
1999), detected several protein differences between the strains (Betts et al. 2000). A more recent
study showed differential expression of the PE-PGRS proteins, speculated to be variable surface
antigens, between clinical isolates of M tuberculosis (Banu et al. 2002).
In a previous study we compared protein expression of two M tuberculosis clinical
strains, originally isolated from patients from a community in Cape Town, South Africa with a
very high TB incidence (Warren et al. 2000), to the laboratory strain H37Rv using one-
dimensional (ID) polyacrylamide gel electrophoresis (PAGE), enzyme-linked immunosorbent
assay (ELISA) and Western blotting (Pheiffer et al. 2002). Based on the number of IS6110
insertions and spoligotyping, the two clinical strains were classified as belonging to the Beijing
family and family 23, respectively (Pheiffer et al. 2002). Between 1993 and 1998, 18.7% of TB
cases in this community were reported to be due to infection with Beijing strains, whereas family
23 strains were responsible for only 1.4% of TB cases (Warren et al. 2000). Twenty eight strain
families have been identified in this community (van HeIden et al. 2002), with the prevalence of
Beijing strains being exceeded only by M tuberculosis strains belonging to family 11, which
were responsible for 24.5% of TB cases during 1993-1998. Results from a previous study
(Pheiffer et al. 2002) showed that protein expression differences between strains could be
growth-phase dependent, although some differences between the strains were observed. However
due to the low resolving power of ID gel electrophoresis, these differences were not identifiable.
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Here, we have extended our previous study through the use of two-dimensional (2D) PAGE
coupled with identification of protein spot differences by mass spectrometry and Western blot
analysis of the expression of 14M tuberculosis antigens. Furthermore we have used plasma from
patients infected with Beijing, family 23 and family 11 strains to investigate differences in
antigen recognition. This study has revealed considerable differences in protein expression
between the three strains, particularly between the two clinical strains compared to H37Rv.
Careful analysis of these differences and the differences in the antibody recognition profiles
could provide us with clues to explain the heterogeneous host humoral immune response and also
the different frequencies of the clinical strains in our study population, where the Beijing strain is
at least ten fold more frequent than the family 23 strain (Warren et al. 2000).
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4.2 Materials and Methods
4.2.1 Mycobacterium tuberculosis strains and culture
M tuberculosis H37Rv (ATCC 25618) and two local clinical strains (Beijing (SAWC
1524) and family 23 (SAWC 1296)) were grown in modified Sauton medium (Andersen et al.
1991). Briefly, mycobacterial strains at late exponential growth (OD6oo>0.6) were diluted 1:10
into 200 ml of Sauton medium and grown at 37°C. After four weeks, cultures were harvested by
centrifugation (1 900 g, 20 min) and mycobacterial pellets were washed twice with PBS
containing 1% (v/v) Tween-20. Proteins used in Western blots with plasma from TB patients
were prepared from strains during logarithmic growth in Middlebrook 7H9 media (Difco, Becton
Dickinson, USA) supplemented with 10% (v/v) albumin-dextrose-catalase and 0.05% (v/v)
Tween-80 as previously described (Pheiffer et al. 2002). Morphology and acid-fastness was
checked by Ziehl-Nielsen staining (Heifets and Good, 1994). All strains were fully sensitive to
isoniazid, rifampicin and ethambutol.
4.2.2 Protein extraction
Whole-cell lysate (WCL) proteins were extracted by bead disruption in lysis buffer (0.3%
(w/v) SDS, 200 mM DTT, 50 mM Tris-HCI pH 7.0, 1 mM PMSF and complete protease
inhibitor cocktail (Roche Molecular Biochemicals, Mannheim, Germany)) as previously
described (Pheiffer et al. 2002). Culture filtrate proteins (CFP) were prepared from culture
supernatants sterilized by sequential filtration through 0.45 urn and 0.22 urn filter units (Coming,
New York, USA). Filtrates were concentrated using Centricon Plus-80 filter units (Biomax-PB
membrane, 5000 MWCO), followed by Centricon units (YM membrane, 3000 MWCO) (Amicon
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Bioseparations, Millipore Corporation, Bedford, USA). WCL and CFP concentrations were
estimated using the Bradford assay (Bradford, 1976).
4.2.3 Two-dimensional gel electrophoresis
Proteins were separated by 20 PAGE as previously described (Betts et al. 2000), with
minor modifications. Briefly, 20 f..lg(60 ug for Western blotting) of protein was resuspended in
rehydration buffer (8 M urea, 2% (w/v) CHAPS, 10 mM OTT, 2% (v/v) immobilized pH gradient
(lPG) buffer (pH 4-7), trace bromophenol blue) and applied to pH 4-7 lPG strips (Amersham
Biosciences, Uppsala, Sweden) for overnight rehydration. Isoelectric focusing was performed
using a Multiphor II system (Amersham Biosciences) as follows: 100 V for 2 h, 300 V for 2 h,
1000 V for 1 h, 3500 V for 20 h (3500 V for 27.5 h for Western blotting). Second dimension
separation was carried out by placing equilibrated IPG strips (Bjellqvist et al. 1993,
http://www.expasy.ch/ch2d/protocols/) onto 12% PAGE gels and sealing with 0.5% (w/v)
agarose in cathode buffer (defined below), containing a trace amount of bromophenol blue.
Anode (375 mM Tris-HCI, pH 8.8) and cathode (192 M glycine, 0.1% (w/v) SDS, pH 8.3)
buffers as described by Herbert et al. (Herbert et al. 1998) were used. Proteins were visualized by
silver staining using an ammoniacal stain (Bjellqvist et al. 1993;
http://www.expasy.ch/ch2d/protocols/). Gels were air dried (BioRad GelAir Dryer, Hercules,
USA) and compared by visualization on a light box. When protein spot differences were noted,
gels were rerun, stained with a silver stain compatible with mass spectrometry (Betts and Smith,
2001) and spots of interest excised from the gel.
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4.2.4 Sample preparation for mass spectrometry
Gel pieces excised from the gel were washed with dd-H20 for 10min, followed by 100%
acetonitrile for 5 min, centrifuged and then dehydrated by vacuum centrifugation. Automated
robotic digestion was carried out using a MassPREP station (Micromass, Manchester, UK),
equipped with four probes for aspirating and dispensing reagent and washing solutions and a
heated incubation platform. Samples were destained with 50 mM ammonium bicarbonate:
acetonitrile (l:1), then reduced and alkylated with 10 mM DTT and 55 mM iodoacetamide
respectively. This was followed by in-gel digestion with porcine trypsin (sequencing grade,
Promega, Madison, WI, USA) (6 ng/ui) in 50 mM ammonium bicarbonate (25 J.l1)for 5 h at
37°C. The resulting peptides were then extracted with 1% formic acid (v/v): acetonitrile (98:2).
4.2.5 Nanoscale liquid chromatography tandem mass spectrometry (LCIMSIMS) and
database searching
Samples were introduced using the Micromass CapLC system (Micromass, Manchester,
UK), comprising a low flow capillary HPLC pump and autosampler. AIO port valve was
configured with a pre-concentration column (300 urn ID x 5 mm C18 PepMap, LC Packings,
Amsterdam, NL) and a nanoscale analytical column (75 urn ID x 15 cm C18 PepMap, LC
Packings, Amsterdam, NL). Peptides were eluted using a reverse phase gradient of 5-50% buffer
B over 30 min (A= 5% (v/v) acetonitrile, 0.1% (v/v) formic acid; B= 95% (v/v) acetonitrile, 0.1%
(v/v) formic acid) at a flow rate of approximately 200 nl/min. All data were acquired using a Q-
TofUltima API (Micromass, Manchester, UK) hybrid quadrupole orthogonal acceleration time of
flight mass spectrometer equipped with a nanospray source. Up to 8 precursor ions were
automatically selected from the TOF/MS survey scan for MS/MS per cycle, and collision
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energies were chosen automatically based on the m/z value and the charge state of the selected
precursor ions. Peptide sequence data generated was searched against the non-redundant protein
database using MASCOT (http://www.matrixscience.com). Search parameters included the fixed
modification carboamidomethyl, due to the alkylation of cysteine residues by iodoacetamide and
the variable modification, oxidation of methionine residues.
4.2.6 Monoclonal antibodies
Mouse monoclonal antibodies (mAbs) IT-4, IT-7, IT-l3, IT-19, IT-23, IT-38, IT-42, IT-
43, IT-49, IT-51, IT-52, IT-53 and IT-58 raised against the 16 kDa (a-crystallin), 40 kDa (L-
alanine dehydrogenase), 65 kDa (Hsp65), 19 kDa, 38 kDa (PstSI), 20 kDa, 82 kDa (KatG), 56
kDa, 32-33 kDa (Ag85 complex), 17 kDa, 25 kDa (MPT51), 96 kDa and 47 kDa M tuberculosis
proteins (Engers et al. 1986; Khanolkar- Young et al. 1992; Sonnenberg and Beslisle, 1997)
respectively were made available by the Department of Microbiology, Colorado State University
through funds from the National Institutes of Health, National Institute of Allergy and Infectious
Disease, Contract NOI-AI-75320. HYB76-8 directed to ESAT6 (Sorensen et al. 1995) was
received from Karin Weldingh (Statens Serum Institut, Copenhagen, Denmark).
4.2.7 One-dimensional gel electrophoresis and Western blotting
Proteins were separated by SDS-PAGE using a 4% stack over a 12% resolving gel and
transferred to PVDF membranes (Amersham Biosciences) by tank blotting. Blots were incubated
with mAbs (IT-4, 1:1000; IT-7, 1:2500; IT-l3, 1:500; IT-19, 1:100; IT-23, 1:100; IT-38, 1:100;
IT-42, 1:100; IT-43, 1:100; IT-49, 1:100; IT-51, 1:100; IT-52, 1:100; IT-53, 1:100; IT-58, 1:100;
HYB76-8, 1:100) and plasma (l:100 and 1:500) and screened for antibody binding with a
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horseradish peroxidase-conjugated goat anti-mouse IgG (1: 10 000, CALTAG laboratories,
Burlingame, USA) as the secondary antibody for mAbs and an alkaline phosphatase-conjugated
goat anti-human IgG (1:2 000, Kirkegaard and Perry Laboratories Inc., Gaithersburg, USA) for
plasma. Bound antigens were detected using chemiluminescence detection reagents (ECL™
Western blotting detection reagents, Amersham Biosciences) or with the 5-bromo-4-chloro-
indolyl-phosphatase (BCIP)/nitroblue tetrazolium (NBT) substrate (Kirkegaard & Perry
Laboratories Inc.) for plasma samples.
4.2.8 Two-dimensional Western blotting
For Western blotting, 2D gels were transferred to nitrocellulose membranes (S&S Protran
BAS5, Schleicher & Schuell Inc., Keene, USA) using semi-dry blotting. Blots obtained from 2D
gels were probed with mAbs IT-4 and IT-23 using the same conditions as for ID Western
blotting. For blots using plasma from TB patients, plasma was diluted 1:150 and screened for
antibody binding using alkaline phosphatase-conjugated goat anti-human IgG (Kirkegaard &
Perry Laboratories Inc.) as previously described. Immunoreactive antigens were detected using
the BCIPINBT substrate (Kirkegaard & Perry Laboratories Inc.) as described above.
4.2.9 Patients
TB patients used in this study were culture positive for M tuberculosis drug sensitive
organisms. The smear status, disease episode, anti-tuberculosis chemotherapy status and IS6110
genotype of the infecting M tuberculosis strain was documented for all patient samples (Table
4.1). Blood was collected by clinical staff, plasma collected by centrifugation at 2 500 g for 5
minutes, and stored at -20°C. Ethical approval for this study was obtained from the University of
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Stellenbosch Faculty of Health Sciences ethics committee and samples were given only after
informed consent.
4.2.10peR amplification and DNA sequence analysis
Primers were designed to amplify approximately 550 bp 5'and 150 bp 3' from the start
codon of the pstSl and katG genes of M tuberculosis. PCR reactions were performed with
HotstarTaq™ DNA polymerase (Qiagen GmbH, Hilden, Germany). Reaction mixtures contained
approximately 500 ug DNA template, 50 pmol of each primer, 1 X Reaction Buffer, and 1 U
enzyme. Cycling conditions included a 15 min 95°C denaturation step, followed by 35 cycles of
94°C for 30 s, 1 min at 56°C for pstSl and 61"C for katG, followed by a 7 min extension step at
72°C. PCR products were electrophoretically fractionated in a 1% (w/v) agarose gel, then
visualized under UV after ethidium bromide staining. PCR products were purified using the
Wizard® SV Gel and PCR Clean-Up System (promega) and sequenced on an ABBI00
automatic sequencer. DNA sequences obtained were blasted against the published H37Rv
sequence (http://genolist.pasteur.fr/TubercuLis!L) using DNAman (DNAMAN Version 4.1).
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Table 4.1 TB patient data
Patient number Strain family" Smear statusb Anti- TB treatment" Culture positived Disease episode"
97 Il positive yes (6 months) yes second
484 Il negative no yes first
522 11 negative no yes first
672 Il positive no yes first
726 23 negative yes (4 days) yes first
880 29/ Beijing positive no yes first
881 29/ Beijing positive no yes first
941 29/ Beijing positive no yes first
OM tuberculosis strains are grouped into families based on the number of IS6J 10 insertion elements identified by DNA fingerprinting. The strain
family of the M tuberculosis strain isolated from the patient sputum is shown.
bSmear status refers to whether a patient's sputum stained positive or negative for acid-fast bacilli.
CAnti- TB treatment refers to the six month TB treatment regimen prescribed by DOTS (isoniazid, pyrazinamide, rifampican, streptomycin). The
time blood was taken after the commencement of treatment is shown.
dCulture positive refers to the ability to culture M tuberculosis from patient sputum.
"Disease episode refers to the TB episode the patient was experiencing.
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4.3 Results
4.3.1 2D PAGE and protein identification
Mycobacterial strains were cultured in modified Sauton medium, a synthetic medium
without protein enrichment (Andersen et al. 1991) for four weeks. This enabled culture filtrate
proteins to be analysed free of BSA contamination. Pilot studies showed that after four weeks
growth all three strains were in late logarithmic growth, thereby minimising growth-related
differences between strains. Whole-cell lysate and culture filtrate proteins were separated by 2D
PAGE using pH 4-7 lPG strips and 12% PAGE gels. Pilot experiments demonstrated that many
M tuberculosis proteins focus between pH 4 and 7 and the best resolution for comparison was
achieved using this pH range. The 2D gels of whole-cell lysate and culture filtrate proteins
derived from M tuberculosis H37Rv, the Beijing strain and the family 23 strain are shown in
Figure 4.1. The 2D maps were highly similar between the strains, enabling visual comparison.
Spot differences consistent between quadruplicate gels and obvious by visual examination were
analysed further. Protein spots of interest were analysed by liquid chromatography tandem mass
spectrometry (LC/MS/MS). All proteins identified had their counterparts in all three strains,
although quantitative expression differences were observed. Eleven spot differences were
observed between H37Rv and the clinical strains. Protein spots identified by LCIMS/MS are
indicated in Figure 4.1 and their identities listed in Table 4.2. Eight protein spots were increased
in the whole-cell lysates of both clinical isolates relative to H37Rv. Seven of these were
identified as a-crystallin and two proteins, Rv2005c and the 35 kDa antigen were identified
within the eighth spot. Previous studies have also reported the appearance of multiple a-crystallin
species with different molecular weights and isoelectric points (Betts et al. 2000; Sonnenberg and
Beslisle, 1997). One of the factors contributing to mobility variants of a-crystallin may be
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oxidation of methionine residues as recently demonstrated by Abulimiti et al. (Abulimiti et al.
2003). Three spots were decreased in the culture filtrates of both clinical strains compared to
H37Rv. Ag85A was identified in each of these spots. However, spot 9 also contained Rv1096
and spot 10 three other proteins; Ag85C, Rv0831c and CysA3. One spot, identified as containing
both PstS 1 and Ag85B was decreased in culture filtrates of the Beijing strain compared to both
H37Rv and the family 23 strain.
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Figure 4.1 2D gels of whole-cell lysate (WCL) and culture filtrate proteins (CFP) extracted from the three M
tuberculosis strains. (A) H37Rv, WCL; (B) H37Rv, CFP; (C) Beijing family strain, WCL; (D) Beijing family strain,
CFP; (E) family 23 strain, WCL; (F) family 23 strain, CFP. Protein spots with increased intensity in clinical strains
are ringed and those with increased intensity in H37Rv are boxed. Their identities are listed in Table 4.2.
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Table 4.2 Protein spot differences observed for whole-cell lysate and culture filtrate fractions of M tuberculosis H37Rv,
the Beijing strain and the family 23 strain.
Spot Fraction ORF Gene Name Protein Matched peptides Mw
a pla
Increased expression in both clinical strains
1-7 WCL/CF Rv2031c hspX heat shock protein, HspX SEFAYGSFVR 16096 5.00
TVSLPVGADEDDIK
8 WCL Rv2005c - conserved hypothetical protein YANAiGSAELAESSVQGR 30985 5.53
Rv2744c 35M_ag conserved 35 kDa alanine-rich protein GLLGSVSSSL VR 29257 5.71
Decreased expression in both clinical strains
9 CF Rvl096b - possible glycosyl hydrolase ANDVIAAATGR 31109 6.52
LVTVSELLGPR
35686 6.08
fbpA antigen 85A
FLEGFVR
Rv3804c ASDMWGPK
NDPLLNVGK
ALGA TPNTGP APQGA
lO CF RvOl29c fbpC antigen 85C NDPMVQIPR 36771 5.92
EMPAWLQANK
Rv0831cb conserved hypothetical protein
NQAIVVETTAYR 33885 5.88-
cysA3 probable thiosulphate sulphurtransferase
DFVDAQQFSK 31014 5.14
Rv3117b
fbpA
NDPLLNVGK 35686 6.08
Rv3804c
antigen 85A ALGATPNTGPAPQGA
11 CF Rv3804c fbpA antigen 85A FLEGFVR 35686 6.08
NDPLLNVGK
ALGA TPNTGP APQGA
Decreased expression in Beijing strain only
12 CF Rv0934 psiS] Periplasrnic phosphate-binding lipoprotein VLAAMYQGTIK 38243 5.14
Rvl886c fbpB antigen 85B AADMWGPSSDPA WER 34580 5.62
apredicted Mwand pI values calculated using the Expasy compute pIlMw tool (http://www.expasy.ch/tools/pi tool.html).
bNovel proteins not previously identified by proteomics (Jungblut et al. 1999; Rosenkrands et al. 2000a and b; http://www.mpiib-berlin.mpg.de/2D-PAGE).
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4.3.2 Reactivity of monoclonal antibodies with proteins extracted from M. tuberculosis
strains
In some cases, spots excised from 20 gels were identified as containing two or more
proteins by LC/MSIMS. This included proteins of the Ag85 complex and PstSl. Western blot
analysis was therefore employed to help determine whether these proteins were responsible for
the differences observed and also to investigate the expression of 12 other antigens in the three
strains. Western blot analysis of whole-cell lysate and culture filtrate proteins harvested from the
different M tuberculosis strains showed that varying levels of the proteins to which the mAbs
react were expressed in the different M tuberculosis strains. The differences in mAb reactivity
between the strains are shown in Figure 4.2 and Figure 4.3.
10 and 20 Western blotting identified PstSI as the protein responsible for the decreased
expression of spot 12 (Figure 4.1 and Table 4.2) in the Beijing strain compared to the family 23
strain and H37Rv (Figure 4.2D and Figure 4.3B). 20 Western blotting showed the existence of
more than one isoform of PstS 1, which has been previously reported by Sonnenberg & Beslisle
(Sonnenberg & Beslisle, 1997) and is probably due to post-translational modifications such as
glycosylation, phosphorylation or acetylation. The absence of PstS 1 in culture filtrates of the
family 23 strain (Figure 4.3B) is probably due to decreased expression in culture filtrates
compared to whole-ceillysates, as observed on 10 Western blots (Figure 4.20). Several isoforms
of a-crystallin were observed and were expressed more highly in the Beijing strain compared to
the family 23 strain and H37Rv (Figure 4.2A and Figure 4.3A). Consistent with 2D results,
expression of a-crystallin was increased in the whole-cell lysate compared to the culture filtrate.
L-alanine dehydrogenase and ESAT6 (Figure 4.2B and I) showed decreased expression in
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H37Rv compared to both clinical strains, while expression of ESAT6 was decreased in the
Beijing strain compared to the family 23 strain. Expression of L-alanine dehydrogenase was
restricted to whole-cell lysates, whereas ESAT6 showed increased expression in both fractions.
Three proteins, Hsp65, the Ag85 complex and the 47 kDa protein were downregulated in both
clinical strains relative to H37Rv (Figure 4.2C, F and H), while Hsp65 and the 47 kDa protein
were also downregulated in the Beijing strain compared to the family 23 strain. Multiple bands of
Hsp65, possibly different isoforms or degradation products, were observed in both whole-cell
lysates and culture filtrates. Hsp65 observed in culture filtrates is probably due to bacterial lysis.
The expression of the other proteins was approximately similar in all the strains analysed,
although some quantitative differences between their expression levels in whole-cell lysates and
culture filtrates were observed. For example, expression of KatG was increased in the culture
filtrate of H37Rv compared to the clinical strains, but decreased in the whole-cell lysate of
H37Rv compared to the clinical strains (Figure 4.2E). The mAb directed to KatG (lT42) reacted
with two bands in both whole-cell lysates and culture filtrates, with the lower band corresponding
to the correct molecular weight. Sonnenberg & Beslisle (Sonnenberg & Beslisle, 1997) have also
reported that IT42 reacts with more than one protein. The upregulation of a-crystallin and L-
alanine dehydrogenase, and the down regulation of Hsp65 and Ag85 in the clinical strains
compared to H37Rv, was confirmed by ELISA (data not shown).
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Figure 4.2 Protein expression in M tuberculosis strains. Ten micrograms of whole-cell lysate (lanes 1, 3, 5)
and culture filtrate proteins (lanes 2, 4, 6) of M tuberculosis H37Rv (lanes 1,2), the Beijing strain (lanes 3, 4)
and the family 23 strain (lanes 5, 6) was separated by 12% SDS-PAGE, transferred onto PVDF membranes
and probed with mAbs directed to a-crystallin (A), L-alanine dehydrogenase (B), Hsp65 (C), PstSI (D), KatG
(E), the Ag85 complex (F), the 96 kDa protein (G), the 47 kDa protein (H), ESAT6 (I), the 19 kDa protein (1),
the 17 kDa protein (K), the 20 kDa protein (L), the 56 kDa protein (M) and the 25 kDa protein (N).
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Figure 4.3 a-crystallin and PstSI expression in M tuberculosis strains. Sixty micrograms of protein extracted
from M tuberculosis H37Rv WCL (1,7) and CF (2,8), the Beijing strain WCL (3, 9) and CF (4, 10) and the
family 23 strain WCL (5, 11) and CF (6, 12) was separated by 12% 2D PAGE, transferred to nitrocellulose
membranes and probed with mAbs directed to a-crystallin (A) and PstSI (B).
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4.3.3 Reactivity of plasma samples to proteins extracted from the three M. tuberculosis
strains
To establish whether there was differential antigen recognition in TB patients between the
M tuberculosis strains investigated in this study, plasma-derived antibodies of TB patients were
tested against proteins extracted from M tuberculosis H37Rv, the Beijing strain and the family
23 strain. After ID PAGE separation and transfer to PVDF membranes, proteins were probed
with plasma from TB patients infected with Beijing, family 23 or family Il strains (Table 4.1,
Figure 4.4). As expected, plasma from TB patients reacted with a wide variety of M tuberculosis
proteins, ranging from 10 kDa to over 105 kDa (Figure 4.4). Plasma samples were tested on
antigens fractionated on different gels, therefore figures were aligned according to molecular
weight markers, which were included on each gel, and mobility of immunodominant antigens.
Our results clearly show that each patient had a characteristic banding pattern (Figure 4.4), with
individual patients generally recognising the same proteins in M tuberculosis H37Rv and the two
clinical strains, as previously reported by Rojas-Espinosa et al. (Rojas-Espinosa et al. 1999).
Some differences in antigen recognition between the strains were noted. Prominent
differences between strains are indicated by arrows in Figure 4.4. A band of approximately 56
kDa (arrow 1), was recognized by patient 880 in H37Rv but not in the family 23 strain or the
Beijing strain (Figure 4.4F). Patient 880 reacted with a protein of about 35 kDa (arrow 2) in
protein extracts of the family 23 strain and the Beijing strain only (Figure 4.4F). Proteins of
approximately 28 and 25 kDa which were recognised strongly by patient 97 in H37Rv only, are
indicated by arrows 3 and 4 (Figure 4.4A). Variation in antigen recognition was observed even
between patients infected with the same strain (patients 941, 880 and 881 were infected with
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Beijing strains, while patients 97, 484, 522 and 672 were infected with family 11 strains),
suggesting that antibody responses are influenced by both M tuberculosis strain type and patient-
to-patient variation.
A B C D E F G H
M tuberculosis
strain family 11 11 II 11 23 Beijing Beijing Beijing
Patient no. 97 484 522 672 726 880 881 941
Lane I 2 3 4 5 6 I 234 5 6 I 2 3 4 5 6 I 2 3 456 I 2 3 4 5 6 I 2 3 4 5 6 I 2 3 4 5 6 I 2 3 4 5 6
Figure 4.4 Antigen expression by M tuberculosis strains. Plasma from TB patients (A) 97; (B) 484; (C) 522; (D) 672; (E) 726;
(F) 880; (G) 881; (H) 941 was probed against proteins extracted from M tuberculosis H37Rv (lane 1=1:100 plasma dilution;
lane 2=1 :500 plasma dilution), the Beijing strain (lane 3=1: 100 plasma dilution; lane 4=1 :500 plasma dilution) and the family 23
strain (lane 5=1:100 plasma dilution; lane 6=1:500 plasma dilution). Proteins were separated by 12% SDS-PAGE under
reducing conditions and then transferred onto PVDF membranes. Molecular weight markers are indicated on the left. Arrows
indicate antigenic variants at approximately 56, 35, 28 and 25 kDa.
105kD.
75 kDa
56kD. - -_--
35 kD.
30kD.
25kD.
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IOkD. hi
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2D Western blotting of patient plasma samples 97, 726, 880 and 941 against proteins
extracted from M tuberculosis H37Rv, the Beijing strain and the family 23 strain confirmed ID
Western blotting where each patient had a characteristic banding pattern (Figure 4.5). The
changes observed in antigen recognition for patient 97 (Figure 4.4A) are obscured by a broad,
diffuse smear on 2D blots (Figure 4.5). The smear may possibly represent lipoarabinomannan
(LAM), an immunodominant glycolipid which migrates between 30 and 40 kDa, as demonstrated
previously (Hunter et al. 1986). The 35 kDa and 56 kDa changes observed on 1D blots using
patient 880 plasma (Figure 4.4F) are in a region containing many spots (Figure 4.5, box 4) on the
2D blots and therefore cannot be clearly identified. Patient 726 recognised more proteins in the
Beijing strain compared to H37Rv and the family 23 strain (Figure 4.5, box 3). Boxes 1, 4 and 7
indicate regions where plasma from patients 97, 880 and 941 reacted with fewer proteins in the
Beijing strain compared to the other strains. However these were not accurately resolved and may
require larger format or narrow range IPGs for identification.
Patients 97 and 941 recognised two spots more strongly in the clinical strains than in
H37Rv (Figure 4.5, spots 2 and 9), whereas patients 880 and 941 showed decreased recognition
of spot 5 and spot 8 in the Beijing strain. Although it is difficult to speculate what proteins these
spots represent, comparison with silver-stained 2D gels suggests that spot number 6, which is
recognised by patient 880 only, represents a.-crystallin. Interestingly, a band migrating at
approximately the molecular weight of n-crystallin was also more prominently recognised by
patient 880 on ID blots (Figure 4.4F).
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Figure 4.5 Antigen expression by M tuberculosis strains. Proteins extracted from cultures of M
tuberculosis H37Rv, the Beijing strain and the family 23 strain were separated by 12% 2D PAGE,
transferred to nitrocellulose membranes and probed with al: 150 dilution of plasma samples from TB
patients 97,726,880 and 941. Molecular weight markers are indicated on the right. Differential antigen
recognition is indicated by circles and boxes.
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4.3.4 Sequence comparisons of the promoter regions of the katG and pstS1 genes of H37Rv,
strain 1296 and the Beijing strain
Since there was a marked difference observed in the expression of PstSl in the Beijing
strain compared to the other strains and a difference in KatG expression between the clinical
strains and H37Rv, the promoter regions of pstSJ and katG in all three strains were analysed.
Sequence comparison of the region encompassing 550 bp upstream and 150 bp downstream of
the start codon of the pstSJ and katG genes showed no difference between the published H37Rv
sequence (http://genolist.pasteur.fr/TubercuLisU) and sequences obtained from peR products
amplified from H37Rv, the Beijing and the family 23 strain (data not shown), suggestingthat
polymorph isms in this region are not responsible for the differential protein expression observed
by these strains.
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4.4 Discussion
Extensive research into development of serological tests to diagnose TB has failed to
produce an accepted serodiagnostic test for clinical use (Chan et al. 2000). One of the factors
hampering serodiagnosis is the humoral heterogeneity of TB patients (Lyashchenko et al. 1998a),
which may be due to, amongst other things, differential antigen presentation by M tuberculosis
strains as they cause disease in different individuals (Lyashchenko et al. 1998a; Samanich et al.
2001). In this study we compared protein expression by M tuberculosis H37Rv and two local
clinical strains, one belonging to the Beijing family of strains and their recognition by the host
humoral immune system. Several proteins showed increased or decreased expression in the
clinical strains compared to the laboratory strain H37Rv. Additionally, the Beijing strain showed
more marked increases or decreases in expression of some of these antigens compared to the
other clinical strain. Furthermore, the probing of proteins extracted from the three strains by
plasma from TB patients demonstrated differences in antigen recognition by these patients.
M tuberculosis strains belonging to the Beijing family are distributed worldwide and are
able to spread in large clonal clusters (Glynn et al. 2002). It is speculated that strains belonging to
the Beijing family have an advantage over other strains of M tuberculosis and that identification
of the factors responsible would aid understanding of the success of Beijing strains compared to
other M tuberculosis strains (Bifani et al. 2002). It has previously been suggested that reduced
expression of certain major antigens may allow strains to evade the host immune response
(Stewart et al. 2001), and therefore the decreased expression of Hsp65, PstSI, ESAT6 and the 47
kDa protein by the Beijing strain compared to the family 23 strain as reported here, may
contribute to the success of the Beijing strain family. Additionally, increased expression of
factors such as a-crystallin which are induced under host-relevant conditions (Betts et al. 2002,
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Monahan et al. 2001; Sherman et al. 2001; Yuan et al. 1998) may help to increase the
pathogenicity and prevalence of Beijing strains compared to the family 23 strains. Differences in
antigen recognition between the strains, as observed from ID and 2D Western blots, may be
significant and may assist the Beijing strain to minimise recognition by the host immune
response, thereby facilitating the increased prevalence of Beijing strains.
Within our study community, Beijing strains have the highest mutation rate, due to
IS6110 insertions, chromosomal mutations and deletions (Warren et al. 2000). It has been shown
that the IS6110 element can insert into coding regions, thereby potentially affecting protein
expression and phenotype (Sampson et al. 1999). Analysis of IS6110 insertion sites in Beijing
strains (Beggs et al. 2000; Sampson et al. 1999; Warren et al. 2000) showed that none of the
genes investigated in this report were disrupted by IS6110 insertion, suggesting that the
differential protein expression observed in our Beijing strain compared to the other strains
investigated is probably not IS6110 insertion-mediated. However, the potential role ofIS6110 in
affecting expression of these proteins cannot be discarded due to polarizing effects.
PstS 1, a 38 kDa phosphate-binding lipoprotein possibly involved in phosphate transport,
is specific for the M tuberculosis complex, and is a known B-and T-cell stimulant (Harboe and
Wiker, 1992). Although studies measuring antibody levels to PstS 1 have reported that the
presence of PstS 1 antibodies is associated with advanced disease (Bothamley et al. 1992; Laai et
al. 1997), PstS 1 has shown the most promise for serological diagnosis of TB. Sensitivities of 70
% and 73 % have been reported for smear negative pulmonary TB and extrapulmonary TB
patients, respectively (Wilkins and Ivanyi, 1990). In a recent evaluation of commercially
available tests the highest sensitivity achieved with PstS 1 was 55 % (Pottumarthy et al. 2000).
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Decreased expression of PstS 1 in the Beijing strain, as shown here, may possibly explain the
absence of PstS 1 antibodies in some TB patients. Similarly, differential expression of other
proteins investigated in this study may contribute to the heterogeneous host humoral response of
TB patients, suggesting that measurement of antibody levels to proteins that are not susceptible to
differential expression by M tuberculosis strains is required for the development of new
diagnostic agents for TB. Furthermore, variation in antigen recognition by patients, as observed
from Western blotting, suggests that both strain-related and host-related differences influence the
humoral immune response, and may be responsible for the heterogeneity observed amongst TB
patients (Lyashchenko et al. 1998a).
One dimensional Western blotting showed that smear-positive patients recognised more
proteins than smear negative individuals. Studies have reported that higher bacterial loads in vivo
result in increased antibody production (Chan et al. 2000). None of the patients used in this study
were infected with HIV, dismissing an HIV-dependent reduced antibody response (Bothamley,
1995; Chan et al. 2000). ID and 2D Western blotting showed that patient 97, who experienced
two episodes of disease, recognised more antigens than any of the other patients. The increased
antibody levels observed for patient 97 is possibly due to previous anti-TB therapy. Many studies
have reported an increase in M tuberculosis specific antibodies during treatment (Bothamley,
1995), possibly due to increased stimulation of the humoral response as antibiotic therapy
destroys mycobacteria, and increases the antigenic load or, alternatively, due to the disappearance
of circulating antigens and therefore release of antibodies trapped in immune complexes. Anti-TB
treatment has been speculated to be one of the reasons for the heterogeneous humoral immune
response of TB patients (Lyashchenko et al. 1998a). In this study we have observed variable
antibody responses amongst patients who had not yet undergone drug treatment, suggesting that
Stellenbosch University http://scholar.sun.ac.za
86
although anti-TB treatment quantitatively affects antibody responses, it does not have a major
effect on humoral heterogeneity.
This study has shown that both differential antigen presentation by M tuberculosis strains
and patient-to-patient variation affect the host humoral immune response, although patient-to-
patient variation appears to be the major factor affecting humoral heterogeneity. Using 2D
Western blots, Samanich et al. (2001) showed that both noncavitary and cavitary TB patients
recognised a subset of 12-15 M tuberculosis culture filtrate antigens, and reported that the
humoral response of TB patients is homogeneous. Our conflicting results are possibly due to the
fact that we measured antibody responses to whole-cell lysate proteins, whereas Samanich et al.
(Samanich et al. 2001) looked at culture filtrate proteins. Furthermore, our patients were recruited
from a high incidence community (Warren et al. 2000), where patients are infected with a wide
variety of M tuberculosis strains. Differential protein expression by M tuberculosis strains, as
shown in this study, may explain the high degree of antibody variability between our patients.
The finding that both host and bacteriological factors contribute to the humoral
heterogeneity observed amongst TB patients may complicate the development of a serodiagnostic
test for TB, suggesting that tests based on single antigens are likely to be of limited use and that
multi-antigen cocktails are more likely to be successful (Al Zahrani et al. 2000; Amicosante et al.
1999). Our study supports the development of a diagnostic test based on detection of several M
tuberculosis antigens, thereby circumventing the heterogeneity of the host humoral immune
response. Furthermore, we have shown that differential protein expression by M tuberculosis
strains may explain why certain strain families, such as the Beijing family, are more "successful"
than others.
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Chapter 5
INVESTIGATION OF PROTEIN AND ANTIGEN EXPRESSION BY
MYCOBACTERIUM TUBERCULOSIS STRAINS UNDER STRESS
CONDITIONS
The results presented in this chapter will be adapted and submitted as a manuscript,
"Investigation of protein and antigen expression by Mycobacterium tuberculosis strains under
stress conditions. Carmen Pheiffer, Joanna Betts, and Paul van HeIden".
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5.1 Introduction
Tuberculosis (TB) is a major source of morbidity and mortality worldwide, resulting in
about 8 million new cases and 2 million deaths annually (Corbett et al. 2003). M tuberculosis
can cause both active disease and latent infection, where bacilli are in a nonreplicating or
dormant state. Individuals with latent TB can remain asymptomatic for years, after which
immunosuppression may result in reactivation of dormant bacilli and the establishment of clinical
disease (Flynn and Chan, 2001). This is most clearly illustrated by HIV coinfection, which
increases the 10% lifetime risk ofTB activation to a 10% annual risk (Bloom and Murray, 1992).
The increasing HIV pandemic, especially in areas where TB is endemic and where latent TB
must be prevalent has created an urgent need to develop new antimycobacterial drugs (O'Brien
and Nunn, 2001) and vaccines (Olsen and Andersen, 2003) to target latent TB and minimize the
progression to active disease. Furthermore, the development of new drugs that will target latent
TB may decrease the duration of TB treatment, thereby reducing patient relapse rates and
minimizing the development of drug resistance.
It is thought that mycobacterial dormancy occurs within granulomas, probably due to
oxygen and nutrient deprivation (Fenton and Vermeulen, 1996) and that survival of bacilli
depends on their ability to mount an effective response to this hostile environment. A number of
in vitro models to mimic the metabolic state of mycobacteria during latent disease have been
developed and are used as tools for identifying proteins that are differentially expressed by
dormant bacteria. The Wayne model mimics dormancy in vitro by subjecting bacterial cultures to
a gradual depletion of oxygen (Wayne, 1994; Wayne and Hayes, 1996). During anaerobic
conditions, bacteria terminate replication and adopt a persistent and viable state, capable of
growth resumption with oxygen reintroduction. Bacteria in this hypoxic environment are resistant
Stellenbosch University http://scholar.sun.ac.za
89
to isoniazid and rifampicin, the frontline antimycobacterial drugs, and could possibly explain the
persistence of the pathogen during chemotherapy (Wayne and Sramek, 1994). This model has
been used extensively to identify mycobacterial factors expressed during oxygen depletion. A
number of studies have shown upregulation of a-crystallin under conditions of hypoxia (Boon et
al. 2001; Desjardin et al. 2001; Rosenkrands et al. 2002; Sherman et al. 2001; Tabira et al. 1998;
Yuan et al. 1998). Other proteins including bacterioferritin and Rv2623 have also been reported
to be induced during oxygen depletion (Boon et al. 2001; Sherman et al. 2001; Rosenkrands et
al. 2002). Monahan et al. (2001) showed upregulation of a-crystallin and Rv2623 during in vitro
macrophage infection, suggesting that these proteins may be important for intracellular survival.
Further evidence for the role of a-crystallin in TB pathogenesis comes from studies reporting that
a-crystallin is necessary for survival in cultured macrophages (Yuan et al. 1998), and is
frequently recognized by sera from TB patients (Lee et al. 1992; Verbon et al. 1992).
Betts et al. (2002a) developed an in vitro model of persistence based on the results of
Loebel et al. (1933). Here, transfer of cultures from a nutrient-rich medium to PBS arrests
bacterial growth, decreases respiration, and alters antimycobacterial drug susceptibility (Betts et
al. 2002a). Transcript expression profiling showed downregulation of genes involved in
transcription and translation, energy metabolism, lipid biosynthesis, and cell division. Two genes
involved in antibiotic resistance were upregulated and nutrient-starved bacteria were resistant to
isoniazid, rifampicin and metronidazole. Resistance to metronidazole suggests that nutrient
starvation does not induce hypoxia since bacilli are sensitive to metronidazole during anaerobic
growth. Proteornics identified several proteins that were induced in response to nutrient
starvation, and microarray analysis confirmed some of the changes at the gene level (Betts et al.
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2002a). In situ hybridization showed that mRNA for Rv2557 and/or Rv2558, two genes
upregulated during nutrient starvation (Betts et al. 2002a), is expressed in human lung
granulomas and may therefore be important for the persistence of infection (Fenhalls et al. 2002).
This study was not able to distinguish expression of Rv2557 and Rv2558 since these gene
products are highly homologous (69% protein and 81% DNA identities).
In previous studies we compared protein expression and antigen presentation by two M
tuberculosis clinical strains, originally isolated from patients from a community in Cape Town,
South Africa with a very high TB incidence (Warren et al. 2000), to the laboratory strain H37Rv
using one-dimensional (ID) and two-dimensional (2D) polyacrylamide gel electrophoresis
(PAGE), enzyme-linked immunosorbent assay (ELISA) and Western blotting (Pheiffer et al.
2002 and unpublished data). Based on the number of IS6110 insertions and spoligotyping, the
two clinical strains were classified as belonging to the Beijing family and family 23 (Pheiffer et
al. 2002; Warren et al. 2000). Our results revealed considerable differences in protein expression
between the three strains, particularly between the two clinical strains compared to H37Rv. Here,
we have extended our previous studies by comparing protein expression and antigen recognition
patterns of these strains during "dormancy" conditions. We chose to mimic dormancy using
hypoxia (Wayne, 1994; Wayne and Hayes, 1996), nutrient depletion (Betts et al. 2002a), and
stationary growth (Yuan et al. 1996). Protein expression during these conditions was compared to
expression patterns obtained from log-phase cultures. Through 2D PAGE and silver staining, and
Western blotting with monoclonal antibodies (mAbs) directed to well-known M tuberculosis
proteins, we were able to identify several proteins induced under these conditions. 2D Western
blotting with patient sera identified several antigens which are differentially recognized by the
host during "dormancy" conditions, thereby suggesting that at least some bacteria were likely in a
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dormant or latent stage in the host. Comparison of the protein expression and antigen recognition
profiles of M tuberculosis H37Rv and two local clinical strains revealed some differences
between the three strains. Careful analysis of these differences could identify factors important
for latency, thereby aiding the development of new drugs and vaccines. Identification and
analysis of differences observed between the clinical strains may provide some clues as to why
patients do not develop adequate protective immunity to TB and why they are susceptible to
reinfection. Furthermore, differences may also explain why some M tuberculosis strain families
are perceived to be more dominant than others.
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5.2 Materials and Methods
5.2.1 M. tuberculosis strains and culture
M tuberculosis H37Rv (ATCC 25618) and two local clinical strains (Beijing (SAWC
1524) and family 23 (SAWC 1296)) were grown in 10 ml of Middlebrook 7H9 media (Difco,
Becton Dickinson, USA) supplemented with 10% albumin-dextrose-catalase (ADC) and 0.05%
Tween-80 (MADCTW). Cultures were stirred with 8 mm Teflon-coated magnetic stirrer bars at
37°C until an optical density at 600 nm (OD6oo) >0.6 was observed (LKB spectrophotometer,
LKB Biochrom, Cambridge, UK). Pre-cultures were diluted 1:50 into 25 ml MADCTW and
cultured for a further 7 days. For log-phase and stationary phase growth, pre-cultures were
diluted 1:100 into 25 ml of MADCTW and stirred for 7 days (log-phase) or grown for 4 weeks
without stirring (stationary) in 50 ml tubes (Corning, NY, USA). For nutrient starvation,
exponential growing cultures were harvested, washed twice with phosphate buffered saline
(PBS), resuspended in 25 ml of PBS and maintained at 37°C for 4 weeks without stirring in 50
ml tubes. For anaerobic conditions pre-cultures were diluted 1:10 into 50 ml MADCTW, and
grown without stirring in 50 ml tubes. Tubes were sealed with parafilm. Oxygen depletion was
monitored by addition of sterile methylene blue solution (500 ug/ml) to a final concentration of
1.5 ug/ml. Proteins were extracted after approximately 12 weeks when cultures appeared
colourless. Morphology and acid-fastness was checked by Ziehl-Nielsen staining (Heifets and
Good, 1994). All strains were sensitive to isoniazid, rifampicin and ethambutol.
5.2.2 Protein extraction
Whole-cell extracts were prepared as previously described (Pheiffer et al. 2002). Briefly,
cultures were pelleted by centrifugation at 1 900 g for 20 min. Pellets were washed twice in
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PBS/1 % (V/V) Tween-20 and centrifuged (4 000 g, 5 min). Mycobacterial cells were resuspended
in lysis buffer (0.3% (w/v) SDS, 200 mM DTT, 50 mM Tris-HCl pH 7.0, 1 mM PMSF and
complete protease inhibitor cocktail (Roche Molecular Biochemicals, Mannheim, Germany)). An
equal volume of Silica/Ceramic Matrix Beads (BIO 101, Vista, USA) was added, samples were
mixed by vortexing and thereafter heat-killed at 80°C for 20 min prior to bead disruption in a
ribolyser (speed of 6.5 for 45 seconds) (BIO 101, Vista, USA). After boiling for 5 min, samples
were clarified by centrifugation at 10000 g for 10 min and protein concentrations estimated using
the Bradford assay (Bradford, 1976).
5.2.3 Two-dimensional polyacrylamide gel electrophoresis
Proteins were separated by two-dimensional gel electrophoresis as previously described
(Betts et al. 2000), with minor modifications. Briefly, 20 !lg (60 ug for Western blotting) of
protein was resuspended in rehydration buffer (8 M urea, 2% (w/v) CHAPS, 10 mM DTT, 2%
(v/v) immobilised pH gradient (lPG) buffer (PH4-7), trace bromophenol blue) and applied to pH
4-7 lPG strips (Amersham Biosciences, Uppsala, Sweden) for overnight rehydration. Isoelectric
focusing was performed using a Multiphor IIsystem (Amersham Biosciences) as follows: 100 V
for 2 h, 300 V for 2 h, 1000 V for 1 h, 3500 V for 20 h (3500 V for 27.5 h for Western blotting).
Second dimension separation was carried out by placing equilibrated lPG strips (Bjellqvist et al.
1993, http://www.expasy.chlch2d/protocolsQ onto 12% PAGE gels and sealing with 0.5% (w/v)
agarose in cathode buffer (defined below), containing a trace amount of bromophenol blue.
Anode (375 mM Tris-HCl, pH 8.8) and cathode (192 M glycine, 0.1% (w/v) SDS, pH 8.3)
buffers as described by Herbert et al. (1998) were used. Proteins were visualized by silver
staining usmg an ammoniacal stain (Bjellqvist et al. 1993;
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http://www.expasy.ch/ch2d/protocols/). Gels were air dried (BioRad GelAir Dryer, Hercules,
USA) and compared by visualization on a light box.
5.2.4 Monoclonal antibodies
Mouse monoclonal antibodies (mAbs) IT-4, IT-13 and IT-23, raised against the 16 kDa
(a-crystallin), 65 kDa (Hsp65) and 38 kDa (PstSI) M tuberculosis proteins (Engers et al. 1986;
Khanolkar et al. 1992; Sonnenberg and Beslisle, 1997) respectively were made available by the
Department of Microbiology, Colorado State University through funds from the National
Institutes of Health, National Institute of Allergy and Infectious Disease, Contract NO l-AI-
75320. HYB76-8 directed to ESAT6 (Sorensen et al. 1995) was received from Karin Weldingh
(Statens Serum Institut, Copenhagen, Denmark).
5.2.5 Western blotting with monoclonal antibodies
Ten micrograms of protein was separated by SDS-PAGE (Mini-PROTEIN
electrophoresis unit, BioRad, Hercules, USA) using a 4% stack over a 12% resolving gel
(Laemmli et al. 1970). After electrophoresis, proteins were transferred to PVDF membranes
(Amersham Biosciences) by tank blotting. Blots were incubated with mAbs (IT-4, 1:1000; IT-13,
1:500; IT-23, 1:100; HYB76-8, 1:100) and screened for antibody binding with a horseradish
peroxidase-conjugated goat anti-mouse IgG (1:10 000, CALTAG laboratories, Burlingame,
USA). Bound antigens were detected using chemiluminescence detection reagents (ECL™
Western blotting detection reagents, Amersham Biosciences).
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5.2.6 Western blotting with patient sera
2D gels were transferred to nitrocellulose membranes (S&S Protran BA85, Schleicher &
Schuell Inc., Keene, USA) using semi-dry blotting. Blots obtained from 2D gels were probed
with sera from a TB patient diluted 1:100 and screened for antibody binding using alkaline
phosphatase-conjugated goat anti-human IgG (1:2 000, Kirkegaard & Perry Laboratories Inc.,
Gaithersburg, USA). Immunoreactive antigens were detected using the BCIPINBT substrate
(Kirkegaard & Perry Laboratories Inc.).
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5.3 Results
5.3.1 Two-dimensional protein expression patterns of M. tuberculosis strains
Whole-cell lysate proteins were extracted from log-phase, nutrient-starved, stationary and
anaerobic cultures of M tuberculosis H37Rv, the Beijing strain and the family 23 strain. Proteins
were analysed by 20 PAGE using pH 4-7 lPG strips and 12% PAGE gels (Figure 5.1). Pilot
experiments demonstrated that many M tuberculosis proteins focus between pH 4 and 7 and the
best resolution for comparison was achieved using this pH range. Duplicate gels were run for
each sample and proteins were visualized by silver staining. Spot differences obvious by visual
comparison were analysed. Some of the proteins observed on 20 gels were putatively identified
by comparison with previous 20 gels (Betts et al. 2002a; Pheiffer et al. unpublished data (chapter
4)) and their identities are listed in Table 5.3. Seven protein spots were downregulated in log-
phase and nutrient-starved cultures of the Beijing strain compared to the M tuberculosis H37Rv
and the family 23 strain (Figure 5.1, Table 5.1, Table 5.3). Spots 3-6 were identified as a-
crystallin, spot 12 contained Rv2629, while spots 1 and 2 each contained Rv2623. Spot number 1
also contained Rv2744c, the 35 kDa antigen. Previous studies have also reported the appearance
of multiple isoforms of a-crystallin with different molecular weights and isoelectric points (Betts
et al. 2000; Sonnenberg and Beslisle, 1997), possibly due to degradation, post-translational
processing or post-translational modification, such as phosphorylation or glycosylation. Protein
spot 13 was upregulated in log-phase and nutrient-starved cultures of the Beijing strain compared
to H37Rv and the family 23 strain. Protein spot 11 was downregulated in proteins extracted from
all cultures of the family 23 strain compared to M tuberculosis H37Rv and the Beijing strain.
Protein expression differences between H37Rv and both clinical strains were also noted. Protein
spot 15, identified as Rv2624c, was downregulated in log-phase and nutrient-starved cultures of
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the clinical strains compared to H37Rv. Spot 14 was only identified in log-phase and anaerobic
cultures of the clinical strains compared to H37Rv. M tuberculosis H37Rv, the Beijing strain and
the family 23 strain showed similar expression of at least seven proteins, although varying levels
of these proteins were expressed during the different culture conditions. Spot 18, Rv0685 or
elongation factor EF-Tu, was downregulated in stationary and anaerobic cultures compared to
log-phase and nutrient-starved cultures (Figure 5.1, Table 5.2, Table 5.3). Two spots (spot 7 and
8) identified as Rv2557 and Rv2558, were upregulated in nutrient-starved and stationary cultures
compared to log-phase and anaerobic cultures. Spots 9 and 10 were downregulated in nutrient-
starved cultures compared to log-phase cultures. Bacterioferritin, spot 16, was upregulated in
stationary and anaerobic cultures compared to log-phase and nutrient-starved cultures. Spot 17
containing Rv2744c (the 36 kDa antigen) was upregulated in anaerobic cultures compared to log-
phase, stationary-phase and nutrient-starved cultures. A number of the protein differences were
not followed up due to limited resources. It was difficult to recognize some spot differences
identified on 2D gels prepared from log-phase and nutrient-starved cultures on 2D gels prepared
from stationary and anaerobic cultures, since protein spots were less defined on the latter gels.
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Figure 5.1 2D gels of proteins expressed during stress conditions. Proteins were extracted from log-phase,
nutrient-starved, stationary and anaerobic cultures of M tuberculosis H37Rv, the Beijing family strain and
the family 23 strain. Protein spots with differential expression between strains and under culture
conditions are circled, while proteins with similar expression between strains, but differential expression
during culture conditions are boxed. The identities of some of the differences are listed in Table 5.3.
Molecular weight markers are indicated on the right.
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Table 5.1 Summary of protein spot differences between log-phase, nutrient-starved, stationary and
anaerobic cultures of M tuberculosis H37Rv, the Beijing strain and the family 23 strain.
M.tuberculosis H37Rv Beijing strain Family 23 strain
Spots 1,2,3-6, 12 ,l- equals standard
Spot 13 t equals standard
log-phase standard" equals standard Spot 11 ,l-
Spot 15 ,l- Spot 15 ,l-
Spot 14 t Spot 14 t
Spots 1, 2, 3-6, 12 ,l- equals standard
Spot 13 t equals standard
nutrient-starved standard"
equals standard Spot Il ,l-
Spot 15 ,l- Spot 15 ,l-
stationary standard" equals standard Spot Il ,l-
anaerobic standard" Spot 14 t Spot 14 t
·standard indicates the point of reference M tuberculosis H37Rv.
The identities of some of the proteins are listed in Table 5.3.
Table 5.2 Protein spots with similar expression between strains but with varying levels of expression
during growth conditions.
log-phase nutrient-starved stationary anaerobic
18 standard" equals standard ,l- ,l-
7 standard" r t equals standard
8 standard" t t equals standard
9 standard" ,l- equals standard equals standard
10 standard" ,l- equals standard equals standard
16 standard" equals standard r t
17 standard" equals standard equals standard r
·standard indicates the point of reference.
The identities of some of the proteins are listed in Table 5.3.
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Table 5.3 Identity ofsome of the protein spots differences observed on 2D gels.
Spot ORF Gene name Protein Matched peptides
Rv2623 conserved hypothetical protein YPNVAITR
LLGSVSSGLLR
SEEAQL VVVGSR
Rv2744c 35kd_ag 35 kDa antigen QALTLADQATAAGDAAK
2 Rv2623 conserved hypothetical protein YPNVAITR
LLGSVSSGLLR
SEEAQLVVVGSR
3-6 Rv2031c hspX heat shock protein, HspX SEFAYGSFVR
TVSLPVGADEDDIK
7 Rv2557 24.3 kDa conserved hypothetical protein Betts et al. 2002*
8 Rv2558 25.7 kDa conserved hypothetical protein Betts et al. 2002*
12 Rv2629 hypothetical protein TDLLSTLPQR
IAPLDGVGALLR
QELIDSLEEA VR
DADMLSELGEPVDR
GSGLAAQGLAEVCAALR
LVDAADPEVVFVSGEVR
15 Rv2624c conserved hypothetical protein GPAGPVLVEASR
DAEMICVGSVGIGR
VQLAVIGGGEAGQLAR
YASSILGSTATELAEK
MTDAPDNEAVLEYAAR
16 Rv3841 bfrE bacterioferritin VEIPGVDTVR
EALALALDQER
HFYSQAVEER
AGANLFELENFV AR
17 Rv2744c 35kd_ag 35 kDa antigen LLSQLEQAK
VQIQQAIEEAQR
QALTLADQATAAGDAAK
YANAIGSAELAESSVQGR
SMSELAAPGNTPSLDEVR
18 Rv0685 tuf elongation factor EF-Tu TTVTGVEMFR
LlQPV AMDEGLR
AFDQIDNAPEER
LLDQGQAGDNVGLLLR
ELLAAQEFDEDAPVVR
Protein spots were putatively identified by comparison with previous 2D gels and mass spectrometry data (Pheiffer et
al. unpublished data (chapter 4».
*Spots 7 and 8 were identified by comparison with 2D gels and mass spectrometry data of Betts et al. 2002a.
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5.3.2 Reactivity of monoclonal antibodies
Western blot analysis with monoclonal antibodies directed to ESAT6, Hsp65, PstS 1 and
a-crystallin was employed to investigate the expression of these proteins under the different
growth conditions. Western blot analysis of whole-cell lysate proteins harvested from the
different M tuberculosis strains showed that expression of these proteins varied with growth
condition and strain genotype (Figure 5.2). Expression of PstS 1 appeared to be independent of
growth condition, but dependent on strain genotype. PstS 1 was not expressed by the Beijing
strain compared to H37Rv and the family 23 strain. Levels of Hsp65 expression appeared to be
maximal during log-phase, with no major differences in expression between strains. ESAT6 was
expressed at lower levels by H37Rv compared to the clinical strains under all growth conditions
studied. Expression of a-crystallin varied for the Beijing strain particularly, with no expression in
log-phase cultures and nutrient-starved cultures. Expression of a-crystallin during stationary and
anaerobic growth appeared to be higher for the Beijing strain compared to M tuberculosis
H37Rv and the family 23 strain. The lack of PstS 1 expression by the Beijing strain, the increased
expression of Hsp65 during exponential growth, the decreased expression of ESAT6 by H37Rv,
and the absence of a-crystallin in log-phase and nutrient-starved cultures of the Beijing strain
was confirmed by ELISA (data not shown).
1Qg1lhase nubient-6tarved s1ationary anaerobic
1 2 3 1 2 3 1 2 3 1 2 3
PstS1 - -
Hsp65
ESAT6
a.-crystallin .. -~
Figure 5.2 Western blot analysis with monoclonal antibodies. Ten microgram of protein extracted from M
tuberculosis H37Rv (lane 1), the Beijing strain (lane 2) and the family 23 strain (lane 3) was separated by 12% SDS-
PAGE, transferred onto PVDF membranes and probed with mAbs directed to PstSI, Hsp65, ESAT6 and a-crystallin.
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5.3.3 Antigen expression during different growth conditions
To determine whether the different growth conditions affected antigen recognition, serum
from a TB patient was tested against proteins extracted from M tuberculosis H37Rv, the Beijing
and the family 23 strain. After 2D PAGE separation, proteins were transferred to nitrocellulose
and probed with serum from a TB patient (Figure 5.3). Antibodies from the TB patient
recognized a wide variety of antigens, which was dependent on culture condition, although also
on strain type. Most of the antigens recognized were expressed during log-phase, nutrient-
starvation and stationary growth, with only a few antigens recognized during anaerobic
conditions. Antibodies from the TB patient recognized several proteins more strongly in
anaerobic cultures, particularly for the clinical strains (Figure 5.3, circle 1). Proteins migrating in
these positions on 2D gels of M tuberculosis have previously been identified as different
isoforms of a-crystallin (Betts et al. 2000; Jungblut et al. 1999). A number of studies have
reported upregulation of a-crystallin during hypoxia (Boon et al. 200 1; Desjardin et al. 200 1;
Rosenkrands et al. 2002; Sherman et al. 2001; Tabira et al. 1998; Yuan et al. 1998). Although
some isoforms of a-crystallin were absent from silver-stained 2D gels of log-phase and nutrient-
starved cultures of the Beijing strain, sera from the TB patient recognised a-crystallin in these
cultures (Figure 5.3, circle 2). Western blotting with a mAb directed to a-crystallin confirmed the
lack of a-crystallin in log-phase and nutrient-starved cultures of the Beijing strain. The
discrepancy could be explained by the fact that 2D gels for Western blots contained three times
the protein concentration used for silver-stained 2D gels and six times the protein concentration
used for ID Western blots. Patient sera recognized spot numbers 3 and 4 more strongly in log-
phase cultures of clinical strains compared to nutrient-starved, stationary and anaerobic cultures
(Figure 5.3). Antibodies from the TB patient did not recognize protein spots 5 and 6 in stationary
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cultures of the family 23 strain, and in anaerobic cultures of both the Beijing and the family 23
strain (Figure 5.3). Generally, fewer antigens were recognised in stationary cultures of the family
23 strain compared to H37Rv and the Beijing strain. Spot 7 was detected only in stationary-phase
cultures of the Beijing strain (Figure 5.3).
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Figure 5.3 2D Western blot analysis with TB sera. Proteins extracted from log-phase, nutrient-starved,
stationary and anaerobic cultures of M tuberculosis H37Rv, the Beijing strain and the family 23 strain were
separated by 12% 2D PAGE, transferred to nitrocellulose membranes and probed with TB sera diluted
1:100. Differential antigen recognition between strains under the different growth conditions is indicated by
circles and boxes. Molecular weight markers are shown on the right.
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5.4 Discussion
Identification of M tuberculosis proteins expressed during dormancy could be important
for the development of new antimycobacterial drugs and vaccines that will target latent infection.
A number of studies have shown differential protein expression in M tuberculosis H37Rv during
dormancy (Betts et al. 2002a; Desjardin et al. 2001; Rosenkrands et al. 2002; Tabira et al. 1998;
Yuan et al. 1998). Concerns that H37Rv may not be a valid model and the findings that virulence
(Lopez et al. 2003) and protein expression patterns (Pheiffer et al. 2002) may vary for different
M tuberculosis strains, initiated the comparison of protein expression in H37Rv and two local
clinical strains during dormancy conditions. The clinical strains investigated exhibited different
frequencies in a TB high incidence community (Warren et al. 2000), and genotyping identified
one of them as a member of the Beijing family. Expression patterns showed that some proteins
were dependent on growth conditions, although some variation between strains was observed.
Examination of the proteins extracted from each of these strains during the different growth
conditions using sera from a TB patient showed differential antigen recognition under the
different growth conditions and some differential antigen expression by the strains.
Various in vitro models to mimic mycobacterial dormancy have been developed, thereby
aiding the identification of genes expressed during stress conditions. Using the Wayne model of
oxygen depletion (Wayne, 1994; Wayne and Hayes, 1996) and the nutrient starvation model
described by Betts et al. (2002a) we demonstrated that protein expression is dependent on both
culture condition and on strain genotype. 2D gels showed that M tuberculosis H37Rv and the
family 23 strain expressed a-crystallin under all culture conditions, whereas the Beijing strain
only expressed a-crystallin during stationary and anaerobic growth. The expression of a-
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crystallin in the Beijing strain is consistent with studies showing upregulation during stationary
growth (Yuan et al. 1996) and during hypoxia (Boon et al. 2001; Desjardin et al. 2001;
Rosenkrands et al. 2002; Sherman et al. 2001; Tabira et al. 1998; Yuan et al. 1998). The trend of
Rv2623 expression in the Beijing strain was similar to that of a-crystallin. Rv2623 has also been
found to be upregulated during hypoxia (Boon et al. 2001; Sherman et al. 2001; Rosenkrands et
al. 2002) and has recently been shown to lie within the same regulon as a-crystallin (Park et al.
2003). The expression of a-crystallin and Rv2623 in H37Rv and the family 23 strain were
independent of culture condition. Differential expression of a-crystallin, a virulence factor
(http://genolist.pasteur.fr/TubercuList/) during host-relevant conditions may help to increase the
pathogenicity and prevalence of Beijing strains compared to the family 23 strains. PstS 1
expression differed between the Beijing and the other two strains. PstS 1 was undetectable in all
cultures of the Beijing strain studied, but present in cultures from M tuberculosis H37Rv and the
family 23 strain. Previous studies have also suggested the absence of or low expression levels of
PstS 1 in the Beijing strain (Pheiffer et al. 2002 and unpublished data). Decreased expression of
PstS 1 in the Beij ing strain, may possibly explain the absence of PstS 1 antibodies in some TB
patients, and why serodiagnosis of TB has been unsuccessful to date (Bothamley, 1995; Chan et
al. 2000). In a similar vein, an unidentified protein appeared to be absent from family 23 strain
compared to H37Rv and the Beijing strain during all growth conditions. Molecular epidemiology
has shown that the Beijing strain is at least 10fold more frequent than the family 23 strain
(Warren et al. 2000). Our finding of differential protein expression by these strains may relate to
strain frequency, as previous studies have reported that reduced expression of certain major
antigens may allow strains to evade host immune responses (Stewart et al. 2001). Interestingly,
probing proteins extracted from the M tuberculosis strains with TB sera showed differential
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antigen recognition, suggesting differential protein expression in vivo. Taken together, our results
suggest that differential protein expression may explain why certain strain families are more
dominant or "successful" than others, and why patients do not develop adequate protective
immunity and are susceptible to reinfection.
The relevance of M tuberculosis H37Rv as a model for human infection is crucial for the
design of new vaccines and antimycobacterial drugs. H37Rv is the most commonly used
laboratory strain and was isolated from a TB patient in 1905. Since then it has been continually
passaged in vitro and in vivo, raising questions about its virulence and relevance as a model
(Jacobs et al. 1996). Although H37Rv seems largely similar to clinical strains of M tuberculosis,
a few differences between H37Rv and the clinical strains were observed. Notably, expression of
ESAT6 and a protein spot identified on 2D gels was decreased in H37Rv compared to the clinical
strains. Although our results seem to support the use of H37Rv as a reference strain, we do not
know how these differences may affect phenotype. 20 gels showed upregulation of Rv2557 and
Rv2558 during nutrient-starvation and stationary growth in all the strains investigated.
Upregulation of these proteins during nutrient starvation has previously been demonstrated in M
tuberculosis H37Rv (Betts et al. 2002a). We have confirmed the results of Betts et al. (2002a)
and showed upregulation of Rv2557 and Rv2558 in two local clinical strains. These findings
provide further evidence that H37Rv may indeed be a reasonable laboratory model.
Proteome examination using 2D gels showed only a few expression level differences
between the strains under the culture conditions analysed. The failure to observe more differences
could be due to several reasons including, 1) hydrophobic proteins are poorly soluble, 2)
hydrophobic and high molecular weigh proteins will not enter the first dimension gels, 3) more
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abundant proteins obscuring low copy proteins, 4) all M tuberculosis proteins do not focus in the
pH 4-7 range, 5) precipitation in the first dimension or 6) inefficient transfer of proteins to the 2D
gel. Many studies have attempted to increase the resolution obtainable with 2D analysis. These
include modification of sample preparation (Herbert, 1999), 2D analysis of subcellular fractions
(Rosenkrands et al. 2000a) and using "proteomic contigs" (Urquhart et al. 1997). "Proteomic
contigs" is the joining of protein maps formed by using a number of overlapping pH gradient
strips to increase protein spot resolution. Future studies could investigate the response to other
latency related factors such as low pH and reactive nitrogen intermediates. Furthermore,
antigenic differences between strains and between the different growth conditions may be more
pronounced in culture filtrates where the secreted proteins are found and future work should
focus on these secreted proteins.
In conclusion, this study has shown that protein expression profiling and Western blotting
may contribute to our understanding of the pathogenesis of tuberculosis by identifying specific
M tuberculosis gene products that are expressed in clinical strains during bacterial persistence.
Careful analysis and identification of these differences may aid the development of new drugs
and vaccines, and warrant further investigation. Rv2557 and/or Rv2558 seems like plausible
chemotherapeutic targets for the persistent phase of infection (Fenhalls et al. 2002), although it is
unlikely that these genes will make tractable drug targets since their function is not known and it
would therefore be impossible to design a functional assay to identify inhibitors. These genes
would possibly be potential vaccine candidates. The finding of differential protein expression by
clinical strains may explain why certain strain families, such as the Beijing family, are more
"successful" than others, and why patients are susceptible to reinfection. However, it is important
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to correlate in vitro findings with latency models in vivo, therefore interesting findings should be
validated in animal models.
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Chapter 6
POTENTIAL FOR SERODIAGNOSIS OF TB IN A HIGH INCIDENCE
COMMUNITY: MEASUREMENT OF CULTURE FILTRATE PROTEINS OF
MYCOBACTERIUM TUBERCULOSIS (CFP), ANTIGEN 85 COMPLEX
(AG85) AND LlPOARABINOMANNAN (LAM)-SPECIFIC
IMMUNOGLOBULIN G (lgG)
The results presented in this chapter were presented at the Fifth International Conference on
the Pathogenesis of Mycobacterial Infections, Stockholm, Sweden, 2002, as "Antibody
responses in patients from a high TB incidence area: effect of smear status, episode of
disease and M. tuberculosis strain type. Carmen Pheiffer, Joanna Betts, Pauline Lukey and
Paul van Helden".
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6.1 Introduction
A major obstacle in the eradication of TB is the lack of rapid and sensitive tests to
diagnose TB early and thereby limit transmission and spread. Currently, TB is diagnosed by
microscopic detection of acid-fast bacilli and/or bacteriological culture. However, these methods
are not sensitive enough, detecting at best 60% of TB cases (Levy et al. 1989) and are relatively
time-consuming. The development of systems utilizing radiometric and fluorescent-based culture
systems have decreased the time required for culture (Pfyffer et al. 1997a, 1997b), but are
thought to be too complex and expensive to use in developing countries where the greatest
portion of the world's TB burden exists, and where they are most needed.
The need to develop a faster, easier, more sensitive and economical method to diagnose
TB has sparked interest in serodiagnosis, especially in developing countries. Serology also has
the potential to diagnose smear negative and extrapulmonary TB (Wilkins and Ivanyi, 1990),
tuberculosis meningitis (TBM) (Chandramuki et al. 2002), and childhood TB (Gupta et al. 1997).
Although many tests have been developed, no test has become accepted for general clinical use
(Bothamley, 1995; Chan et al. 2000). The failure to develop a serodiagnostic test is thought to be
due to the heterogeneous host humoral response, which is thought to be due to, amongst other
things, host immunogenetics, extent of disease, bacillary load in vivo, antituberculosis therapy
and differential gene expression byM tuberculosis strains (Lyashchenko et al. 1998a).
The aim of this study was to assess the possibility of applying serology to diagnose TB in
a high incidence setting in South Africa. South Africa has the third highest TB incidence
worldwide, viz. 509/100 000 (Corbett et al. 2003). The community we investigated has
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notification rates of TB above 1 0001100 000 (Beyers et al. 1996). We investigated whether
bacterial load (smear status), disease episode and M tuberculosis strain genotype (lS6110 DNA
fingerprint) affected antibody levels. Using enzyme-linked immunosorbent assay (ELISA) we
measured M tuberculosis culture filtrate proteins (CFP), antigen 85 (Ag85) and
lipoarabinomannan (LAM)-specific immunoglobulin G (IgG). The IgG isotype has the most
discriminative diagnostic potential (Daniel and Debanne, 1987; Kardjito et al. 1982). The
antigens used in this study were previously identified to be strongly seroreactive (LaaI et al.
1997; Samanich et al. 1998; Samanich et al. 2000). We show that serodiagnosis is potentially
useful for the diagnosis of TB in a high incidence setting. Our results suggest that although
bacillary load, disease episode and strain type may affect antibody levels, additional factors, such
as host genetics are largely responsible for regulating humoral immunity.
Stellenbosch University http://scholar.sun.ac.za
113
6.2 Materials and Methods
6.2.1 Patients and controls
HIV negative individuals who were clinically diagnosed with TB and who were culture
positive for drug sensitive M tuberculosis strains were selected for this study. Samples were
collected from TB patients at diagnosis. Patients were divided into two groups according to the
presence (smear positive) or absence (smear negative) of acid-fast bacilli in sputum samples
using the Ziehl-Nielsen stain. The genotyping of the infecting M tuberculosis isolate was done
using IS61 JO, as described elsewhere (Warren et al. 2000). Controls used in this study included,
1) apparently healthy individuals residing in the same community as the TB patients and with no
previous diagnosis of TB (community controls), 2) Mantoux (PPD skin test) positive laboratory
volunteers (Mantoux size of ~15 mm) and 3) Mantoux negative laboratory volunteers (Mantoux
size of <15 mm). Each group of five controls was pooled. Ethical approval for this study was
obtained from the University of Stellenbosch Faculty of Health Sciences ethics committee and
samples were only taken after informed consent was given.
6.2.2 Plasma samples
Blood was collected from patients and controls by venipuncture. Lymphocytes were
allowed to settle at room temperature for approximately two hours and plasma was collected by
removing supernatants. Plasma samples were clarified by centrifugation at 2 500 g for 30 seconds
and was stored at -20°C until use.
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6.2.3 M. tuberculosis antigens
M tuberculosis antigens used in this study were obtained from Colorado State University.
Proteins were purified from mid logarithmic phase M tuberculosis H37Rv grown in GAS
(Glycine Alanine salts) medium. Purified Protein Derivative (PPD), a mixture of extracellular
proteins of M tuberculosis, was supplied by the Ministry of Agriculture Fisheries and Food,
Central Veterinary Laboratory, New Haw, Surrey.
6.2.4 E. coli whole-cell lysate proteins
Escherichia coli strains XL-I, DH5a, and top 10 were cultured with shaking at 3rC
overnight. Cultures were centrifuged at 6 000 g for 15 min and pellets were resuspended in 0.1 M
NaHC03/O.5 M NaCl pH 8.3. After pooling the three E. coli cultures, cells were sonicated for 2
min. Lysates were clarified by centrifugation at 10 000 g for 20 min and protein concentrations
were determined using the Bradford assay (Bradford, 1976). One times (v/v) complete protease
inhibitor cocktail (Roche Molecular Biochemicals) and 1 mM PMSF in isopropanol was added.
Aliquots of E. coli proteins were stored at -70°C until use.
6.2.5 Enzyme-linked immunosorbent assay
Fifty microlitres of antigen diluted to 10 ug/rnl (except for Ag85 and LAM, which were
used at 1 ug/rnl and 2 ug/ml, respectively) in 0.05 M NaHC03, was allowed to bind to duplicate
wells of ELISA plates (Nunc, Roskilde, Denmark) at 4°C overnight. After three washes with
PBS/0.05% (v/v) Tween-20 the wells were blocked with 2% (w/v) non-fat milk powder (Clover,
Roodepoort, South Africa) in PBS/0.05% (v/v) Tween-20 (blocking buffer) for two hours at
37°C. Thereafter, fifty microlitres of plasma in blocking buffer (1: 100-1 :500) was added to the
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wells and incubated for two hours at 37°C. Following this, plates were washed five times with
PBS/0.05% (v/v) Tween-20 and 50 f..llhorseradish peroxidase (HRP)-conjugated goat anti-human
immunoglobulin (IgG; CALTAG laboratories, USA) diluted I: 10 000 in blocking buffer was
added to the wells and allowed to stand for one hour at 37°C. Plates were washed five times with
PBS/0.05% (v/v) Tween-20 as before and developed with 100 ul of tetramethylbenzidine
substrate (TMB, Kirkegaard & Perry Laboratories Inc. USA). After 10 minutes at room
temperature, colour development was stopped by adding 100 f..ll1 M H2S04• Plates were read at
450 nm using a bench top microplate reader (Bio-Rad laboratories, USA). Three standard
deviations (SD) above the optical density (OD) readings of controls were used as cut-off values
to determine the sensitivity of the assays.
6.2.6 Standardization and statistical analysis
Assays were standardized for plate-to-plate and day-to-day variation by comparing the
OD450 values of all test samples with a reference standard. Statistical analysis was done using
GraphPad Prism version 2.01 (unpaired t tests).
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6.3 Results
6.3.1 Patient data
The data of TB patients used in this study are shown in Table 6.1.
Table 6.1 Clinical details of subjects evaluated.
Patient Smear status" Disease episode" Strain family"
1-4 - 1 0
5 + 1 2
6 - 1 2
7-8 - 1 11
9-14 + 1 11
15 + 1 14
16 - 1 14
17 - 1 21
18 + 1 23
19 + 1 28
20-26 + 1 29
27 + 2 4
28 - 2 9
29 - 2 11
30-31 + 2 11
32 + 2 14
33 + 3 10
34 - 3 14
35 - 4 11
36 + 4 29
'Smear status refers to whether acid-fast bacilli was detected (smear +) or not detected (smear -) in patient
sputum samples using the Ziehl-Nielsen stain.
"Disease episode refers to the episode of disease the patient is currently experiencing (I-first episode, 2-
second episode, etc.)
'Using IS6110 genotyping, closely related M tuberculosis strains were divided into families. In this study
strains belonging to Il different families were analysed (Warren et al. 2000).
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6.3.2 Specificity of M. tuberculosis antigens
Individuals are likely to have antibodies to commensal bacteria, environmental bacteria
and from BCG vaccination that may cross-react with many M tuberculosis proteins (Laai et al.
1997). We compared the antibody response of 5 pooled TB patients and 5 pooled controls to M
tuberculosis CFP and whole-cell lysate (WCL) proteins, PPD and E. coli WCL proteins. Table
6.2 shows the ratio obtained by dividing OD450 readings of IgG responses of TB patients by the
OD450 readings of IgG responses of controls. TB patients had significantly higher antibody
responses than controls against the three M tuberculosis antigens tested (range 3.9-8.34 fold
higher). The ability to discriminate between TB patients and controls varied according to the M
tuberculosis antigen analysed. Depending on plasma dilutions used, the differences between TB
patient and controls were between 3.9-6.2 fold, 5.46-8 fold, and 6.44-8.34 fold for WCL, CFP
and PPD, respectively. The lowest discrimination between TB patients and controls was seen
when measuring reactivity towards WCL proteins. This is expected, as the WCL contains many
heat shock proteins that are conserved between most bacteria including mycobacteria (Shinnick
et al. 1988). CFP and PPD contain mostly secreted proteins, most of which are M tuberculosis
specific (Andersen et al. 2000). No significant difference between TB patients and controls (1.33-
1.61x) was seen when comparing antibody responses to E. coli WCL proteins. This is expected,
as E. coli is a commensal pathogen and all individuals, healthy or diseased, will have E. coli
reactive antibodies. Our results show that a higher plasma dilution improved the ability to
discriminate between TB patients and controls, possibly due to an increase in antibody titres of
patients during TB. The same antibodies may be present in controls but their titres will be lower
than in active TB and therefore will not be detectable at higher dilutions.
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M tuberculosis CFP
M tuberculosis WCL
PPD
E. coli WCL
1008
5.46
3.9
6.44
1.33
2008 3008
8 7.6
5.9 6.2
8.34 7.62
1.61 1.29
Table 6.2 M tuberculosis eFP and WeL, PPD and E. coli WeL-specific IgG levels of TB patients
relative to controls. The IgG responses of TB patients obtained by ELISA, were divided by the IgG
responses of controls (OD45o TB patientslOD45o controls), so that the numbers represent the ratio
between TB patients and controls as explained.
TB patient / control
"Three different plasma dilutions were used, 1:100, 1:200 and 1:300.
6.3.3 Antibody responses of TB patients and controls against M. tuberculosis CFP, Ag85 and
LAM
To minimize individual patient heterogeneity, plasma samples from TB patients and
control individuals were pooled. IgG responses were measured in plasma pooled from 36 TB
patients, 5 community controls, 5 Mantoux positive controls and 5 Mantoux negative laboratory
controls with no evidence of active TB. The mean antibody levels of the various groups of
subjects against CFP, Ag85 and LAM, using 1:100 (A) and 1:500 (B) plasma dilutions are shown
in Figure 6.1. TB patients had higher antibody titres than controls against CFP, Ag85 and LAM.
Mantoux positive laboratory staff generally had higher plasma antibody levels than Mantoux
negative and community controls. This agrees with published results that showed raised antibody
levels in PPD positive individuals (Kardjito et al. 1982). Community controls showed slightly
higher antibody levels than Mantoux negative individuals at a dilution of 1:100, but similar levels
were observed when analysing plasma at 1:500.
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Different antigens were immunodominant in the groups of subjects investigated. TB
patients and Mantoux positive laboratory controls recognized LAM most strongly, followed by
Ag85 and CFP. Mantoux negative laboratory controls and community controls recognized Ag85
most strongly, followed by LAM and CFP. Our results agree with previous findings from
Bothamley et al. (l992b), who also showed differences in antigen recognition in exposed versus
non-exposed individuals.
B 1:500
A 1:100
2
1.5
Ec
0
10
'<t
0.5
0
TB Mantoux + Mantoux - corrmmity
control
1.4
1.2
1
ê 0.8
o
~ 0.6
0.4
0.2
o
TB Mantoux + Mantoux - community
control
Figure 6.1 Measurement ofIgG levels to CFP, Ag85 and LAM. IgG levels ofTB patients, Mantoux
positive and Mantoux negative volunteers and community controls to culture filtrate proteins (CFP)
(clear bars), antigen 85 (Ag85) (striped bars), and lipoarabinomannan (LAM) (shaded bars) was
measured using plasma diluted 1:100 (A) and 1:500 (B). Error bars represent standard deviation
between duplicate samples.
Stellenbosch University http://scholar.sun.ac.za
6.3.4 Reactivity of TB patients
Antibody responses of 36 individual TB patients were characterized by measuring the
response of each patient to CFP, Ag85 and LAM. Sensitivity refers to the ability of a test to
correctly identify TB positive individuals. The mean OD450 readings plus three standard
deviations (SO) obtained with Mantoux positive individuals, Mantoux negative individuals or
community controls were used as cut-off values to allow discrimination between TB patients and
controls. The sensitivity of the assay varied with cut-off values chosen, antigen tested and with
plasma dilution used (Table 6.3). Sensitivities when using Mantoux negative controls as a cut-off
were 66.7-80.6%, 69.4-75% and 77.7% for CFP, Ag85 and LAM, respectively. Sensitivities
ranged between 44.4-63.8% and 58.3-83.3% for Mantoux positive and community controls,
respectively. The overall sensitivity when combining all three antigens was 94.4% (100% for
smear positive, 85.7% for smear negative), 77.8% (84.2% for smear positive, 71.4% for smear
negative), and 88.8% (94.7% for smear positive, 78.6% for smear negative) using cut-off values
equal to the response of Mantoux negative, Mantoux positive and community controls,
respectively.
Table 6.3 Sensitivity of assay using different groups of controls as cut-off values. The percentage ofTB patients
reactive to CFP, Ag85 and LAM was measured using OD450 readings of Mantoux positive, Mantoux negative and
community controls plus 3 standard deviations (SD) of the mean as cut-off values.
LAMCFP Ag85
1.ioo- 1:500a 1:100a 1:500a
bMantoux positive
"Mantoux negative
dCommunity control
58.3% 63.8% 52.8%
77.7%
75%
50%
77.7%
80.6%
44.4% 44.4%
66.7%
83.3%
69.4%
58.3%
75%
63.9%
80.6%
72.2%
"Plasma samples were diluted 1:100 and 1:500.
~antoux positive and "Mantoux negative controls refers to PPD skin test positive and PPD skin test negative
laboratory individuals, respectively.
dCommunity controls are controls recruited from the same community as TB patients.
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We compared antibody levels to CFP, Ag85 and LAM with patient smear status (Figure
6.2) to determine whether bacterial load in vivo affects antibody levels as previously suggested by
Lyashchenko et al. (1998a). Patients were defined as smear positive when acid-fast bacilli were
detected in sputum samples by the Ziehl-Nielsen stain, or smear negative when no bacilli was
detected. Our results show that the mean antibody responses of smear positive patients were
slightly higher than that of smear negative patients for CFP (p=0.11 05), Ag85 (p=0.9307) and
LAM (p=0.6324), although differences were non-significant.
p=O.1105
p=O.63243
p=O.9307
E 2
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o
~
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'.' ::'... :.
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----- ..' '.' '" .'.. . · '..... . '.I:' ..·.'
+ + +
CFP Ag85 LAM
o~~----------------------
Smear status
Figure 6.2 IgG levels and smear status. M. tuberculosis CFP, Ag85 and LAM-specific IgG levels in sputum
smear positive (+, .) and smear negative (-, "') patients. Mean antibody levels are indicated for each group
of patients.
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Figure 6.3 IgG levels and disease episode. M. tuberculosis CFP, Ag85 and LAM-specific IgG levels in
patients experiencing a primary episode ofTB (1, .) and patients presenting with repeat episodes of TB (> I,
...). Mean antibody levels are indicated for each group of patients.
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Antibody titres of TB patients increase during antituberculosis chemotherapy, suggesting
that patients with repeat episodes of TB may have higher antibody titres than patients with
primary TB (Bothamley and Rudd, 1994; Imaz and Zerbini, 2000). We compared patient disease
episode with antibody levels to CFP, Ag85 and LAM (Figure 6.3). Repeat episode patients had
higher antibody levels than patients presenting with a first TB episode to CFP (p=0.0138), Ag85
(p=0.2959) and LAM (p=0.0715), with the only significant difference at 95% confidence level
between the two groups observed for CFP-specific IgG, but at 92% level also for LAM.
It has been suggested that bacteriological factors may affect the humoral response
(Lyashchenko et al. 1998a). We investigated whether M tuberculosis CFP, Ag85 and LAM-
specific IgG correlated with M tuberculosis strain, as genotyped using IS6110. Figure 6.4 shows
a comparison between M tuberculosis strain type and IgG levels to CFP, Ag85 and LAM.
Although most strain families are not well represented in our cohort, comparing antibody
responses of patients infected with strain families 11 and 29 showed that patients infected with
family 11 strains generally had higher antibody levels, although the differences were not
significant.
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Figure 6.4 IgG levels and IS6110 genotype. Antibody responses of patients against CFP (A), Ag85 (B)
and LAM (C) were correlated with the genotype of their infecting M tuberculosis isolate to determine if
there is a correlation between antibody responses and strain type. The mean antibody response is
indicated where more than three patients were infected with the same strain type.
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6.4 Discussion
One of the major problems facing TB control is the lack of inexpensive, rapid, easy and
accurate diagnosis of TB, particularly in developing countries. Serodiagnosis offers several
advantages over traditional methods and is potentially more amenable for use in developing
countries than other more recently developed methods (Bothamley, 1995; Chan et al. 2000;
Daniel and Debanne, 1987). However, one of the major factors hampering the use of serology to
diagnose TB is the heterogeneous humoral immune response of TB patients (Lyashchenko et al.
1998a). In this study we wanted to determine whether serodiagnosis could potentially be applied
in a high TB incidence area. Furthermore, we investigated factors that could possibly explain the
heterogeneity in antibody levels of TB patients.
The success of a serodiagnostic test is dependent on the cut-off values chosen (Daniel and
Debanne, 1987). We decided to assess the potential of serodiagnosis in our community using
three different control groups as cut-off, unexposed individuals (Mantoux negative laboratory
volunteers) and exposed individuals (Mantoux positive laboratory volunteers and controls
recruited from the same community as the TB patients (community controls)). There was no
significant difference in the sensitivity of the assay when using Mantoux negative laboratory
volunteers or community controls as cut-offs, although the sensitivity of the test was significantly
reduced when using Mantoux positive laboratory volunteers. The reasons for the low antibody
titres in community controls are not known since these individuals are thought to be constantly
exposed to TB. A possible explanation is that strong cell-mediated immune responses, and
therefore low antibody responses, in these individuals protect them against development of active
TB (Bhatnager et al. 1977; Daniel et al. 1981; Lenzini et al. 1977).
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Sensitivities obtained using single antigen preparations were not ideal. Combining
reactivities to all three antigens showed at least 84.2% and 71.4% sensitivity in smear positive
and smear negative patients, respectively, irrespective of the control group used as cut-off. These
results support the idea that the development of serodiagnostic tests should be based on multi-
antigen cocktails (AI Zahrani et al. 2000; Amicosante et al. 1999). These results are promising,
especially since at least 50% of pulmonary TB patients are smear negative when reporting to
clinics for the first time (Corbett et al. 2003) and culture will confirm TB in only about 50% of
these individuals (Levy et al. 1989). Although smear negative TB is arguably less infectious and
lower case mortalities are observed with smear negative patients, more than 50% of smear
negative cases progress to active disease and transmission still occurs, albeit at a reduced rate
(Behr et al. 1999a; Coleblunders et al. 2000).
Various factors, including bacterial load in vivo (Samanich et al. 1998), antituberculosis
treatment (Bothamley and Rudd, 1994; Imaz and Zerbini, 2000), and strain type (Lyashchenko et
al. 1998a; Samanich et al. 2001) may affect antibody responses. We compared antibody
responses between smear positive and smear negative patients, patients presenting with their first
disease episode and repeat episode TB patients, and patients infected with genotypically different
M tuberculosis strains. Our results show that although generally non-significant, smear positive
individuals had higher antibody levels than smear negative patients. Increased bacterial load, as
observed in smear positive compared to smear negative individuals, decreases cell-mediated
responses (Spell berg and Edwards, 2001), and therefore higher antibody levels are expected in
smear positive individuals (Bhatnager et al. 1977; Daniel et al. 1981; Lenzini et al. 1977).
Patients with recurrent TB tended to have increased antibody titres, compared to patients with
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newly acquired TB. This finding is consistent with studies reporting that antibody titres increase
during the course of antituberculosis therapy and persist for up to 3 years after treatment
(Bothamley and Rudd, 1994; Imaz and Zerbini, 2000). Our results suggest that the time since the
previous TB episode should be taken into account for recurrent patients, to avoid false positivity
due to antibody persistence after previous treatment. Ideally, antibodies that are not affected by
antituberculosis treatment or antibodies that are involved in disease progression should be used
for a serodiagnostic test, enabling discrimination between active and cured TB patients.
Correlating patient CFP, Ag85 and LAM-specific IgG levels with the genotype of the M
tuberculosis strain isolated from the patient sputum (Warren et al. 2000) showed no significant
correlation between antibody levels and strain genotype. Molecular epidemiological studies in
our community have shown that strain families 11 and 29 are responsible for 24.5% and 18.7% of
TB cases in our community respectively (Warren et al. 2000). Our results show that patients
infected with family 11 strains have higher antibody levels than patients infected with strain 29
families, irrespective of their bacillary load or disease episode. The hypothesis that antibody
responses are inversely proportional to cell-mediated immune response may explain why family
11 strains are more frequent than family 29 strains, as patients infected by these strains may
develop weaker cell-mediated responses, which are thought to be protective against TB
(Bhatnager et al. 1977; Daniel et al. 1981; Lenzini et al. 1977). This hypothesis could potentially
be confirmed by analysing the chest x-rays of these patients to determine whether antibody
responses correlate with increased tissue damage and cavity formation.
Our results support earlier studies that report the heterogeneous antibody response of TB
patients (Lyashchenko et al. 1998a), but in addition demonstrate the effect of bacterial load in
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vivo, disease episode and M tuberculosis strain genotype on antibody levels. Our findings seem
to suggest that the above-mentioned factors minimally affect antibody levels, and we feel that
additional factors, such as the extent of disease (Samanich et al. 1998) and the immunogenetic
background of the host (Bothamley et al. 1989) are the major contributory factors. We have
recently shown that antigen expression inM tuberculosis varies with growth stage and to a lesser
extent with strain type (Pheiffer et al. 2002). Lyashchenko et al. (1998b) demonstrated that
different antigens become immunodominant over time during experimental bovine TB, further
supporting the hypothesis that the heterogeneous host humoral immune response may be due to
differential gene expression by M tuberculosis strains during the course of disease. Furthermore,
Lyashchenko et al. (1998b) showed that cattle infected with the same strain of Mbovis also
develop a heterogeneous humoral response, showing that strain type alone does not dictate the
humoral response and supporting the involvement of host factors in antibody production. Our
findings suggest that regulation of the humoral response is complex and that a number of factors
work together to affect humoral immunity.
In conclusion, our results suggest that serodiagnosis of TB patients, especially smear
negative cases, in a high incidence setting such as ours may be possible and provides justification
for further studies in larger cohorts. Our results show promise and development of the type of
analysis used in this study could greatly assist earlier case detection with prompt instigation of
treatment and therefore limitation of disease transmission, the main cause of recurrent TB after
successful cure in our community (van Rie et al. 1999a). Future studies should assess the efficacy
of assays, such as the one described here, in TB patients dually infected with human
immunodeficiency virus (HIV). The increasing prevalence of HIV infection, especially in areas
where TB is epidemic (Corbett et al. 2003) has provided further support for the development of
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serodiagnostic tests, however there are conflicting reports in the literature about whether the
immunosuppression observed after HIV infection affects the humoral response, which could
potentially hamper serodiagnosis of TB (Wilkins, 1994).
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Chapter 7
ANTIBODY RESPONSES OF PATIENTS DURING
ANTI MYCOBACTERIAL TREATMENT
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7.1 INTRODUCTION
Antimycobacterial chemotherapy to treat tuberculosis (TB) involves taking a combination
of drugs for at least six months because the current drugs available are targeted against actively
replicating bacteria and are less active against "persistent" bacilli (Parrish et al. 1998). The
development of new drugs that will eradicate "persistent" bacilli, thereby shortening the length of
treatment, reduce the risk of patient relapse, and minimize the development of multiple drug
resistance is urgently needed (O'Brien and Nunn, 2001). These drugs should probably also be
able to eliminate latent TB, a source for great concern with the HIV/AIDS epidemic (Corbett et
al. 2003). However, the development of new drugs is hindered by numerous problems, such as
the lengthy duration of clinical trials and associated high costs.
In an attempt to speed up the clinical evaluation of new drugs, various researchers are
exploring the possibility of identifying surrogate markers of disease eradication. Surrogate
markers could be either bacterial or host factors which are expressed early during treatment and
which should predict patient outcome. Mitchison (1993) reported that patient sputum culture
conversion after two months of antimycobacterial chemotherapy is one possible predictor of
treatment success or failure. However, the limited predictive value and the relatively long culture
period required for identification of M tuberculosis is a major limitation and makes culture
unsuitable as a surrogate marker. Monitoring sputum smears of refugees in Thailand has shown
that sputum smear conversion after two months of DOTS appears to correlate with clinical
outcome (Rieder, 1996), and is currently the most widely used method to monitor the efficacy of
antimycobacterial chemotherapy. This method, while simple and inexpensive, is not as accurate
as culture testing and relatively insensitive (Levy et al. 1989). Other potential surrogate markers,
such as detection of mycobacterial growth in mycobacterial growth indicator tubes (MOlT)
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(Epstein et al. 1998), quantifying M tuberculosis antigen (Wallis et al. 1998), M tuberculosis
messenger RNA (mRNA) (Desjardin et al. 1999; Hellyer et al. 1999) and host cytokine levels
(Ribeiro-Rodrigues et al. 2002) in patient sputum, and measuring antibody secreting cells (Sousa
et al. 2000), interferon (lFN) y producing T cells (Ulrichs et al. 2000), and immunoglobulin (lg)
G levels (Drowart et al. 1991; Hwang and Kim, 1993; Sánchez-Rodriguez et al. 2002; Sousa et
al. 2000) in patient blood have also been investigated.
Serum antibody levels may reflect disease progression and may give important clues
regarding treatment outcome. Antibody titres increase during the first weeks of treatment,
possibly due to rapid bacterial killing and antigen release, and/or the disappearance of circulating
immune complexes (Bothamley, 1995). Antibodies of different specificity are expressed during
treatment, suggesting that the antigenic make-up of M tuberculosis evolves in relation to disease
progression (Bothamley et al. 1992a; Imaz and Zerbini, 2000). Using antibodies as surrogate
markers to predict treatment outcome offers several advantages over other methods, which
include accessibility of blood, speed of antibody detection assays, it obviates the requirement of
cell culture and minimizes the risk of infection to laboratory workers.
In this study we report the measurement of Antigen 85B (Ag85B) (the dominant member
of the Ag85 complex (Harth et al. 1996)) specific-IgG I, IgG2, IgG3 and IgG4 by enzyme-linked
immunosorbent assay (ELISA). The aim of this work was to determine whether IgG subtype
levels can differentiate between treatment "responders" (defined as those who sputum smear
converted after two months of therapy) and "nonresponders" (defined as those who remained
smear positive after two months of therapy) after four weeks of antimycobacterial chemotherapy.
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Measurement of IgG subclasses, which are distinct in terms of structure, function and levels in
serum (Shakib and Stanworth, 1980), is possibly more informative than measurement of total IgG
(Gibson et al. 1987; Hussain et al. 1995,2000,2001). We chose to measure anti-Ag85B antibody
levels since isoniazid, one of the frontline antituberculosis drugs, induces Ag85 expression
(Garbe et al. 1996), and Wallis et al. (1998) reported that monitoring Ag85 levels in sputum may
be useful to evaluate treatment outcome.
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7.2 MATERIALS AND METHODS
7.2.1 Patients
Patients with primary pulmonary TB (sputum smear positive) were recruited from a
suburb in the Western Cape Region of South Africa, with notification rates of TB above
0001100000 (Beyers et al. 1996). Patients were diagnosed by microscopic detection of acid-fast
bacilli in their sputum, bacteriological culture and radiographic examination. All patients were
HIV negative, culture positive for drug sensitive M tuberculosis and did not have any other
diseases known to affect the immune system at the time of diagnosis. Patients received
combination therapy under supervision (DOTS) as prescribed by the South African National TB
Programme, which is based on WHO guidelines. The intensive phase (two months) consisted of
daily doses of isoniazid, rifampicin, pyrazinamide and ethambutol, while the continuation phase
(four months) consisted of daily doses of only isoniazid and rifampicin. All patients were fully
compliant with treatment. Compliance is defined as taking at least 80% of the prescribed drug
regimen during antimycobacterial chemotherapy. Patients were classified into two groups,
"responders" and "nonresponders" according to their smear status after two months of
antimycobacterial chemotherapy. "Responders" were defined as patients who responded to
treatment and who smear converted after two months of treatment, while "nonresponders" were
defined as patients who remained smear positive after two months of treatment. Ethical approval
for this study was obtained from the Ethics committee, Faculty of Health Sciences, University of
Stellenbosch. Permission for this work was also given by the Head of Health Services in the City
of Tygerberg.
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7.2.2 Sera
After informed consent, blood was collected by venipuncture at diagnosis and after four
weeks of treatment. Blood was allowed to coagulate at room temperature for one hour and serum
was collected by centrifugation at 2 500 g for 7 minutes at 4°C, aliquoted into 0.5 ml and stored
at -70°C until use.
7.2.3 Antigens
Recombinant M tuberculosis Ag85B expressed in Escherichia coli was purchased from
Lionex Diagnostics and Therapeutics, Braunschweig, Germany. Purified IgG1, IgG2, IgG3 and
IgG4 proteins (Sigma-Aldrich, Missouri, USA) were used to standardise assays. Proteins were
supplied lyophilised and reconstituted in distilled H20 according to the manufacturer's
instructions.
7.2.4 Enzyme-linked immunosorbent assay
Fifty microlitres of Ag85B (10 ug/ml) and IgG subclass protein at various concentrations
(20 ug/ml, 10 ug/ml, 5 ug/rnl, 2 ug/ml, 1 ug/rnl, 0.2 ug/ml, 0.02 ug/ml) in 0.05 M NaHC03 was
allowed to bind to duplicate wells of ELISA plates (lmmulon 4HSX, Thermosystems, USA) at
37°C for 2 hours, and plates were stored at 4°C overnight. After three washes with PBS/0.05%
(v/v) Tween-20, PBS (phosphate buffered saline; 0.01 M phosphate buffer, 0.0027 M potassium
chloride, 0.137 M sodium chloride, pH7.4) containing 5% (w/v) BSA was added to the plates and
incubated for 2 hours at 37°C to block free sites. Following this, plates were washed thrice with
PBS/0.05% (v/v) Tween-20 to remove unbound protein. Sera diluted in 1% (w/v) BSA/0.05%
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(v/v) Tween-20 in PBS was added to the plates and incubated for 2 hours at 37°C, and then
stored at 4°C overnight. Plates were washed thrice with PBS/0.05% (v/v) Tween-20, as before.
Mouse monoclonal antibodies (mAbs) specific for each of the human IgG subclasses (HP6001,
anti-IgG 1; HP6002, anti-IgG2; HP6047, anti-IgG3; HP6023, anti-IgG4; Sigma-Aldrich,
Missouri, USA) were added at saturating concentrations (1:5 000 dilution), incubated for 2 hours
at 37°C, and then stored at 4°C overnight. Plates were washed thrice with PBS/0.05% (v/v)
Tween-20, as before. Horseradish peroxidase (HRP)-labelled goat anti-mouse IgG (CALTAG
laboratories, Burlingame, USA) was added at pre-determined optimal concentrations of 1:1 000
for anti-IgG 1 and anti-IgG4 and 1:5 000 for anti-IgG2 and anti-IgG3, and plates incubated for 2
hours at 37°C. Plates were washed thrice with PBS/0.05% (v/v) Tween-20 and developed with
100 ,..tl of tetramethylbenzidine substrate (TMB, Kirkegaard & Perry Laboratories Inc.,
Gaithersburg, USA). After 10 minutes at room temperature, colour development was stopped by
adding 100 JlI of 1 M H2S04. Plates were read at 450 nm using a bench top microplate reader
(Bio-Rad laboratories, Hercules, USA). Sera were analysed at four different dilutions and activity
expressed as optical density relative to the standard included in each assay.
7.2.5 Statistical analysis
Statistical analysis was performed using the GraphPad Prism version 4.00 for Windows
software package (GraphPad Software, San Diego, California, USA, http://www.graphpad.com).
Paired t-tests were used to determine the significance between patient status and antibody
responses.
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7.3RESULTS
7.3.1 Optimisation of antibody concentrations
The optimal concentration of anti-IgG subclass mAb and goat HRP-Iabelled anti-mouse
IgG was determined by calculating the signal-to-noise ratio of six dilutions of each of the four
anti-IgG subclass mAbs and eight dilutions of secondary antibody against 0.25 ug/well of IgG
subclass protein specific for each of the mAbs. Results showed that the optimal dilution for anti-
IgG 1, anti-IgG2, anti-IgG3 and anti-IgG4 was 1:5000, whereas the optimal dilution for the
secondary antibody was 1:5 000 for anti-IgG2 and anti-IgG3, and 1:1 000 for anti-IgG 1 and anti-
IgG4 (data not shown).
7.3.2 Standard curve
Various concentrations (0.5 J..lg-O.OOOIug) of purified IgG subclass protein were probed
with the previously determined optimal concentration of subclass-specific mAb and the optimal
concentration of secondary antibody. Plotting 00450 against protein concentration on a semi-log
scale allowed the generation of straight lines with correlation co-efficients ranging between 0.94
and 0.98 (Figure 7.1). The gradient of each of these curves was used to standardise assays.
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Figure 7.1 Reactivity of IgG subclass proteins with their specific antibodies. Various concentrations of IgOI
purified protein (A), Ig02 purified protein (B), Ig03 purified protein (C) and IgG4 purified protein (D) were
probed with optimal concentrations of the corresponding mouse monoclonal antibody. Standard curves were
obtained by plotting protein concentration against OD450 on a semi-log scale. The circles and squares represent
duplicate experiments. The thicker line represents the linear trendline generated.
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7.3.3 IgG subtyping
Preliminary experiments were done with sera collected from ten TB patients at diagnosis
and after four weeks of compliant therapy. Pilot experiments with these patients served to
validate the assay for future experiments with "responders" and "nonresponders". Ag85B-IgG
subclass levels showed inter-patient variability, with the difference in antibody levels between
diagnosis and after four weeks of therapy being statistically non-significant (IgG 1 (p=O.7337),
IgG2 (p=O.8340), IgG3 (p=O.9657) and IgG4 (p=0.2888» (Figure 7.2). Despite this, it was
decided to measure IgG subtype levels in "responders" and "nonresponders" identified by smear
conversion after two months of antimycobacterial chemotherapy. These patients were matched
for age, sex and extent of disease. These two groups were analysed to determine whether their
IgG subclass levels at diagnosis and/or after fours weeks of antimycobacterial chemotherapy
could predict smear status after two months of treatment. Slight differences between "responders"
and "nonresponders" were noted, however, these were not statistically significant. At diagnosis,
IgGl (p=0.3538) and IgG4 (p=0.4414) were higher for "responders" compared to
"nonresponders". IgG3 (p=O.5446) was slightly higher in "nonresponders" compared to
"responders", while the levels of IgG2 (p=O.9479) was almost the same in the two groups
(Figures 7.3). After four weeks of treatment, levels of IgG 1 were still higher in "responders"
(p=O.5786) and levels of IgG3 were still higher in "nonresponders" (p=O.7778). "Responders"
appeared to have slightly higher levels of IgG2 (p=O.8760), while "nonresponders" had slightly
higher levels of IgG4 (p=O.6025) after four weeks of treatment. Dissecting the antibody response
at diagnosis and after four weeks of treatment for the "responder" and "nonresponder" group
separately did not show a pattern in IgG isotype production (Figure 7.5 and Figure 7.6). For some
patients a decrease in Ag85B-specific IgG subtype levels was observed, while for others patients,
levels of the same IgG subtypes increased during treatment. Dissecting the IgG subtype response
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for individual patients did not show any significant patterns in IgG subtype responses for
individual patients. Analysis of the difference between IgG subclass levels at diagnosis and after
four weeks antimycobacterial chemotherapy for each of the patients individually also showed no
significant profile difference for "responders" and "nonresponders" (Figure 7.7).
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Figure 7.2 Pilot IgG subtyping study. Ag85B-specific IgGl (A), IgG2 (B), IgG3 (C) and IgG4 (D) often TB
patients were measured at diagnosis and after four weeks of antimycobacterial chemotherapy. The y-values
represent units relative to the standard included in each assay. Each point represents the mean of duplicate
samples.
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Figure 7.3 IgG subclass levels of "responders" and "nonresponders" at diagnosis. Ag85B-specific IgG 1
(A), IgG2 (B), IgG3 (C) and IgG4 (D) of patients who were smear negative (responders) or smear positive
(nonresponders) after two months of antimycobacteri al chemotherapy. The y-values represent units
relative to the standard included in each assay. Each point represents the mean of duplicate samples and
two independent assays.
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Figure 7.4 IgG subclass levels of "responders" and "nonresponders" after four weeks of
antimycobacterial chemotherapy. Ag85B-specific IgGI (A), IgG2 (B), IgG3 (C) and IgG4 (D) of patients
who were smear negative (responders) or smear positive (nonresponders) after two months of
antimycobacterial chemotherapy. The y-values represent units relative to the standard included in each
assay. Each point represents the mean of duplicate samples and two independent assays.
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Figure 7.5 IgG subclass levels of "responders" at diagnosis and after four weeks of antimycobacterial
chemotherapy. Ag85B-specific IgGl (A), IgG2 (B), IgG3 (C) and IgG4 (D) of patients who were smear
negative (responders) after two months of antimycobacterial chemotherapy. The y-values represent units
relative to the standard included in each assay. Each point represents the mean of duplicate samples and two
independent assays.
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Figure 7.6 IgO subclass levels of "nonresponders" at diagnosis and after four weeks of
antimycobacterial chemotherapy. Ag85B-specific IgO 1 (A), Ig02 (B), Ig03 (C) and Ig04 (D) of
patients who were smear positive (nonresponders) after two months of antimycobacterial
chemotherapy. The y-values represent units relative to the standard included in each assay. Each point
represents the mean of duplicate samples and two independent assays.
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Figure 7.7 Difference in IgG subclass levels at diagnosis and after four weeks of antimycobacterial
chemotherapy. The increase in Ag85B-specific IgG 1 (A), IgG2 (B), IgG3 (C) and IgG4 (D) levels between
diagnosis and after four weeks of antimycobacterial chemotherapy is plotted for each matched nonresponder
(shaded bars) and responder (clear bars) pair. Each bar represents the mean of duplicate samples and two
independent assays.
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7.4 DISCUSSION
Cell-mediated immunity (CMI) confers protection against TB (Flynn and Chan, 2001),
while the role of humoral immunity is controversial (Glatman-Freedman and Casadevall, 1998).
Recent reports suggest that antibodies may playa protective role in TB (Glatman-Freedman,
2000; Pethe et al. 200 1; Teitelbaum et al. 1998). A direct link between CMI and humoral
immunity was suggested when Hussain and co-workers demonstrated that opsonizing antibodies
(IgG 1) may aggravate disease pathology by upregulating pro inflammatory cytokines (Hussain et
al. 2000, 200 1). Regardless of their role in disease pathogenesis, antibodies are markers of
antigen expression in vivo, and therefore may reflect the metabolic state of the bacillus in the
host. Patients vary in their response to treatment, which may be due to different metabolic
activities of tubercle bacilli during antimycobacterial chemotherapy. Antibodies may reflect the
differences in antigenic make-up of bacilli during these different metabolic states, allowing
differentiation between patients experiencing successful treatment and those who will relapse.
Furthermore, the development of antibodies to cytoplasmic antigens of M tuberculosis may
confirm successful killing of bacilli by antimycobacterial drugs. We decided to assess Ag85B-
specific IgG 1, IgG2, IgG3 and IgG4 levels of two groups of TB patients who smear converted
(responders), or who remained smear positive (nonresponders) after two months of
antimycobacterial chemotherapy. These patients were fully compliant during treatment, HIV
negative, had drug sensitive bacilli, and did not have any other disease known to affect the
immune system.
Analysis of IgG subclass levels at diagnosis, after four weeks of antimycobacterial
chemotherapy, and the difference in antibody levels between week four and diagnosis showed no
significant difference between "responders" and "nonresponders" . Sousa et al. (2000) also failed
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to see a difference in IgG levels to mycobacterial antigens during treatment. Patient-to-patient
variation underlies humoral immunity (Lyashchenko et al. 1998a) and probably explains the lack
of significant differences between the two groups. Several factors could explain the humoral
heterogeneity, including genetic variability between patients, M tuberculosis strain differences,
extent of disease at diagnosis, bacterial load and antimycobacterial chemotherapy (Lyashchenko
et al. 1998a). Patients investigated in this study were smear positive, had primary TB and were
all at the same stage of therapy, disputing the suggestion that humoral heterogeneity is due to
bacterial load and antimycobacterial chemotherapy. Previous findings by us and others support
the involvement M tuberculosis strain type (Pheiffer et al. 2002), host genetics (Bothamley et al.
1989) and extent of disease (Pheiffer et al. 2002; Samanich et al. 1998) in the host humoral
immune response.
Sánchez-Rodriguez et al. (2002) reported that positive anti-Ag85 antibody titres
correlated with a good outcome. Our conflicting results are possibly due to the fact that we
measured IgG subtype levels to recombinant Ag85B whereas Sanchez-Rodriguez et al. quantified
native Ag85 complex-specific IgG. Ag85 consists of Ag85A, Ag85B and Ag85C, and perhaps all
of these should be investigated. Furthermore, recombinant proteins expressed in E. coli may not
contain the same epitopes as native Ag85B or recombinant Ag85B expressed in mycobacterial
hosts (Triccas et al. 1998). Studies have shown that many mycobacterial antibodies are
complexed to antigens in immune complexes (Bhattacharya et al. 1986) and maybe these should
be investigated. Raja et al. (1995) reported that the kinetics of circulating immune complexes
(CICs) changes during treatment and these could possibly serve as markers for treatment
efficacy. However, more recently Sousa et al. (2000) showed no correlation between circulating
IgG antibodies to several M tuberculosis antigens (38 kDa, short term culture filtrate, DAT or
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LAM) or CICs with treatment. We analysed patients categorised into "responders" and
"nonresponders" usmg smear culture conversion after two months of antimycobacterial
chemotherapy. This classification of patients may be flawed, and using a more accurate
distinction, such as comparing antibody levels of patients who relapse to antibody levels of
patients who are successfully cured and do not relapse may yield interesting differences between
the two groups. However, this study was designed to investigate whether patient antibody levels
early during treatment could predict treatment response.
Studies have shown a reduction in antigenic load in sputum (Wallis et al. 1998) and in
blood (Sethna et al. 1998) in response to treatment, suggesting that measurement of
mycobacterial antigen may be more useful than measurement of antibody levels. Furthermore,
calculating the ratio of secretory antigens (indicative of active growth) and cytoplasmic antigens
(indicative of bacterial lysis) in patient sera may be a better indicator of treatment response and
therefore outcome than measurement of antibody to a single antigen (Sethna et al. 1998). Future
work should investigate the difference in secreted and cytoplasmic antigens from a number of
samples for each patient and monitor the ratio of IgG and CICs to these antigens.
This study has shown that Ag85B-specific IgG subclass antibodies do not correlate with
smear status, and are therefore not useful in predicting treatment outcome. However,
mycobacterial antigen and antibody detection offers several advantages over microscopic
detection, bacterial culture, and culturing of host cells, and should therefore be explored further.
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7.5 APPENDIX
Preliminary experiments were performed to optimize conditions for profiling the humoral
immune response of patients undergoing chemotherapy.
7.5.1 Optimization of antigen and secondary antibody concentration
The optimal concentration of recombinant mycobacterial antigens (Ag85B, MPT64,
Hsp65 and u-crystallin, Lionex Diagnostics and Therapeutics, Braunschweig, Germany) and
secondary antibody (HRP-labelled goat anti-human IgE, IgG, IgGl, IgG4, IgM, CALTAG
laboratories, Burlingame, USA) was determined in an indirect ELISA. Briefly, antigen diluted in
0.05 M NaHC03 (concentrations ranging from 0.05 ug/well to 0.5 ug/well) was allowed to bind
to duplicate wells of ELISA plates (Nunc, Roskilde, Denmark) overnight. The following day,
wells were washed six times with PBS containing 0.05% (v/v) Tween-20. Unbound sites were
blocked with 2% (w/v) non-fat milk powder (Clover, Roodepoort, South Africa) in PBS/0.05%
(v/v) Tween-20 (blocking buffer) for 2 hours at 37°C. Thereafter wells were washed as before
and serum from a Mantoux positive laboratory volunteer was added for 2 hours at 37°C. After
washing wells, secondary antibodies were diluted according to the manufacturers suggestions and
used at dilutions ranging from 1:1 000 to 1:15 000. Plates were incubated for 1 hour at 37°C,
washed with PBS/0.05% (v/v) Tween-20 and 100 f..llof tetramethylbenzidine substrate (TMB,
Kirkegaard & Perry Laboratories Inc., Gaithersburg, USA) was added. After 10 minutes at room
temperature, colour development was stopped by adding 100 f..ll1 M H2S04. Plates were read at
450 nm using a bench top microplate reader (Bio-Rad laboratories, Hercules, USA). In two
independent experiments, we found that the optimal dilution of secondary antibodies was 1:1 000
for all four antigens, although the optimal concentration of antigen varied (Table 7.1).
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Table 7.1. Optimal antigen concentrations.
Concentration (ug/well)
Ag85B 0.25
MPT64 0.005
Hsp65 0.125
a-crystallin 0.5
7.5.2 Inter-assay variation
To determine variability between experiments, a series of serum dilutions (1:50, 1:100,
1:200, 1:500, 1:1 000, 1:1 500) of the Mantoux positive laboratory donor used in section 7.5.1
was probed against each of the four antigens at pre-determined optimal concentrations. Anti-
human IgG was used as the secondary antibody. Slight differences in absolute OD450 readings
between experiments were observed, although the overall trend remained the same. Results of
experiments performed on different days were consistent (Figure 7.8). In an independent
experiment we found that the intra-assay and inter-assay co-efficient of variation was less than
5% and 10%, respectively (data not shown).
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Figure 7.8 Inter-assay analysis of the internal standard. IgG levels of the Mantoux positive laboratory
donor to Ag85B (.), MPT64 (.), Hsp65 (X) and a-crystallin (..&.). Experiments A and B were done
on two different days. Results are expressed as the mean between duplicate samples ± standard
deviation from the mean.
7.5.3 Validation with patient sera
The IgG and IgM responses of ten TB patients were measured. Antibody levels were
measured in sera collected from patients at diagnosis and after four weeks of antimycobacterial
chemotherapy. All patients were 90% compliant during this time (Table 7.2). Probing three
different sera dilutions of each of the ten patients against Ag85B, MPT64, Hsp65 and a-crystallin
showed no significant difference in IgG levels at diagnosis and after four weeks of treatment
(Figure 7.9).
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Table 7.2. Compliance, as measured by drug taking, ofTB patients analysed.
Patient No. Diagnosis Week4 Doses Missed Doses
4831 12/07/2000 08/08/2000 20/20
2928 07/07/1999 03/08/1999 20/20
4959 08/11/2000 05/12/2000 20/20
4536 07/01/2000 03/02/2000 20/20
4715 24/05/2000 20/06/2000 19/20 16/06/2000
2900 30/06/2000 27/07/2000 20/20
2901 30/06/1999 27/07/1999 19/20 14/07/1999
5033 29/01/2001 23/02/2001 20/20
4614 09/0312000 05/04/2000 20/20
4816 05/0712000 01/08/2000 20/20
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Figure 7.9 Serum IgG levels of ten TB patients. Sera at diagnosis (solid blocks) and after four weeks of
treatment (open blocks) were diluted 1:100, 1:500 and 1:1 000 and probed against recombinant Ag85B (A),
MPT64 (B), Hsp65 (C) and a-crystallin (D). Each point represents the mean of duplicate samples.
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To simplify the analysis of patient IgG levels, OD450 readings were plotted against sera
dilutions on a semi-log scale, a linear relationship between OD450 readings and sera dilutions was
assumed and the activity of each patient serum sample expressed as one unit, relative to the
internal standard (Mantoux positive laboratory donor). It was decided to use seven different
patient sera dilutions, since using only three dilutions did not show any significant differences
(Figure 7.9). As before, IgG levels of patients to Ag85B, MPT64, Hsp65 and a-crystallin at
diagnosis and after four weeks of treatment was not significantly different (Ag85B, p=0.0978;
MPT64, p=0.5698; Hsp65, p=0.7912, a-crystallin, p=0.7078) (Figure 7.10). IgM levels against
Ag85B, MPT64, Hsp65 and a-crystallin were measured using the same range of serum dilutions
as used for IgG measurement. IgM levels were higher after four weeks of treatment, although the
difference between the response at diagnosis and after four weeks of treatment was not
statistically significant (Ag85B, p=0.6394; MPT64, p=0.7356; Hsp65, p=0.7694; a-crystallin,
p=0.1091) (Figure 7.11).
s-
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Figure 7.10 IgG responses to mycobacterial antigens. Levels of serum IgG to recombinant
antigens of M. tuberculosis at diagnosis (solid blocks) and after four weeks of treatment
(open blocks) are expressed as units of activity relative to a reference calibrator. Each point
represents the mean of duplicate samples.
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Figure 7.11 IgM responses to mycobacterial antigens. Levels of serum IgM to
recombinant antigens of M tuberculosis at diagnosis (solid blocks) and after four weeks
of treatment (open blocks) are expressed as units of activity relative to a reference
calibrator. Each point represents the mean of duplicate samples.
7.5.4 Total IgG versus IgG subclasses
It has been suggested that measurement of IgG subclasses may be more informative than
measurement of total IgG (Gibson et al. 1987; Hussain et al. 1995). This hypothesis was tested
by measuring antibody responses to M tuberculosis whole-cell lysate proteins using HRP-
labelled anti-human IgG (CALTAG laboratories, Burlingame, USA), HRP-labeled anti-human
IgGI (CALTAG laboratories) and HRP-labelled anti-human IgG4 (CALTAG laboratories) as
secondary antibodies. No significant difference in total IgG was observed, although IgG 1 levels
varied between patients, supporting the hypothesis that IgG subtyping is more useful than
measuring total IgG (Figure 7.12). No whole-cell lysate specific IgG4 was detected in any of the
patients. No Ag85B-specific IgG 1 nor IgG4 were detected in any of these patients (data not
shown). These results suggest that future subtyping should be done using mouse mAbs specific
for human IgGI, IgG2, IgG3 and IgG4 in a sandwich ELISA which is more sensitive than the
Stellenbosch University http://scholar.sun.ac.za
154
indirect ELISA. ELISA plates with a higher binding capacity should also be used (Hussain et al.
1986a, 1986b).
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Figure 7.12 IgG responses to M tuberculosis whole-cell lysate proteins. Levels of
IgGI (clear), IgG4 (dotted), and total IgG (shaded) were measured in sera from TB
patients.
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Chapter 8
GENERAL DISCUSSION AND CONCLUSION
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8.1 Introduction
Despite extensive research, TB remains a devastating disease associated with high
morbidity and mortality. The development of new diagnostics, vaccines and antimycobacterial
drugs, is dependent on understanding the mechanisms of pathogenesis of M tuberculosis. TB is a
complex disease and its expression depends on both host and pathogen related factors. A variety
of innate and acquired host factors have been described that affect the variability in the response
to M tuberculosis infection and the severity of disease (Bellamy and Hill, 1998b). However, very
little is known about the role of the pathogen in disease establishment and progression.
8.2 Protein expression and antigen presentation patterns of clinical isolates
In this thesis one aspect of the biological significance of genotypic variation between M
tuberculosis strains was investigated by comparing protein expression profiles and antigen
recognition patterns of clinical strains. The results described in this thesis reveal some insights
into immune evasion mechanisms, strain prevalence, failure of serodiagnostic tests and
exogenous reinfection.
8.2.1 Strain prevalence
Molecular epidemiological studies have identified M tuberculosis strains families that are
more "successful" or "fit" than others, as assessed by their ability to spread in a community
(Warren et al. 2000). The most well-known example of this is the Beijing family, a family of M
tuberculosis strains thought to have originated in Asia (van Soolingen et al. 1995). M
tuberculosis strains belonging to the Beijing family are distributed worldwide and are able to
spread in large clonal clusters (Glynn et al. 2002). It is speculated that these strains have an
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advantage over other less prevalent isolates, and that identification of the factors responsible
would aid understanding of the success of the Beijing strain family (Bifani et al. 2002).
To investigate this hypothesis we compared protein expression patterns and antigen
recognition profiles of a strain belonging to the Beijing family to a less prevalent clinical isolate.
The differential protein expression and antigen recognition profiles observed for these strains in
our patients may relate to strain prevalence, possibly due to immune evasion. The ability to cause
disease due to immune evasion mediated by differential protein expression patterns has been
reported for a number of other pathogens (Smith et al. 2002), and our results suggest that a
similar mechanism for disease establishment may exist for M tuberculosis, and may relate to
strain prevalence.
Development of techniques such as genome-directed priming (Talaat et al. 2000), protein
microarrays (Cahill, 2001) and proteomics using isotope-coded affinity tags (ICAT) (Gygi et al.
2000) should facilitate the analysis of global gene expression in vivo, an important requirement to
validate the significance of our in vitro findings. Moreover, analysis of additional M tuberculosis
genotypes may reveal expression profiles characteristic of specific strain families, and possibly
identify strain-specific factors that may be tested in animal models to determine their role in
disease pathogenesis.
8.2.2 Implications for serodiagnosis of TB
The development of antibody detection-based tests for the diagnosis of TB has received
extensive attention, however, no test has become available for general clinical use (Bothamley,
1995; Chan et al. 2000). This study has provided some clues about the failure to develop
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serodiagnostic tests with sufficient sensitivity, by showing that protein expression by M
tuberculosis strains is dynamic, varying with growth stage and to a certain extent with strain type.
Extensive humoral heterogeneity between TB patients, possibly due to differential protein
expression by M tuberculosis strains or due to host factors may further complicate the
development of serodiagnostic tests.
The most significant finding of this study was decreased expression of PstS 1 by the
Beijing strain compared to the other clinical strain and H37Rv. PstS 1 is a mycobacterial
phosphate binding protein that has been extensively evaluated as a possible serodiagnostic
candidate (Bothamley, 1995; Chan et al. 2000). Failure of certain M tuberculosis strains to
express PstS 1, or decreased expression, may have important implications for serodiagnosis of TB
and may explain the absence of PstS I-specific antibody levels in some TB patients.
8.2.2.1 Mechanism of differential PstS1 expression
It has been reported that IS6110 insertions occur predominantly in coding regions of M
tuberculosis (Sampson et al. 1999; Warren et al. 2000), thereby creating "natural gene
knockouts". Reviewing the literature available on IS6110 insertion (Beggs et al. 2000; Sampson
et al. 1999; Warren et al. 2000), showed that reduced expression of PstS 1 by the Beijing strain
was not due to IS6110 insertion. Decreased expression of PstS 1 was also shown not to be due to
pstSl sequence variations, suggesting that expression of PstS 1 is probably regulated at the
transcriptional and/or translational level. Transcriptional and/or translational control is an
adaptive strategy available to a number of other pathogens (Weiser et al. 1989; Zhang and Wise,
2001). Negligible genetic diversity within coding regions of M tuberculosis (Musser et al. 2000;
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Sreevatsan et al. 1997) highlights the importance of transcriptional and/or translational regulation
in protein expression by M tuberculosis.
8.2.3 Vaccine and drug development
Investigation of protein expression and antigen recognition profiles of M tuberculosis
strains during conditions which are suggested to be host-relevant revealed possible vaccine and
drug candidates to target the persistent phase of M tuberculosis infection. For example, Rv2557
and Rv2558, which were upregulated during nutrient deprived and stationary growth in all
clinical strains, is expressed in human tuberculous granulomas (Fenhalls et al. 2002), and are
potential vaccine candidates. The finding of differential antigen recognition profiles may have
important implications for the development of subunit and DNA vaccines.
8.3 Antibody responses of TB patients
8.3.1 Potential for serodiagnosis of TB
To investigate the potential of serodiagnosis in our community, we measured IgG levels
to three mycobacterial antigens that have been extensively used as possible serodiagnostic
antigens (Bothamley, 1995; Chan et al. 2000). The sensitivity of the assay was significantly
improved by combining all three antigens, rather than measuring reactivity to individual antigens,
thereby confirming patient-to-patient variation in antigen recognition, and supporting the
development of tests based on multi-antigen cocktails. This study has also shown that
serodiagnostic tests may be prone to false-positivity due to persistence of antibodies after the
previous TB episodes.
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8.3.2 Potential as surrogate marker to predict treatment outcome
Drug development is hindered by the lengthy duration of clinical trials and associated
high costs. Antimycobacterial chemotherapy affects the antibody profile of TB patients
(Bothamley et al. 1992a; Imaz and Zerbini, 2000), supporting the potential of antibody levels as
surrogate markers for treatment outcome. In this study we explored the possibility of using
patient antibody levels after four weeks of treatment as a surrogate marker to predict treatment
response, measured by smear status after two months of treatment. Although Ag85B-specific IgG
levels did not correlate with treatment response, our work has demonstrated the advantages of
using antibodies as surrogate markers and we feel that further work, measuring mycobacterial
antigen or antibody in patient samples, is justified.
8.4 Conclusion
This study may be the first extensive investigation of protein expression by genetically
characterised M tuberculosis strains. The results described here have shown that protein
expression by M tuberculosis is dynamic and that genotypically different strains express proteins
differentially. These differentially expressed proteins may influence strain "fitness", and may
partially explain the observation of different frequencies of strain families within the study
community. In addition, these findings have potential implications for future diagnostic and
vaccine development initiatives. Differential protein expression may possibly explain why
serodiagnosis of TB has been unsuccessful to date, and why previous M tuberculosis infection is
not able to adequately protect against subsequent infection.
Our findings confirm the extensive humoral heterogeneity between TB patients and
support the development of immunodominant multi-antigen serodiagnostic tests and vaccines
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since formulations based on single antigens may be of limited use in high incidence communities
where patients are infected with a variety of genetically and phenotypically distinct strains. This
study has emphasized the importance M tuberculosis strain variation in TB pathogenesis, and
careful analysis of the differences observed in this study may identify the functional significance
of strain variation and ultimately the discovery of novel mechanisms of immune evasion
strategies, strain "fitness", diagnostic and vaccine design strategies.
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